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Abstract 
The prevalence and incidence of type 2 diabetes mellitus (T2DM) is worrisome and places a great 
burden on health care systems worldwide, while negatively affecting the quality of life of countless 
individuals.  Continuous glucose monitoring (CGM) has not only improved the quality of diabetes 
care, but has also identified differences in the glucose profiles of individuals with otherwise 
seemingly healthy glucose control.  The question arises whether CGM and the measurement of 
glycaemic variability would be more sensitive in identifying individuals who are at risk for imminent 
insulin resistance and subsequent T2DM.   
 
It may have significant clinical value if it can be determined if free-living glycaemic variability is 
closer related to lifestyle factors, such as diet and exercise, than the traditional measures of glucose 
control.  Hence, this study investigated glucose control and glycaemic variability during free-living 
conditions in apparently healthy men in relation to cardiorespiratory fitness (CRF) and dietary 
glycaemic load (GL).   
 
Twenty-seven apparently healthy men of varying CRF levels and aged between 30 – 47 years, were 
included in the study.  The participants underwent at least 7 days of CGM, while logging all food and 
drink.  A modified treadmill Vam-éval ramp test was completed to measure peak aerobic exercise 
capacity.  Each participant had blood samples drawn for the measurement of HbA1c and completed a 
2-h 75 g oral glucose tolerance test (OGTT) during which [glucose] and [insulin] was measured every 
30 minutes. Inferential statistical analysis was done using Excel, while Cohen’s effect sizes were 
calculated to describe the magnitude of differences between sub-groups. 
 
CFR was best correlated to insulin sensitivity (HOMA-IR: r = -0.74; Matsuda index: r = 0.72), while 
dietary GL correlated most strongly with MAGE (r = 0.45).  A K-means cluster analysis of the dietary 
macronutrient composition of the participants revealed three groups: high carbohydrate-low fat, low 
carbohydrate-high fat, and high-carbohydrate-high fat.  The high carbohydrate-low fat cluster had the 
highest glycaemic variability, while the insulin levels were highest in the high carbohydrate-high fat 
cluster.  No differences between clusters were found in traditional glucose control measures.  The 
variation in the OGTT [insulin] was significantly more than the variation in [glucose].  Glycaemic 
variability indices did not identify more at-risk individuals than were identified with the traditional 
measures of glucose control. 
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This study could not vouch for early health risk detection among healthy, non-diabetic individuals 
using CGM. The results, however, showed that dietary macronutrient composition elicited larger 
differences in glycaemic variability, than in glucose control.  Overall, it was evident that increases in 
insulin secretion occurs before there are any sustained increases in glucose levels. 
This study provides evidence for the importance of both CRF and diet in the maintenance of metabolic 
health, as well as the importance of measuring insulin concentrations.  Healthy, glucose tolerant 
individuals are not necessarily protected against hyperinsulinaemia after a high-carbohydrate meal. 
It is proposed that attention should shift from the measurement of glucose to the measurement of 
insulin for early risk detection - at least until future longitudinal studies are able to link risk to different 
glycaemic variability profiles. 
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Abstrak 
Die voorkoms en groeikoers in die voorkoms van tipe 2 diabetes mellitus (T2DM) is 
kommerwekkend, plaas groot druk op gesondheidsorgstelsels wêreldwyd, en verlaag die 
lewenskwaliteit van ontelbare individue.  Deurlopende glukose monitering (DGM) het die kwaliteit 
van diabetesbehandeling baie verbeter en het verskille geïdentifiseer in die glukose profiele van 
gesonde individue wat andersins blyk om gesonde glukose beheer te hê.  Die vraag ontstaan of DGM 
en die meet van glisemiese variasie meer sensitief is om individue te identifiseer met verhoogde risiko 
vir toekomstige insulienweerstandigheid en gevolglike T2DM.  
 
Indien vrylewende glisemiese variasie nader verwant aan leefstyl faktore (dieet en oefening) is as 
tradisionele maatstawwe van glukose beheer, kan dit betekenisvolle kliniese waarde inhou.  Die doel 
van hierdie studie was om glukose beheer and glisemiese variasie gedurende vrylewende 
omstandighede in oënskynlik-gesonde mans, te ondersoek, asook die verband van hierdie parameters 
met kardiorespiratoriese fiksheid (KRF) en glisemiese lading (GL). 
 
Sewe en twintig oënskynlik-gesonde mans, met verskillende vlakke van KRF en tussen 30 – 47 jaar 
oud, was by die studie ingesluit.  Elke deelnemer het ten minste 7-dae se DGM deurgaan, waartydens 
hy dagboek gehou het van alle kos- en drank-inname.  ‘n Gemodifiseerde trapmeul Vam-éval toets is 
voltooi om piek aerobiese oefenkapasiteit te bepaal.  Elke deelnemer het bloed laat trek vir die meet 
van HbA1c en het ook ‘n 75 g, 2-uur modelinge glukose toleransie toets afgelê waartydens [glukose] 
en [insulien] elke 30 minute gemeet is. Afleidende statistiese analise is met behulp van Excel gedoen, 
terwyl Cohen se effekgroottes bereken is om die grootte van verskille tussen sub-groepe te beskryf. 
 
KRF het die beste met insuliensensitiwiteit gekorreleer (HOMA-IR: r = -0.74; Matsuda indeks: r = 
0.72), terwyl GL die sterkste met MAGE gekorreleer het (r = 0.45).  ‘n K-gemiddelde bondel analiese 
is op die makronutriënt samestelling van die deelnemers se diëte gedoen om drie groepe te 
identifiseer: hoë koolhidraat-lae vet, lae koolhidraat-hoë vet, en hoë koolhidraat-hoë vet.  Die hoë 
koolhidraat-lae vet groep het die hoogste gliseiese variasie getoon, terwyl die insulienvlakke van die 
hoë koolhidraat- hoë vet groep die hoogste was.  Geen verskille in tradisionele glukose beheer is 
tussen die groepe gevind nie.  Die variasie in die [insulien] van die glukose toleransie toets was 
betekenisvol meer as die variasie in [glukose].  Die glisemiese variasie maatstawwe het nie meer 
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Hierdie studie kon nie ‘n saak uitmaak vir die vroeë risiko bepaling in gesonde, nie-diabetiese 
individue met behulp van DGM nie.  Die resultate wys wel dat die makronutriënt samestelling van ‘n 
dieet gepaardgaan met groter verskille in glisemiese variasie, as glukose beheer.  Oor die algemeen 
was dit duidelik dat verhogings in insulienvlakke voor volgehoue verhogings in glukosevlakke 
voorkom. 
 
Hierdie studie wys op die belangrikheid van KRF vir dieet vir die handhawing van metaboliese 
gesondheid.  Gesonde, glukose tolerante individue is nie noodwendig beskerm teen hoë vlakke van 
insulien ná ‘n hoë-koolhidraat maaltyd nie.  Dit word voorgestel dat die aandag verskuif word vanaf 
die meet van glukose na insulien vir vroeë risiko-identifisering – ten minste totdat longitudinale 
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Chapter 1 Problem statement 
1.1 Background 
Research suggest that the degree of blood glucose control is very much dependent on the intra- and 
inter-day variability in glucose levels, as well as the magnitude of glucose excursions in response to 
foods containing carbohydrate. For instance, Kohnert et al. (2012) are of the opinion that the effects 
of postprandial hyperglycaemia and large fluctuations in daily blood glucose concentrations are more 
damaging to one’s health than chronically elevated daily glucose levels, while Hirsch (2005) stated  
that these parameters are more closely related to the risk for diabetic complications than fasted blood 
glucose levels.  Evidence (Brownlee & Hirsch, 2006; Monnier et al., 2006) also points to the harmful 
effects of glycaemic variability and postprandial hyperglycaemia in apparently healthy individuals.  
 
Brownlee and Hirsch (2006) demonstrated that high postprandial glucose excursions are positively 
correlated to the production of free radicals and subsequent atherosclerotic pathogenesis in diabetic, 
as well as healthy individuals. Monnier et al. (2006) assessed the increased oxidative stress in type 2 
diabetic patients and reported that acute glucose fluctuations are strongly correlated with free 8-iso 
prostaglandin F2α (8-iso PGF2α) (a reliable marker of oxidative stress), and is independent of mean 
24-hour glucose levels, fasting plasma glucose values and HbA1c.  Similar observations were made 
by other researchers who also attributed the production of oxidative stress to glucose excursions and 
linking it to a heightened risk for vascular injury and subsequent cardiovascular disease (CVD) 
(Ceriello et al., 2008; Quagliaro et al., 2003).  Furthermore, Esposito and colleagues (2002) found 
that acute hyperglycaemia in healthy individuals and those with impaired glucose tolerance caused 
an increase in the plasma concentrations of inflammatory cytokines.  Inflammation has been widely 
linked to the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM) (Akash et al., 
2018; Chen et al., 2015; Moller, 2000) and to the increased risk for endothelial dysfunction in healthy 
individuals (Esposito et al., 2002).  It is alarming that the incidence of impaired glucose tolerance has 
risen among non-diabetic individuals and this reportedly triples their risk for future cardiovascular 
events or disease (Standl et al., 2011). 
 
The advancement in technology in recent years has made the application of continuous glucose 
monitoring (CGM) in clinical and research settings much easier. This has led to a shift in focus from 
measuring static parameters of glucose control to the continuous and dynamic measurement of 
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glycaemic variability (i.e. frequency and magnitude of 24-hour glucose oscillations) in the 
management of metabolic diseases, such as diabetes mellitus.  However, it seems that CGM has a 
wider application than the management of already diagnosed diabetics, namely, it could serve as an 
early warning for individuals who may be at risk for future metabolic disease. 
 
Supporting this rationality is a study by Thomas and colleagues (2016), for example, where CGM 
was used to determine the glucose profile of 10 sub-elite athletes over six days. They observed that, 
among these apparently healthy athletes, four individuals presented with a degree of glycaemic 
variability that could potentially indicate a pre-diabetic state as per their postprandial glucose 
excursions (i.e. > 7.8 mmol·L-1).  The authors specifically commented that the athletes demonstrated 
differences in their tolerance of carbohydrates (regarding their abilities to maintain healthy 
postprandial glucose levels).  Similar observations were made by Zeevi et al. (2015) on more than 
800 healthy individuals.  They found that an individual’s glucose response to specific meals is not 
only dependent on the glycaemic load of the meal and insulin sensitivity of the individual, but also 
on lifestyle factors (e.g. diet and physical exercise), genetics and features of the gut microbiome.  
Although the researchers established that the amount of carbohydrate in a given meal is the primary 
determinant of the extent of the postprandial rise in blood glucose, the same meals had varying effects 
on the postprandial glucose response of the participants.  The authors commented that individuals’ 
tolerance to carbohydrate may vary considerably and suggested that sensitivity to carbohydrate is 
specific to each person.  
 
In addition to diet, physical exercise is also regarded as an important aid in glycaemic control.  It is, 
however, not clear what the exact mechanisms are whereby physical exercise exerts beneficial effects 
on glycaemic control (Roberts et al., 2013), but the general consensus is that it lowers postprandial 
glucose (Cassidy et al., 2017), insulin sensitivity (Gill, 2007; Roberts et al., 2013) and HbA1c 
(Solomon et al., 2015; Winding et al., 2018).  Although acute exercise has been shown to improve 
postprandial glucose (Borror et al., 2018; Shambrook et al., 2018) and insulin resistance (Short et al, 
2013), cardiovascular fitness has also been found to be inversely related to insulin resistance (Chen 
et al., 2008) and positively related to glucose tolerance (Solomon et al., 2015).  In addition to the 
direct beneficial effects on glucose control, exercise is also implicated as a mediator in the 
development of chronic disease through its anti-inflammatory effects (Mathur & Pedersen, 2008).  
Although it could be asserted that exercise exerts protective effects towards one’s health, the findings 
of Thomas et al. (2017) allude that certain individuals may actually be predisposed to insulin 
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resistance, irrespective of high physical fitness levels. In light of the findings of Zeevi et al. (2015) 
this predisposition may be related to carbohydrate intolerance.  
 
In order to address questions relating to glucose control, it has to be established which markers are 
most appropriate for diagnoses of impaired glycaemic control, as well as to evaluate the effectiveness 
of interventions, such as diet or physical exercise.  It seems, however, that there is not yet consensus 
in the literature as to which measure is most sensitive to detect changes in glucose control, or impaired 
glucose control.  The diabetes and pre-diabetes diagnostic criteria of the American Diabetes 
Association (2017) (ADA) are based on either: i) glucose level after an 8-h fasted period; ii) 2-h post 
a 75 g glucose challenge; or iii) the level of HbA1c.  Numerous authors  suggested, however, that the 
utilisation of fasting blood glucose levels and/or HbA1c may not be the best methods for assessing 
glucose control, or the associated micro- and macrovascular risk in diabetic patients (Gorst et al., 
2015).  It also needs to be considered that fasting blood glucose can fall within healthy ranges, while 
postprandial glucose tolerance is impaired (Bartoli et al., 2011; Nathan et al., 2007).  HbA1c is closely 
related to the average concentrations of blood glucose of the preceding two- to three-month period, 
but does not necessarily account for the degree of glycaemic variability (Brownlee & Hirsch, 2006; 
Cohen & Smith, 2008).  Measuring postprandial glucose control rather than, or in addition to fasting 
blood glucose levels and HbA1c, may provide valuable and additional information on an individual’s 
degree of carbohydrate tolerance, and thus glucose control.  The oral glucose tolerance test (OGTT) 
is more sensitive and specific than elevated fasting blood glucose, or HbA1c, in identifying individuals 
with impaired glucose tolerance and those at higher risk of developing T2DM (Iskandar et al., 2019; 
Kim et al., 2016).  Nonetheless, the 2-h [glucose] of the OGTT, on its own, is likely only 90% accurate 
in the diagnosis of diabetes mellitus (Kim et al, 2017). 
 
Taking all of the above into account, as well as the convenience of CGM, it should be determined 
whether traditional measures of glucose control, including the OGTT, are sufficiently sensitive to 
identify individuals who may present with early signs of insulin resistance or pre-diabetes.  
Furthermore, the evidence that postprandial hyperglycaemia is associated with higher levels of 
oxidative stress and inflammation, even in non-diabetics, warrants the investigation of glycaemic 
variability in apparently healthy individuals. 
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1.2 Rationale for the study  
With the prevalence and incidence of T2DM rising to epidemical numbers, it is crucial to establish 
what predisposes individuals to develop insulin resistance, as the latter is key in the pathogenesis of 
pre-diabetes and eventually, overt T2DM and metabolic disease.  Since it is in every sense better to 
prevent than to treat, this study is important to determine whether the traditional markers of glucose 
control and insulin sensitivity, or alternatively, measures of glycaemic variability, are most sensitive 
in the detection of at risk individuals.  Therefore, the potential exists that CGM may have broader 
applicability in the fight against metabolic disease, and specifically, T2DM.  
 
The OGTT is widely used as a diagnostic test to determine whether an individual has impaired glucose 
tolerance.  It has been suggested to be a more sensitive and specific marker of glycaemic control than 
HbA1c or levels of fasting glucose.  The question remains, though, what causes the transition from 
healthy glucose tolerance to impaired glucose tolerance?  Is the data that can be obtained from an 
OGTT sufficient to determine whether an individual’s glucose control is adequate, or are there other 
factors, especially lifestyle factors, that could contribute to varying degrees of glycaemic variability 
in individuals, even though they present with healthy glucose tolerance?  If it is established that 
overall, intra-, and inter-day glycaemic variability, measured using CGM, show differences between 
individuals who otherwise present with healthy glucose control, the continuous measurement of blood 
glucose levels may become a useful diagnostic tool for earlier detection of declines in glucose control. 
1.3 Purpose of the Study 
Good evidence exists to support the link between exaggerated postprandial deviations in blood 
glucose levels and the risk for future cardiometabolic disease, even in apparently healthy persons and, 
in the absence of atypical traditional markers of glycaemic control.  Therefore, the purpose of this 
study is to investigate glucose control and glycaemic variability during free-living conditions in 
apparently healthy men and in relation to cardiorespiratory fitness and dietary glycaemic load.   
1.4 Aims 
1.4.1 Primary Aims 
• To explore the relationships between cardiorespiratory fitness (CRF) and glycaemic 
variability, the traditional markers of glucose control (HbA1c, OGTT, and fasting plasma 
glucose) and insulin sensitivity.  
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Hypothesis 1: Cardiorespiratory fitness will be most strongly correlated with insulin 
sensitivity, followed by glycaemic variability and HbA1c. 
• To determine the relationships between dietary glycaemic load and glycaemic variability, 
glycaemic control, and insulin sensitivity.  
Hypothesis 2: Glycaemic load will be most strongly correlated to glycaemic variability, 
followed by insulin sensitivity (negative correlation) and glucose control (negative 
correlation).  
1.4.2 Secondary Aims 
• To investigate the effects of dietary intake with different macronutrient ratios on glycaemic 
variability, glucose control and insulin sensitivity. 
Hypothesis 3:  Low carbohydrate-high fat food consumption will be associated with least 
glycaemic variability, healthy glucose control and high insulin sensitivity.  
• To investigate the relationship between glycaemic variability and markers of glucose control.  
Hypothesis 4: There will be weak correlations between glycaemic variability and traditional 
glucose control measures. 
• To determine the relationships between the parameters of glycaemic variability and insulin 
sensitivity. 
Hypothesis 5: There will be an inverse relationship between insulin sensitivity and glycaemic 
variability.  
1.5 Objectives 
1. Determine the CRF of participants via a maximal treadmill test. 
2. Calculate the dietary glycaemic load of the participants over a 14-day period.  
3. Perform a K-means cluster analysis using the macronutrient intake of the participants to group 
them according to dietary macronutrient composition. 
4. Quantify the intra- and inter-day glycaemic variability of the participants over a 14-day period 
via CGM.  
5. Test and quantify the traditional glycaemic control markers (HbA1c, fasting glucose, 2-h 
glucose, and glucose and insulin area under the curve [AUC] of the OGTT) of the participants. 
6. Measure the insulin resistance of the participants.  
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1.6 Overview of chapters 
The second chapter reviews the literature on glucose control, as well as the importance and 
measurement thereof.  Factors influencing glucose control are also discussed, as well as the 
deterioration of glucose control and subsequent health effects.  Studies reviewed include those that 
have identified increased glycaemic variability and/or postprandial glucose excursions in apparently 
healthy individuals.   
 
Chapter three describes the study design, measures and methods used for data collection and analysis. 
 
The results of the study are encapsulated in the fourth chapter.  This includes the characteristics and 
CRF of the participants, as well as their glucose control and insulin sensitivity, and glycaemic 
variability.   
 
Chapter five discusses the findings and limitations of the study. 
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Chapter 2 Literature review 
2.1 Introduction 
High postprandial glucose excursions have been positively correlated to the increased production of 
free radicals (Monnier et al., 2006) and pro-inflammatory cytokines (Esposito et al., 2002) which is 
linked to a heightened risk for vascular injury and subsequent cardiovascular disease (CVD) (Ceriello 
et al., 2008; Quagliaro et al., 2003).  It has also been linked to the pathogenesis of insulin resistance 
and type 2 diabetes (T2DM) (Akash et al., 2018; Chen et al., 2015; Moller, 2000).  It is alarming that 
the incidence of impaired glucose tolerance has risen among non-diabetic individuals and this 
reportedly triples their risk for future cardiovascular events or disease (Standl et al., 2011).  
 
Traditionally, fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and the 2-h [glucose] 
after an oral glucose tolerance test (OGTT) are used as indicators of glucose control.  Specified levels 
in the blood serve as the diagnostic criteria for T2DM and pre-diabetes (ADA, 2017); nevertheless, 
these cut-off values are not universally agreed on.  Furthermore, these traditional measures do not 
reflect the degree of glucose fluctuations during the day (MacLeod et al., 2013; Roberts et al., 2013) 
as they only provide a snapshot of an individual’s state of glucose control.  The quantification of 
glucose control is complex, as it involves many aspects of bodily function and physiological 
conditions wherein glucose homeostasis needs to be maintained.  Thus, it is very unlikely that a single 
measure can account for all aspects of glucose control (McDonnell et al., 2005).  It has been proposed 
that glycaemic variability is more sensitive to assess glucose control (Mikus et al., 2012a; Mikus et 
al., 2012b) and its parameters are better able to distinguish between healthy individuals and those 
with impaired glucose tolerance or T2DM (Acciaroli et al., 2018; Longato et al., 2018).  Supporting 
this rationality are studies that revealed pre-diabetic glucose levels among apparently healthy sub-
elite athletes (Thomas et al., 2016).  Furthermore, there is evidence that an individual’s glucose 
response to specific meals is not only dependent on the glycaemic load of the meal, or the insulin 
sensitivity of the individual (Zeevi et al., 2015). 
 
The consensus is that regular exercise improves postprandial glucose (Cassidy et al., 2017), insulin 
sensitivity (Gill, 2007; Roberts et al., 2013) and HbA1c (Solomon et al., 2015; Winding et al., 2018).  
Notably, acute exercise has also been shown to improve postprandial glucose (e.g. exercising after a 
meal) (Borror et al., 2018; Shambrook et al., 2018) and insulin resistance, which is improved for 
several hours after a bout of exercise (Short et al., 2013).  
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2.2 Control of blood glucose levels 
The principle of homeostasis (i.e., the maintenance of a constant internal environment) is just as 
applicable to blood glucose levels as to all other physiological systems in the human body (Widmaier 
et al., 2014).  Control of blood glucose levels involves hormones and signalling pathways to maintain 
glucose levels within a certain range during two different conditions, namely the fasted (3 mmol·L-1 
– 5.7 mmol·L-1) and the postprandial state (< 5.7 mmol·L-1 – 7.8 mmol·L-1).  After the ingestion and 
metabolism of food, the fasted state resembles the homeostatic condition whereby stored energy is 
relied upon.  Alternatively, the postprandial state resembles the homeostatic condition which includes 
immediate energy utilisation or the storage thereof (Widmaier et al., 2014).  Blood glucose regulating 
hormones and signalling pathways that take effect during the fasted state are responsible for the 
maintenance of constant blood glucose levels.  Although other hormones, such as catecholamines, 
growth hormone and cortisol, influence blood glucose levels under certain conditions (Gerich, 2000; 
Lecavalier et al., 1989), the principle hormones responsible for the control of blood glucose levels 
are the two pancreatic hormones, namely: insulin and glucagon (Widmaier et al., 2014).  During the 
postprandial state, raised blood glucose levels are counteracted by the disposal of glucose from the 
circulation into the systemic cells (ranging from the skeletal muscles to the brain and red blood cells) 
(Widmaier et al., 2014). 
 
An individual’s postprandial blood glucose response is mostly related to the intake of food, in 
conjunction with the secretion of insulin and the sensitivity of the body’s tissues to insulin (Blaak et 
al., 2012).  In healthy individuals, insulin is produced and secreted by the pancreatic islet beta-cells 
(Corkey, 2012; White & Copps, 2016) mainly in response to a rise in blood glucose levels (Meglasson 
& Matschinsky, 1986) and results in a subsequent lowering in glucose levels (Liang, 1994).  An 
insulin response is also elicited by incretin hormones that are secreted into the circulation by the 
enteroendocrine cells of the stomach and intestines in response to the ingestion of food, especially 
carbohydrates (Drucker, 2007; Greiner & Bäckhed, 2011).  The hormone, insulin, primarily facilitates 
the uptake of glucose from the blood into the systemic cells (Saltiel & Kahn, 2001).   
 
After the consumption of food, pure sugars in their simplest forms (monosaccharides) are directly 
absorbed by the intestinal cells (Boron & Boulpaep, 2009).  Monosaccharides that are bound in more 
complex forms, for example polysaccharides (e.g. starches comprised of long glucose polymer 
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chains), or sucrose (glucose and fructose) are digested into their monosaccharide constituents and 
then absorbed.  Due to starches and carbohydrates consisting mostly of glucose subunits, the resultant 
product of digestion is mostly glucose (Widmaier et al., 2014).  Galactose (forms lactose when bound 
to glucose) and fructose (the sugar naturally found in fruits; the other constituent of sucrose besides 
glucose) (Widmaier et al., 2014) are ingested in smaller amounts.  However, when the diet consists 
of excessive amounts of added sugar or high-fructose corn syrup, fructose is ingested in larger 
amounts (Fung, 2018).  Many factors influence the rate of gastric emptying, the rate at which nutrients 
are absorbed, and subsequently the rate and extent at which blood glucose levels rise after ingestion 
of carbohydrate-containing foods (Russell et al., 2016).  Sugars and processed carbohydrates are 
absorbed faster and subsequently cause higher glucose excursions than complex and fibre-rich 
starches (Jenkins et al., 1987). 
 
Skeletal muscles are the main sites of postprandial glucose disposal (Defronzo, 2009), accounting for 
up to 75% of glucose uptake from the circulation via the action of insulin (Saltiel & Kahn, 2001).  
Insulin allows glucose to be transported from the blood into muscle cells via the activation of 
signalling pathways to facilitate translocation of GLUT4 transporters (glucose transporter type 4) to 
the plasma membranes of the cells (Petersen & Shulman, 2018; Samuel & Shulman, 2016).  By 
allowing glucose transport into the muscle cells (otherwise termed glucose disposal), insulin promotes 
glucose utilisation (Petersen & Shulman, 2018).  About 25% of the glucose that enters the cell is 
broken down via glycolysis and used for immediate energy production.  The rate-limiting enzyme of 
glycolysis, hexokinase II, is upregulated by insulin for this purpose (Petersen & Shulman, 2018).  The 
remaining 75% of the glucose is stored via glycogen synthesis, which is also promoted and enabled 
by insulin (Petersen & Shulman, 2018).  Stored glycogen is broken down to glucose-6-phosphate and 
then directly used for energy production.  Thus, all the glucose that is taken up by skeletal muscles is 
for the sole purpose of its own energy production (Petersen & Shulman, 2018). 
 
White adipose tissue is another site of glucose disposal.  This tissue only accounts for 5 – 10% of 
total glucose uptake, and is also dependent on the actions of insulin, via similar pathways as those in 
skeletal muscle cells (Samuel & Shulman, 2016). 
 
The liver is responsible for about 25% of the postprandial uptake of glucose (MacLeod et al., 2013), 
but is not dependent on insulin action for glucose transportation from the circulation  (Gerich, 1993; 
Petersen & Shulman, 2018; Widmaier et al., 2014).  The transition between the catabolic and anabolic 
processes of the liver is, however, largely regulated by insulin (Samuel & Shulman, 2016).  Hepatic 
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glucose production is downregulated through the inhibition of  the enzyme, glycogen phosphorylase 
(involved in glycogenolysis, the breakdown of stored muscle and liver glycogen to produce glucose) 
by insulin (Samuel & Shulman, 2016) and also through the inhibition of gluconeogenesis (hepatic 
glucose production from non-glycogen substrates such as lactate, glycerol and amino acids) (Gerich, 
2000; Saltiel & Kahn 2001).  Simultaneously, insulin stimulates glycogen synthesis (Petersen & 
Shulman, 2018) by activating the enzyme glycogen synthase (Samuel & Shulman, 2016), which 
results in an increased rate of glycogen synthesis (Caputo et al., 2017).  Excess glucose that could not 
be stored as glycogen, is utilised by de novo lipogenesis (Caputo et al., 2017).   
 
Although insulin promotes the hepatic synthesis of macromolecules (Petersen & Shulman, 2018), the 
anabolic processes of the liver are, however, not solely dependent on insulin.  The rate of 
gluconeogenesis and lipogenesis are also raised by an increased flux of substrates (Samuel & 
Shulman, 2016).  Importantly, the liver is the only organ that can metabolise the monosaccharide, 
fructose.  High levels of fructose in the liver also enhance hepatic glycogen production and de novo 
lipogenesis (Samuel & Shulman, 2016). 
 
The liver is the main contributor to the maintenance of fasting blood glucose levels.  It supplies about 
80% of the glucose in post-absorptive conditions (Gerich, 2000), while insulin levels are at basal 
concentrations and glucagon levels are high (Breckenridge et al., 2007).  Glucagon is secreted by the 
pancreatic alpha cells when blood glucose levels are low in order to stimulate glycogenolysis and 
gluconeogenesis in the liver (Widmaier et al., 2014).  The presence of the enzyme, glucose-6-
phosphatase, allows the liver to produce glucose from glucose-6-phosphate (the product of 
glycogenolysis), which is then released into the circulation (Gerich, 1993; Widmaier et al., 2014).   
 
Although skeletal muscle is another storage site for glycogen, this glycogen does not generate glucose 
for release into the bloodstream (Gerich, 1993).  Rather, glucose-6-phosphate is directly broken down 
and used for energy by the skeletal muscle itself, without converting back to pure glucose (Widmaier 
et al., 2014).  Skeletal muscles do, however, release lactate or alanine, which are alternative products 
of glycogen breakdown (Gerich, 1993) during anaerobic glycolysis (Petersen & Shulman, 2018).  
These three-carbon units are released into the circulation and mostly taken up and used by the liver 
as substrates for gluconeogenesis (Petersen & Shulman, 2018; Widmaier et al., 2014).  During fasted 
or post-absorptive conditions, as well as during physical exercise, the liver therefore stands central to 
the regulation of blood glucose levels by producing and secreting glucose to prevent drops in blood 
glucose levels (Samuel & Shulman, 2016).   
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During fasting conditions, the control of blood glucose levels revolves mostly around the supply of 
glucose to the blood from the tissues in order for blood glucose levels to remain constant and not drop 
to hypoglycaemic levels.  The liver is responsible for most of the glucose that is needed to maintain 
euglycaemia during fasted conditions of up to 12 – 14 hours (Gerich, 1993).  As the period of a fast 
continues for longer, the glycogenolysis of other tissue, such as skeletal muscle, increases.  Only after 
48 hours of fasting does gluconeogenesis become the predominant blood glucose supply process and 
by 60 hours of fasting, gluconeogenesis is the only process whereby the liver provides glucose 
(Gerich, 1993).  Ketone bodies also start increasing after two days of fasting and become a major 
source of energy as the fasted condition continues (Cahill, 2006; Newman & Verdin, 2014). 
2.2.1 Typical fluctuations in blood glucose concentrations 
Tight control of blood glucose levels is imperative in the maintenance of health (Blaak et al., 2012; 
Fowler, 2011) since deleterious health consequences have long been attributed to frequent episodes 
of hypo- and hyperglycaemia (Gerich, 1993).  Interestingly, oscillating glucose levels are more 
detrimental to the maintenance of health than consistent elevated fasting or daily mean levels of 
glucose (Ceriello et al., 2008; Ceriello et al., 2012; Ceriello & Kilpatrick, 2013).  This finding will 
be discussed in more depth in section 2.5.1.   
 
The typical range within which blood glucose fluctuations should and may occur is difficult to define, 
as various minimum and maximum concentrations are proposed by various authors.  A typical healthy 
range has also not been defined by organisations, such as the American Diabetes Association (ADA) 
and the World Health Organization (WHO).  For example, suggested ideal or healthy ranges vary 
from: > 2.2 mmol·L-1 to < 10.0 mmol·L-1 (Ludwig, 2002); 4.0 mmol·L-1 to 9.0 mmol·L-1 (Gerich, 
2000); 4.4 mmol·L-1 to 6.6 mmol·L-1 (Ramasarma & Rafi, 2016); and 4.0 mmol·L-1 to 6.0 mmol·L-1 
(Thomas et al., 2016).  Hypo- and hyperglycaemia are also terms that are widely used, without always 
being defined in absolute terms.  
 
It is generally agreed that blood glucose levels should remain relatively stable, that fluctuations should 
be rare after an overnight fast, and that an average concentration of 5.0 mmol·L-1 in this state is 
deemed “healthy” (Gerich, 2000).  According to two research groups, it was suggested that fasting 
blood glucose should never drop below 2.8 mmol·L-1 (Consoli et al., 1987) or 3.0 mmol·L-1 (Gerich, 
1993), however, there is no consensus on what is considered hypoglycaemia.  In research and clinical 
settings, blood glucose concentrations below concentrations of 3.0 mmol·L-1 to 3.9 mmol·L-1 have 
Stellenbosch University https://scholar.sun.ac.za
 
Page | 12  
 
been labelled either ‘hypoglycaemic’, or the lower threshold for “healthy” fasting glucose.  In other 
words, there is no consensus on what the minimum “healthy” glucose concentration is. 
 
Hypoglycaemia is one of the major concerns for type 1 diabetes (T1DM) patients, as it occurs most 
frequently in this group (Joy et al., 2010) compared to healthy individuals or type 2 diabetics (Lessan 
et al, 2015), unless the latter patients receive intensive drug treatment (SEMDSA, 2017).  Severe and 
prolonged hypoglycaemia should not occur in healthy individuals; it is usually prevented by the 
actions of the physiological control systems and feedback loops that maintain glycaemic homeostasis.   
 
Nirantharakumar et al. (2012) determined the prevalence of hypoglycaemia among non-diabetic in-
patients from the University Hospital Birmingham using different cut-off glucose concentrations, i.e., 
3.3 mmol·L-1; 3.0 mmol·L-1; 2.7 mmol·L-1; 2.5 mmol·L-1; and 2.2 mmol·L-1.  They estimated that 13 
patients per 10 000 hospital admissions younger than 65 years would be considered hypoglycaemic 
with a 2.7 mmol·L-1 cut-off value, and 50 per 10 000 hospital admissions with a 3.3 mmol·L-1 cut-
off value.  Additionally, they discovered that all hypoglycaemic events were accompanied by co-
morbidities namely: sepsis, kidney disease and alcohol-dependence.  As a final comment, the 
researchers concluded that hypoglycaemia, defined as blood glucose levels lower than 2.7 mmol·L-1, 
was very rare in non-diabetics outside of critical care.  According to Gerich (1993), the liver can 
maintain blood glucose levels up to 60 hours of fasting (Gerich, 1993) and prevent significant drops 
in blood glucose during exercise.  Remarkably, Stewart & Fleming (1973) reported no hypoglycaemic 
symptoms in an overweight, 27-year old male patient during a supervised therapeutic fast of 382 days.  
 
A similar issue exists for the definition of hyperglycaemia.  It is more difficult to define, with an 
absolute threshold, what is deemed “healthy”, or what is associated with elevated risk.  Once again, 
many different glucose concentrations have been used to classify postprandial hyperglycaemia.  The 
ADA (2017) has set the upper threshold for ideal fasting glucose at 5.7 mmol·L-1, while 7.8 mmol·L-1 
is set as the pre-diabetes cut-off value after a 2-h OGTT.  The ADA (2017) also contends that the 
peak glucose value in healthy individuals after a meal very rarely exceeds 7.8 mmol·L-1.  
Consequently, a number of researchers consider this value (7.8 mmol·L-1) the maximum postprandial 
glucose concentration in healthy individuals (Acciaroli et al., 2018; Borg et al., 2010; Madhu et al., 
2013; Rodriquez-Segale et al., 2018), although others define hyperglycaemia at a higher limit of 10.0 
mmol·L-1 (Cassidy et al., 2017; MacLeod et al., 2013).  As will be discussed in section 2.5.1, the 
upper threshold is a critical parameter since a higher “glucose spike” after a meal is associated with 
more serious health risks.   
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Insulin reacts to the ingestion of food and the subsequent rising levels of blood glucose to stunt the 
postprandial surge in glucose and to lower the levels in the circulation.  The secretion of insulin should 
match the relative rate of entry of absorbed glucose into the bloodstream.  As glucose levels begin to 
drop due to the actions of insulin, the blood levels of insulin also decrease, following the same pattern 
as glucose (assuming healthy insulin sensitivity).  Blood glucose levels are thus regulated via a typical 
negative feedback loop (Widmaier et al., 2014).   
 
Depending on the content and volume of the meal that was consumed, blood glucose typically reaches 
peak levels between 30 and 90 minutes and should return to basal levels between 120 to 180 minutes 
after a meal (ADA, 2001; Brand-Miller et al., 2009; Gerich, 1993).  It is suggested that postprandial 
glucose levels should not rise by more than 3.0 mmol·L-1 above fasting or basal levels (Tabák et al., 
2012) and should, ideally, only drop to the pre-prandial, fasting or basal concentrations (Jenkins et 
al., 1987; Ludwig, 2002).  The latter is more likely to occur when glucose absorption from the 
intestines and the subsequent rise in blood levels happen over a prolonged period.  In contrast, faster 
absorption rates cause higher postprandial blood glucose peak concentrations, as well as a larger area 
under the curve (AUC) of the total postprandial glucose response (Jenkins et al., 1987).  Thus, the 
higher and quicker blood glucose rises after ingestion of carbohydrates or glucose, the more likely 
blood glucose levels are to “spike” and “over-shoot” typical postprandial glucose concentrations, as 
well as temporarily drop below basal levels in response to the secretion and action of insulin.  Even 
though the latter situation could be seen as a typical response and usually occurs in the absence of 
hypoglycaemic symptoms (Gerich, 1993), it is an unfavourable reaction (Jenkins et al., 1987).  The 
latter view is substantiated by evidence from more recent studies that are discussed in the next section. 
2.3 Development of insulin resistance 
The development of insulin resistance is the main driver for the increasing prevalence of elevated 
fasting glucose concentrations and postprandial hyperglycaemic episodes in an individual (Kahn, 
2003; Templeman et al., 2017).  Thus, the deterioration of glucose control and rising circadian 
glucose levels could be described as the symptomatic manifestation of the development of, and 
progression towards T2DM in the presence of insulin resistance.   
 
Petersen & Shulman (2018) defined insulin resistance as the state during which “higher circulating 
insulin levels are necessary to achieve the integrated glucose-lowering response”, thus describing a 
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condition where the target tissues of insulin are less sensitive to the effects thereof, than what is 
typically expected.  Hyperinsulinaemia is one of the major contributing causative factors leading to 
insulin resistance (Rizza et al., 1985; Schofield & Sutherland, 2012).  The development of insulin 
resistance due to hyperinsulinaemia necessitates for even more insulin to be secreted.  Initially, 
glucose tolerance remains within healthy limits through compensatory increases in the secretion of 
insulin (Corkey et al., 2012).  However, persistent hyperglycaemia and hyperinsulinaemia exacerbate 
each other and systematically deteriorate towards the development of overt disease states.  Pre-
diabetes develops when blood glucose levels rise above healthy concentrations due to the pancreatic 
beta-cells being unable to secrete enough insulin (Tabák et al., 2012).  Further deterioration of beta-
cell function and glucose control eventually leads to T2DM (Defronzo, 2009). 
 
The precise mechanisms behind the development of insulin resistance is still an area of extensive 
research.  Nevertheless, growing evidence suggests that the most likely explanation for deteriorating 
insulin sensitivity of the body’s tissues is as a result of the body’s reaction to over-nutrition (Caputo 
et al., 2017), which can at least partly be attributed to improper nutrition (Ludwig & Ebbeling, 2018).  
Caputo et al. (2017) argues that over-nutrition has the ability to stimulate the vicious cycle of 
hyperinsulinaemia-insulin resistance. 
 
The liver and skeletal muscles are the organs most involved in the development of insulin resistance 
and the consequential metabolic effects thereof (DeFronzo, 2009).  White adipose tissue (WAT) 
insulin resistance has more recently been appreciated as an important role player in the 
pathophysiology of whole-body insulin resistance and related low-grade chronic inflammation 
(Caputo et al., 2017; Petersen & Schulman, 2018; Shimobayashi et al., 2018).  Although glucose 
control processes are indeed integrated, the consequences of insulin resistance are tissue-specific 
(Petersen & Schulman, 2018).  
 
Insulin resistance of the skeletal muscles leads to a decrease in insulin-dependent glucose uptake from 
the circulation (DeFronzo, 2009; Tabák et al., 2012).  As skeletal muscles are a large depot for 
postprandial glucose disposal, their insulin sensitivity is therefore important for the maintenance of 
healthy glucose tolerance.  Accordingly, whole-body glucose turnover is largely dependent on 
skeletal muscle insulin sensitivity (Petersen & Schulman, 2018).  Hyperinsulinaemia influences the 
insulin receptors of the skeletal muscle cells by altering the number of receptors, lowering their 
affinity for insulin and impairing signal transduction (Schofield & Sutherland, 2012).  Hence, with 
the development of insulin resistance, GLUT4 translocation to the plasma membrane of muscle cells 
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is impaired so that glucose uptake decreases, and total body glucose uptake lowers as a result (Tabák 
et al., 2012).  When insulin resistance is not yet too severe, however, compensatory 
hyperinsulinaemia helps to preserve glucose transport so that healthy glucose tolerance levels are 
initially maintained (Peterson & Schulman, 2018).  Impaired glucose tolerance develops when beta-
cell dysfunction becomes evident, in addition to worsening insulin resistance (Schofield & 
Sutherland, 2012; Tabák et al., 2012).  Consequently, postprandial glucose levels elevate as a result 
(Nathan et al., 2007).  The development and progression of T2DM is especially related to postprandial 
hyperglycaemia (DiNicolantonio et al., 2015), which adds to the vicious cycle.   
 
The liver plays a very crucial and central role in the metabolic homeostasis of blood glucose levels 
and the progressing nature of insulin resistance towards T2DM (Caputo et al., 2017).  When insulin 
action becomes less potent to suppress hepatic glucose production, hepatic insulin resistance ensues.  
Otherwise stated, the postprandial switch from net hepatic glucose production to net glucose uptake 
is less pronounced so that gluconeogenic rates in insulin-resistant livers are increased (Petersen & 
Schulman, 2018).  Insulin-resistant skeletal muscle and WAT are largely involved in the development 
and progression of hepatic insulin resistance.  
 
Insulin-resistant extrahepatic tissues cause an increased flux of substrates (i.e., glucose, glycerol, and 
free fatty acids) to the liver (Caputo et al., 2017; Samuel & Shulman, 2016) and the uptake of these 
substrates by the liver is independent of insulin (Peterson & Schulman, 2018).  This increased flux of 
substrates results in a series of effects.  Firstly, an increased substrate flux to the liver results in 
upregulation of gluconeogenesis and lipogenesis (Samuel & Shulman, 2016). Increased hepatic fat 
production, or de novo lipogenesis, together with increases in free fatty acid delivery to the liver, 
contribute to high liver fat content and hepatic insulin resistance (Corkey et al., 2012; Samuel & 
Shulman, 2016; Schofield & Sutherland, 2012), hepatosteatosis (Caputo et al., 2017) and over time, 
non-alcoholic fatty liver disease (Samuel & Shulman, 2016).  De novo lipogenesis is especially 
upregulated by excessive glucose and fructose delivery to the liver (Caputo et al., 2017; Samuel & 
Shulman, 2016; Sevastianova et al., 2012).  Insulin potentiates de novo lipogenesis (Samuel & 
Shulman, 2016) which is, paradoxically, not diminished in the case of hepatic insulin resistance 
(Caputo et al., 2017; Petersen & Schulman, 2018).  The only present explanation of this paradoxical 
phenomenon, is that the increase in both de novo lipogenesis and liver fat content are due to the 
increased substrate delivery to the liver (which strongly associates with hepatic insulin resistance) in 
the case of chronic over-nutrition and extrahepatic insulin resistance (Caputo et al., 2017; Petersen & 
Schulman, 2018).  Over time, increases in liver fat content gives rise to the onset of chronic liver 
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inflammation, which is associated with tissue remodelling and fibrosis present in non-alcoholic 
steatohepatitis (Caputo et al., 2017).  
 
Insulin resistance of the liver also has extrahepatic effects, namely increases in circulatory levels of 
glucose and lipids.  In fact, a marker of an insulin-resistant liver is high fasting plasma glucose levels 
(Nathan et al., 2007; Tabák et al., 2012).  Insulin also regulates glycogen synthase (Petersen & 
Schulman, 2018), so that a decline in glycogen synthesis and storage by an insulin-resistant liver 
results in more glucose release into the circulation (Artese et al., 2019).  The concomitant diminished 
suppression of hepatic glucose production and the subsequent release of glucose into the circulation 
contributes to postprandial hyperglycaemia, in addition to fasted hyperglycaemia (Tabák et al., 2012).   
 
The major consequence of WAT insulin resistance is the failure to adequately suppress lipolysis 
(Artese et al., 2019; Petersen & Schulman, 2018).  The result is an increased release of free fatty acids 
into the circulation and subsequently the increased flux of free fatty acids to the liver (Caputo et al., 
2017).  With adipocyte hypertrophy, there is a decrease in insulin-dependent glucose uptake, 
accumulation of oxidative stress products and development of endoplasmic reticulum dysfunction.  
Remodelling of WAT takes place secondary to chronic over-nutrition and obesity (Caputo et al., 
2017).  Furthermore, insulin resistance of WAT is strongly associated with the increased expression 
and presence of pro-inflammatory macrophages and cytokines in the adipose tissue and subsequent 
chronic, low-grade inflammation (Caputo et al., 2017; Shimobayashi et al., 2018).  This increase in 
systemic inflammation that is being ascribed to originating from insulin-resistant adipose tissue, has 
been proposed to contribute to the decline in whole-body insulin sensitivity (Caputo et al., 2017; 
Schofield & Sutherland, 2012) and a major contributing factor to the metabolic syndrome (Caputo et 
al., 2017).   
2.4 Factors influencing glucose control 
Poorly controlled blood glucose is a hallmark of type 1 and 2 diabetes mellitus (Lakhtakia, 2013). In 
addition to declining whole-body insulin sensitivity, which is the major factor contributing to 
worsening of glucose control, there are other independent factors that also influences the insulin 
response and insulin sensitivity of the body’s tissues, namely: diet, gut microbiota, exercise, and 
cardiorespiratory fitness.  
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2.4.1 Dietary characteristics 
One of the main factors that influences the postprandial blood glucose (and insulin) response is meal 
composition.  
 
Carbohydrates cause the most marked increase in blood glucose levels, although the resultant 
postprandial glucose responses are not the same for all carbohydrate-containing foods.  For this 
reason, Jenkins et al. (1987) first described the concept of the glycaemic index (GI) as a measure 
whereby carbohydrate foods are characterised according to its effect on blood glucose levels (Vrolix 
& Mensink, 2010).  Although the GI of carbohydrates correlates (r = 0.730; p < 0.001) with the peak 
in blood glucose after ingestion (Brand-Miller et al., 2009), the postprandial glucose AUC, however, 
does not purely depend on the type and characteristics of the ingested carbohydrate; it also depends 
on  the amount of carbohydrates consumed.  Therefore, it was suggested that the glycaemic load (GI 
× amount of carbohydrates) should be calculated (Willett et al., 2002; Russell et al., 2016), as 
glycaemic load is the best predictor (r = 0.930; p = 0.022) of postprandial glucose responses (Wolever 
& Bolognesi, 1996). 
 
Refined carbohydrates, sugary foods and potatoes are typical high GI foods, while whole-wheat, high 
dietary fibre foods are usually of lower GI (Willet et al., 2002).  As was already mentioned, the speed 
at which carbohydrates are digested (influenced by the GI of the carbohydrates) and subsequently 
absorbed from the intestines into the blood, is a large determinant of the extent to which blood glucose 
rises (Jenkins et al., 1987).  The rate of absorption also influences the total AUC of the glucose 
response (Jenkins et al., 1987).  It is therefore not surprising that the consumption of habitual diets 
with a low glycaemic load associates (although weakly) (β = 0.003; p = 0.034) with lower levels of 
HbA1c in T2DM Latino adults (Wang et al., 2015). 
 
The importance of postprandial blood glucose responses, even in healthy individuals, is underwritten 
by the “Carbohydrate-Insulin Model of Obesity” (CIMO) (Ludwig & Ebbeling, 2018).  This model 
proposes that chronic over-nutrition leads to the development of insulin resistance (Caputo et al., 
2017).  According to the CIMO, the relative hypoglycaemia that is extremely prevalent after the 
ingestion of high GI meals further stimulates hunger and successive food intake (Ludwig & Ebbeling 
2018; Ludwig 2002).  The incremental rise in blood glucose in response to high GI carbohydrate 
foods stimulates a greater secretion of insulin and suppression of glucagon compared to the response 
following a low GI meal.  This elicits a more exaggerated postprandial anabolic response with the 
effects of the high insulin-glucagon ratio persisting after GI nutrient absorption has ceased. The result 
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is a drop in blood glucose levels into the range of relative hypoglycaemia (below typical fasting 
levels).  This hypoglycaemia triggers persistent hunger and food intake (Campfield et al., 1996; 
Friedman & Granneman, 1983), and reportedly, with a preference for more high GI or sugary foods 
(Rodin et al., 1985).  Thus, a cycle of increased (high GI) food intake, hyperglycaemia and 
hyperinsulinaemia, followed by hypoglycaemia ensues (Ludwig, 2002).  In other words, it could be 
suggested that excessive intakes of high GI foods can lead to higher glycaemic variability.  
 
The results of a study by Ebbeling et al. (2020) support the CIMO.  Ebbeling et al. (2020) found that 
energy expenditure increases with low- compared to high-carbohydrate diets.  After at least 10% body 
weight loss during participation in the Framingham State Food Study (Shimy et al., 2020), 164 
participants were randomised to consume one of three diets with either 60%, 40% or 20% of energy 
from carbohydrates and 20%, 40% or 60% of energy from fats.  All three diets comprised 20% of 
energy from proteins and continued for 20 weeks.  Energy intake was controlled individually to 
ensure weight maintenance.  This study revealed that energy requirements decreased as the 
percentage of carbohydrates increased.  These findings support the rationality that greater amounts 
of ingested carbohydrates hinder the utilisation of energy, by promoting energy storage.  The 
mechanism for the latter relates to the higher levels of insulin that accompany consumption of 
carbohydrates. Therefore, insulin is also referred to as the “fat-storing” hormone (Fung, 2018).   
 
In theory, GI and/or glycaemic load should be ideal to establish which carbohydrate elicit more 
favourable postprandial glucose responses.  However, there are additional meal components that 
influence, or effectively change, the GI and postprandial glucose response of mixed meals.  For 
example, adding protein or fats to a meal usually (Venn & Green, 2007), but not always (Wolever & 
Bolognesi, 1996) lowers the effective GI of the meal.  Fats tend to slow gastric emptying and 
subsequently slow the rate of absorption of ingested food, thus contributing to a lower postprandial 
glucose peak.  The addition of protein to a meal also has the potential to lower the postprandial 
glucose response, although this is achieved through an increase of insulin secretion (Jenkins et al., 
1981; Linn et al., 2000; Linn et al., 1996).  Certain essential and non-essential amino acids, such as 
arginine, leucine, isoleucine, alanine and phenylalanine, act as glucose-independent stimuli for 
insulin secretion (Russell et al., 2016).  Interestingly, there is evidence that vinegar added to a high 
GI meal may also lower the postprandial glucose response (Russell et al., 2016). 
 
As shown by Vrolix & Mensink (2010), GI cannot be used to accurately predict the incremental blood 
glucose AUC of a healthy individual, as significant variation exists between individuals in response 
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to the same GI carbohydrates.  Otherwise stated, the postprandial glucose of a healthy individual is 
not fully accounted for by the GI and glycaemic load of the food that was ingested.  This notion is 
supported by Hopper et al. (2013), who found that high glycaemic load meals correlated significantly 
with blood glucose concentrations at two hours after an OGTT in young adults, however, this 
relationship weakened with medium and low glycaemic load meals.  Their data also revealed that 
postprandial glucose levels varied significantly among participants, as it is also dependent on the 
degree of insulin sensitivity of individuals. 
 
To fully evaluate the effect of diet on glucose control, it is necessary to look at the long-term effects 
of diets or dietary constituents as well, and not only the immediate postprandial effect of certain foods. 
 
Seidelmann et al. (2018) conducted a prospective cohort study over 25 years, which they included in 
a subsequent meta-analysis to investigate the association between carbohydrate intake and all-cause 
mortality in adults of all ages and from various countries.  The meta-analysis revealed high (> 70% 
of energy) and low (< 40%) intakes of carbohydrates were associated with increased mortality (hazard 
ratios of 1.20 and 1.23, respectively), while a diet comprising of ~ 50% energy from carbohydrates, 
was associated with the lowest mortality.  The authors noted that it is important to consider either 
which macronutrients replace carbohydrates when lowering carbohydrate intake, or which 
macronutrients are replaced by carbohydrate foods when increasing carbohydrate intake, as well as 
the sources of these foods.  Although associations between carbohydrate intake and mortality were 
found, it cannot be said with certainty what percentage of carbohydrate intake holds the highest 
mortality risk.  Results from studies included in the meta-analysis were not consistent and there were 
also significant trends of increased risk with other lifestyle factors, such as smoking and low physical 
activity.  The inclusion of the number of different types of carbohydrates in a specific diet was also 
not accounted for in the meta-analysis.  If it is true that individuals react differently to identical foods, 
it cannot be expected that large cohort studies on total carbohydrate intake can provide conclusive 
evidence that are generalizable.   
 
It is suggested that lower GI diets decrease the risk for the development of T2DM (Willet et al., 2002) 
and diets high in sugar are implicated in the aetiology of coronary heart disease, insulin resistance 
and subsequent impaired glucose tolerance (DiNicolantonio et al., 2016).  A meta-analysis by Ajala 
et al. (2013) reviewed numerous randomised controlled trials on the effects of dietary interventions 
lasting at least six months in adults older than 18 years.  They found that the best diets for improving 
cardiovascular risk factors and glucose control, as measured by HbA1c, were the low-carbohydrate 
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(20 g – 120 g carbohydrates per day, or 13% - 45% of energy intake from carbohydrates), low GI, 
Mediterranean and high-protein diets.  This study’s main finding was that modifying the 
macronutrient composition of various diets was effective in improving glucose control in people 
diagnosed with T2DM.  Ajala et al. (2013) concluded that all diets where the intake of carbohydrates 
or glycaemic load are limited, had beneficial effects on glucose control, weight management and 
CVD risk in T2DM patients.  Similarly, and in another systematic review and meta-analysis, Meng 
et al. (2017) reported that HbA1c levels are positively affected by low-carbohydrate diets in 
comparison to normal- or high-carbohydrate diets in T2DM patients. 
 
Tay et al. (2018) conducted a randomised controlled trial over a period of two years in type 2 
diabetics.  Both dietary intervention groups participated in supervised exercise sessions. They found 
that an energy-restricted, low-carbohydrate (14% of energy), high unsaturated fat (58% of energy) 
diet was equally effective to lower weight and HbA1c, than an isocaloric high-carbohydrate (53% of 
energy), low-fat (< 30% of energy) diet.  However, the low-carbohydrate diet was superior in 
sustaining greater reductions in diabetic medications.  The blood lipoprotein profile and diurnal 
glucose stability (glycaemic variability) were also more favourably affected by the low-carbohydrate 
diet.   
 
The diets and metabolic disease risk of more than 13 000 Koreans were analysed by Lee et al. (2018).  
Significant associations were found between the intake of carbohydrates, higher levels of triglycerides 
and lower levels of high-density lipoprotein cholesterol (HDL-cholesterol).  This finding is consistent 
with many other studies (Dashti et al., 2006; Hussain et al., 2012; Meng et al., 2017; Santos et al., 
2012; Tay et al., 2014).  Furthermore. elevated blood triglycerides, together with low [HDL-C] are 
associated with insulin resistance and a higher risk for CVD (Da Luz et al., 2008; Ferrannini et al., 
2007; Ormazabal et al., 2018). 
 
The beneficial effects of lowering dietary carbohydrates are not limited to T2DM patients.  Stentz et 
al. (2016) studied obese men and women with pre-diabetes, who were randomised into two groups.  
One group followed a high-protein diet (30% protein, 30% fat, 40% carbohydrate) and the other a 
high-carbohydrate diet (15% protein, 30% fat, 55% carbohydrate).  All the participants (n = 12) on 
the high-protein diet experienced remission of their pre-diabetes, while two-thirds (8 of the 12 
participants) in the high-carbohydrate group remained pre-diabetic.  With the amount of fat 
controlled, the results of this study suggest that replacing carbohydrates for protein improves glucose 
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tolerance as measured by the OGTT.  In fact, the high-protein group also presented with a large 
improvement in insulin sensitivity.  
 
2.4.2 Carbohydrate sensitivity and the gut microbiome 
Two independent studies conducted by Zeevi et al. (2015) and Thomas et al. (2016) (both discussed 
in more detail under “Continuous glucose monitoring and glycaemic variability”) mentioned that it 
could be deducted from their results that the response to carbohydrate foods is an individualised 
phenomenon, with factors besides insulin sensitivity playing a role.  Zeevi et al. (2015) specifically 
commented that individuals with similar glucose tolerance may have varying sensitivity to 
carbohydrates and subsequent diverse glucose responses to mixed meals.  This perspective is 
supported by emerging evidence that the gut microbiota plays a definitive role in the blood glucose 
response to ingested food.  
 
There is evidence that links obesity and diabetes mellitus, as well as low-grade inflammation to 
particularities of the gut microbiome (Cox et al., 2015; Festi et al., 2014; Greiner & Bäckhed, 2011; 
Van Olden et al., 2015).  The intestinal bacteria are highly involved in a number of physiological 
processes and regulatory systems (Van Olden et al., 2015), among which are their involvement in the 
extraction of energy from ingested foods (Cox et al., 2015; Zhang et al., 2013).  There is also a 
definitive role of the gut microbiota in glucose tolerance as seen in a study done by Suez et al. (2014).  
They found that the consumption of non-nutritive artificial sweeteners induced a worsening of 
glucose tolerance in relation to alterations of the gut microbiota.  It seems that the composition and 
diversity of the gut microbiota, which is influenced by diet (Festi et al., 2014), genetic make-up and 
immune status (Greiner & Bäckhed, 2011), directly affect metabolic processing,  energy balance and, 
ultimately, metabolic health (Van Olden et al., 2015).  Numerous studies (reviewed by Cox et al. 
(2015) and Gentile and Weir (2018)) found that the intestinal microbiota is altered when habitual diet 
is changed, whether it be changes in macronutrient composition or a pronounced shift between the 
intake of plant or animal products.  Thus, it seems that levels of low-grade inflammation, insulin 
sensitivity and postprandial metabolism of glucose and lipids are significantly affected by changes in 
the gut microbiome (Van Olden et al., 2015).  
 
The concentration of insulin after 30 minutes into a standard OGTT is used to distinguish between 
people who have a high or low insulin response to carbohydrates (Ludwig & Ebbeling, 2018).  After 
ingestion of glucose (or any meal), the initial signal for insulin secretion by the pancreatic beta-cells 
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is mediated by the incretin hormones (Drucker, 2007).  In other words, insulin secretion has been 
signalled even before blood glucose concentration increases significantly.  This first-phase insulin 
secretion is signalled rapidly and is generally used to determine beta-cell function.  It can also be 
determined by the amount of insulin that is secreted in the first 10 minutes of a hyperglycaemic clamp 
(Stumvoll et al., 2000).  The incretin hormones, therefore, play a crucial role in controlling the 
excursion in blood glucose in response to the consumption of glucose in any form (Drucker, 2007).  
 
It can be argued that the incretin effect, considered together with the role of the gut microbiome in 
glucose tolerance, provides evidence that the extent of postprandial glucose excursions is not solely 
determined by insulin sensitivity.  If healthy individuals, with the same insulin sensitivity, have 
differing incretin effects in response to carbohydrate-rich foods (Blaak et al., 2012), it could explain 
the phenomenon of glucose tolerant individuals with varying responses to identical meals, as 
described by Zeevi et al. (2015).  Although more evidence is needed, it could provide a preliminary 
explanation as to why free-living postprandial glucose excursions cannot be adequately predicted by 
the results of an OGTT.  Furthermore, although not yet described, this explanation could also provide 
differential definitions for insulin sensitivity and carbohydrate sensitivity.   
2.4.3 The role of exercise and cardiorespiratory fitness in glucose control 
Exercise is widely considered important in the prevention and treatment of T2DM.  Different types 
of physical activity and exercise have beneficial effects on both insulin resistance and glucose control 
(Roberts et al., 2013).  Lower levels of cardiorespiratory fitness (CRF) are also associated with an 
increase in the number of cardiometabolic disease risk factors (Grundy et al., 2012).  It is generally 
accepted that exercise is needed and beneficial for glucose control, but research is ongoing to 
determine how, when and what exercise should be implemented to be most effective in the 
improvement of glucose control.  What type of exercise should be emphasised?  At what intensity 
should one exercise, for how long and how frequently?  What time of day is most effective to 
exercise?  In an attempt to bring light to these questions, researchers have measured different aspects 
of glucose control, in combination with different exercise strategies.   
 
HbA1c has consistently been found to decrease with long-term exercise and improvements in CRF.  
Meta-analyses have been done that showed HbA1c improves when T2DM patients participate in 
various types of exercise interventions that lasted at least six weeks to several months.  One such 
meta-analysis (Snowling & Hopkins, 2006) summarized the effects of exercise interventions that 
lasted for at least 12 weeks, on glucose control and insulin sensitivity.  They found that small 
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improvements in HbA1c are elicited by aerobic, resistance and combination exercise.  Slightly larger, 
(i.e. small to moderate improvements) were evident for fasting plasma glucose, 2-h [glucose] and 
insulin sensitivity.  Resistance and all modes of aerobic exercise seemed to effectively improve all 
health outcomes, although there is a possible small benefit to combining aerobic and resistance 
exercise.  Another meta-analysis and systematic review was done by Grace et al. (2017) which 
confirmed that aerobic exercise interventions of at least six weeks are effective in reducing HbA1c 
and insulin resistance in T2DM patients.  These improvements were concomitant with increases in 
CRF.  In a cross-sectional study of obese individuals with and without T2DM (HbA1c < 9%), Moxley 
et al. (2018) reported that cardiorespiratory fitness was significantly related to HbA1c.  Additionally, 
HbA1c explained 19% of the variance in peak oxygen uptake (VO2peak) and this relationship was 
independent of insulin sensitivity.   
 
Liu et al. (2019) did a meta-analysis to investigate the effect of ~ three months of high-intensity 
interval training (HIIT) (at least three sessions per week) in T2DM individuals.  In general, HIIT 
interventions improved HbA1c, fasting insulin and glucose, as well as VO2peak.  HIIT was superior to 
moderate-intensity continuous aerobic exercise when comparing the improvements in HbA1c and 
CRF.  However, the two training interventions were equally effective in lowering fasting insulin and 
glucose.   
 
It is understandable that higher intensities of exercise may bring about additional glucose control 
benefits, since glucose utilisation (and thus the rate of glucose uptake from the blood) by working 
skeletal muscles is greatly increased during exercise.  Sylow et al. (2017) confirmed that the uptake 
of glucose by working skeletal muscles increases as the duration and intensity of exercise increases, 
thus explaining the superior results obtained with high intensity exercise.  
 
Hopper et al. (2013) reported that the 2-h OGTT glucose concentration of young adults correlated 
significantly with their self-reported fitness levels (r = 0.485; p = 0.028). These results may also mean 
that a person’s level of physical activity (i.e. low to high), in addition to objectively determined 
aerobic fitness, are positively related to glucose tolerance.  These findings are in agreement with the 
results of the meta-analysis by Snowling and Hopkins (2006), as well as Solomon et al. (2015). In 
the latter cross-sectional study that included healthy and T2DM participants, there was a moderately 
strong association between CRF and glucose tolerance (r = -0.325; p < 0.0001).  They also reported 
associations between CRF and HbA1c (r = -0.333; p < 0.001), fasting plasma glucose (r = -0.336; p < 
0.001), and insulin sensitivity (r = 0.734; p < 0.001).   
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In a cross-sectional study on T2DM patients, Jelleyman et al. (2017) found that  physical activity (of 
any duration or intensity; as measured by accelerometers over seven days) was not related to fasting 
glucose.  However, longer durations and intensity of physical activity was associated with lower 2-h 
glucose and improvements in insulin sensitivity.  
 
In a study similar to that of Jelleyman et al. (2017), Sardinha et al. (2017) used accelerometers to 
investigate the role sedentary time and breaks in sedentary time in glucose control in 66 adults with 
T2DM.  Breaks in sedentary time were defined as a period of more than one minute of physical 
activity.  Increased sedentary time was  associated with detrimental changes in all glucose control 
measures (HbA1c, fasting- and 2-h glucose) and insulin resistance (HOMA-IR and Matsuda index), 
while higher number and duration of breaks in sedentary time were associated with improved glucose 
control measures and insulin resistance.  When adjusted for time spent in moderate to vigorous 
physical activity, total sedentary time was associated with increases in fasting glucose (β = 0.32; p = 
0.037) and breaks in sedentary time were associated with decreases in HOMA-IR (β = -0.28; p = 
0.047) and fasting glucose (β = -0.25; p = 0.046).  When adjusted for CRF, total sedentary time 
remained associated with increases in HbA1c (β = 0.25; p = 0.044) and breaks in sedentary time 
remained associated with HOMA-IR (β = -0.25; p = 0.036), the Matsuda index (β = 0.26; p = 0.036), 
and fasting glucose (β = -0.22; p = 0.038). 
 
Duvivier et al. (2017) also reported that limiting sedentary time leads to lower 24-h glucose AUC and 
improves insulin sensitivity in T2DM patients.  They also speculated that insulin sensitivity may 
actually be more improved by the reduction in sedentary time through low intensity physical activity, 
rather than incorporating an acute exercise session during the day but not minimizing sedentary time. 
 
Continuous glucose monitoring has enabled researchers to gain more insight on the role of exercise 
in glucose control.  MacLeod et al. (2013) conducted a meta-analysis on the role of short-term (< 2 
weeks) exercise interventions on the glucose levels of T2DM participants.  The eight studies that 
were included in the analysis mostly involved a single exercise session, mostly cycling exercise and 
post-CGM was started either directly after the bout of exercise or measured during the day on which 
exercise was performed.  The analysis revealed that acute exercise had no effect on fasting glucose 
levels or time spent at hypoglycaemic glucose concentrations.  However, average 24-hour glucose 
and time spent above glucose concentrations of 10.0 mmol·L-1 were both lower (average reductions 
of 0.8 mmol·L-1 and 129 minutes per day, respectively) after a bout of exercise. 
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Borror et al. (2018) did a systematic review assessing the effect of different types of postprandial 
exercise on glucose levels in T2DM participants.  Only randomised controlled trials were included 
and only if exercise was performed within three hours of a standardised meal.  Study outcomes 
focussed on postprandial glucose AUC and 24-h glucose measures. The authors concluded that 
T2DM patients should ideally undertake moderate intensity aerobic exercise one hour after a meal.  
This type and timing of exercise was found to be safe and the most effective to minimise postprandial 
glucose levels.  They also pointed out that not enough studies have been done on HIIT that was 
properly matched to moderate intensity continuous aerobic training.  Studies on resistance exercise 
were also too few to make definitive conclusions, although it may be effective.  Exercise is not only 
important for already diagnosed diabetic patients.  Shambrook et al. (2018) reported positive and 
immediate effects on the glucose responses of inactive men after exercising 30 minutes after a meal 
and at any intensity. 
 
An important observation by Moore et al. (2020) was that the acute benefits of exercise on glucose 
responses seems to be independent of CRF.  They found that postprandial stair climbing was equally 
effective in lowering postprandial glucose excursions in non-diabetic individuals and irrespective of 
fitness level.   
 
In summary, it seems that insulin sensitivity is most consistently improved by any form, intensity and 
duration of physical activity or exercise, in both diabetic and otherwise healthy individuals (Duvivier 
et al., 2017; Grace et al., 2017; Jelleyman et al., 2017; Sardinha et al., Snowling & Hopkins, 2006). 
Changes in insulin sensitivity in response to exercise training also seems to correlate with an 
individual’s aerobic fitness (maximal oxygen uptake, VO2max) (Cancino-Ramírez et al., 2018; 
Solomon et al., 2015). 
 
Furthermore, acute exercise is a moderating factor in the immediate postprandial glucose response 
through the facilitation of enhanced glucose disposal (Ryder et al., 2001; Stanford & Goodyear, 
2014).  Even in healthy individuals, habitual physical activity needs to be sustained to experience the 
postprandial glucose lowering benefits of exercise (Mikus et al.,2012a; Moore et al, 2020).  
Improvements in CRF do, however, also seem to be independently related to improvements in glucose 
control and insulin sensitivity (Liu et al., 2018; Moxley et al., 2018; Sui et al., 2012). 
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2.4.4 Other factors influencing glucose control 
Glucose control and glucose tolerance have also been related to other factors.  For instance, obesity 
(as defined by BMI and waist circumference), together with a family history of T2DM, are strong 
predictors of  declining glucose tolerance in non-diabetic individuals (Walker et al., 2005).  Brunner 
et al. (2006) also found that impaired glucose tolerance is associated with the degree of obesity, higher 
systolic blood pressure, and poorer lung function.  The comorbidities of declining glucose control 
could possibly be described as mutual effects that occur due to the same root cause (i.e., 
hyperinsulinaemia), rather than necessarily being contributing factors (Crofts et al., 2015).  For 
example, does insulin resistance cause or precede obesity, and vice versa, or are insulin resistance 
and obesity both caused by hyperinsulinaemia?   
 
Advancing age is widely associated with insulin resistance and declining glucose control (Brunner et 
al., 2006; Ko et al., 2006; Shimokata et al., 1991, Zeevi, et al., 2015), but the risks can be mitigated 
when individuals stay healthy and physically active (Rosenthal et al., 1982).  Age could thus be 
considered an overlapping or mediating factor in the development of insulin resistance which leads 
to a decline in glucose control and ultimately disease (Facchini et al., 2001).  
 
Although the influences of aging, obesity, a family history of T2DM, hypertension and poor lung 
function on glucose control are acknowledged, they will not be discussed in depth as these factors are 
beyond the scope of this thesis.  
2.5 Consequences of insulin resistance 
Primary hyperinsulinaemia that occurs secondary to postprandial hyperglycaemia can, over time, lead 
to chronic over-nutrition and the subsequent development of insulin resistance (Ludwig & Ebbeling, 
2018).  Type 2 Diabetes Mellitus has long been associated with increased morbidity and mortality, 
mainly due to CVD (McGurnaghan et al., 2019), however, being pre-diabetic or having impaired 
glucose tolerance already increases one’s risk for CVD (Ceriello & Motz, 2004; Haffner et al., 1990).  
Clear associations exist between high levels of fasting insulin in pre-diabetic individuals and 
atherogenic CVD risk factors (Haffner et al., 1990) and BMI (Hopper et al., 2012; Odegaard & 
Chawla, 2013).  Likewise, hyperinsulinaemia and insulin resistance stand central in the 
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The presence and degree of insulin resistance is a good predictor of age-related diseases, including 
hypertension, coronary artery disease, stroke, certain cancers and T2DM.  In fact, it was proposed 
that the absence of insulin resistance completely negates the risk for age-related disease events 
(Facchini et al., 2001). 
 
Insulin resistance is a central characteristic of the metabolic syndrome (DeBoer, 2019).  The 
metabolic syndrome is a clustering of risk factors that are strongly predictive of future CVD (DeBoer, 
2019; McCracken et al., 2018), as it accelerates the atherogenic process due to it being a pro-
inflammatory, pro-atherogenic and pro-thrombotic state (McCracken et al., 2018).  Metabolic 
syndrome also increases the risk for the development of T2DM (DeBoer, 2019; Esser et al., 2014; 
Nolan & Prentki, 2019).  Insulin resistance is not necessarily the principle causative factor leading to 
the development of other risk factors that collectively define the metabolic syndrome.  Rather, insulin 
resistance is another consequence of a common underlying cause (hyperinsulinaemia) that also leads 
to the collective manifestation of central obesity, hypertension, elevated fasted levels of triglycerides, 
decreased HDL-C and increased fasting glucose (Nolan & Prentki, 2019; Reaven, 1988).  Nolan and 
Prentki (2019) identified hyperinsulinaemia, in combination with chronic over-nutrition, as the 
common precursor of the clustering of symptoms seen in the metabolic syndrome.  Inflammation 
plays a large pathological role in the development of insulin resistance and is independently 
associated with CVD risk associated with the metabolic syndrome (Esser et al., 2014).   
 
Chronic, low-grade systemic inflammation is well recognised as the key pathological factor of most, 
if not all chronic diseases, atherosclerosis, and CVD.  Previously, high serum cholesterol levels were 
incorrectly labelled as the cause of atherosclerosis and subsequent disease (Tsoupras et al., 2018).  
However, today it is recognised that atherosclerosis, which leads to CVD, is a chronic inflammatory 
disease (Taleb, 2016; Wu et al., 2017).   
 
Hypertrophied, insulin-resistant adipose tissue is believed to be the major origin of low-grade 
systemic inflammation (Asghar & Sheikh, 2017; McCracken et al., 2018; Shimobayashi, et al., 2018).  
Hyperinsulinaemia contributes to an increase in low-grade systemic inflammation, together with 
numerous other related factors.  These factors include hyperglycaemia, excessive nutrient entry into 
cells (Nolan & Prentki, 2019) and increases in levels of oxidative stress (Tsoupras et al., 2018).  
Oxidative stress occurs due to an overload of the electron transport chain, subsequent mitochondrial 
dysfunction (Nolan & Prentki, 2019) and accumulation of advanced glycation end products (Wu et 
al., 2017) via increased glucose flux into glucose-metabolising tissues.  
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Sustained inflammation also contributes to endothelial dysfunction, which is strongly associated with 
atherosclerosis and CVD (Tsoupras et al., 2018).  Chronic oxidative stress is also a strong predictor 
of atherosclerosis (Wu et al., 2017).  Hyperglycaemia and oxidative stress are strongly implicated in 
the oxidation of low-density lipoprotein cholesterol (LDL-C) molecules (Wu et al., 2017), which 
plays a significant role in endothelial dysfunction and atherosclerosis (Taleb et al., 2016; Wu et al., 
2017).  Moreover, insulin resistance and hyperinsulinaemia are also strongly implicated in the 
development of endothelial dysfunction, atherosclerosis, and CVD (Ormazabal et al., 2018).   
 
If insulin resistance persists and progresses without intervention (i.e. lifestyle modification), 
metabolic syndrome, pre-diabetes and T2DM are the eventual fate (Esser et al., 2014; Tabák et al., 
2012).  With the amount of diabetic complications that occur due to the resultant hyperglycaemia 
(Fowler, 2011), the hallmark of diabetes, in addition to an even greater risk for CVD, the development 
of this overt disease state is, of course, not ideal. 
2.5.1 Consequences of hyperglycaemia 
In addition to the indirect effects of postprandial hyperglycaemia, namely the development of insulin 
resistance, obesity and associated conditions, hyperglycaemia itself also has direct negative health 
effects.  Higher than healthy fasting glucose levels, postprandial glucose and HbA1c are independent 
risk factors and predictors of vascular disease and mortality (Tabák et al., 2012). 
 
Several epidemiological studies highlight the importance of well-controlled glucose levels.  The 
Whitehall study (Fuller et al., 1983) and the UK Diabetes prospective study (Baldeweg & Yudkin, 
1999) involved a large number of participants (18 403 men and over 5 000 men and women with 
T2DM, respectively) to assess the outcomes of long-term glucose levels.  From the Whitehall Study 
it was evident that individuals in the highest percentiles of blood glucose (> 5.4 mmol·L-1) 2-h after 
a 50 g glucose tolerance test had significantly higher rates of mortality due to stroke and coronary 
heart disease (Brunner et al., 2006; Fuller et al., 1983).  The UK Diabetes Prospective Study found 
that fewer diabetic complications and risk of complications were attributable to lower levels of fasting 
plasma glucose (Colagiuri et al., 2002) and reductions in HbA1c levels (Manley, 2003).   
 
Overall, the UK Diabetes Prospective Study supports the notion that the lowering of blood glucose 
in T1DM and T2DM patients reduces the incidence of microvascular complications, together with 
decreasing morbidity and mortality, which coincides with chronic conditions related to diabetes 
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(Baldeweg & Yudkin, 1999).  Cavalot et al. (2011) investigated the role of glycaemic control 
parameters (fasting blood glucose, HbA1c, and blood [glucose] 2-h after meals) in all-cause mortality 
and cardiovascular events and concluded that in addition to utilising HbA1c, postprandial glucose 
levels also associate strongly with mortality and cardiovascular events.  Another observational study 
in more than 15 000 non-diabetic individuals also reported that the 2-h postprandial [glucose] adds 
to the ability to predict risk of death due to cardiovascular disease (Lin et al., 2009). 
 
Ceriello and Motz (2004) proposed that to prevent the development of T2DM and CVD, postprandial 
hyperglycaemia should be controlled in order to minimise the production of oxidative stress and the 
subsequent inflammation.  The latter is considered to be involved in the root causes of beta-cell 
dysfunction and the pathogenesis of insulin resistance, T2DM (Akash et al., 2018), atherogenesis 
(Wu et al., 2017) and CVD (via endothelial dysfunction) (Förstermann et al., 2017).  Furthermore, 
hyperglycaemia also provides favourable carcinogenic conditions (Chang & Yang, 2016), implicating 
hyperglycaemia in almost all non-communicable diseases.  
 
A key observation from the literature is that persistent glucose oscillations have more detrimental 
health effects than chronically elevated, but stable glucose concentrations.  Ceriello et al. (2008) 
explored the effects of acute increases in blood glucose in comparison to constantly high glucose 
levels over a period of 24 hours in T2DM patients and healthy controls.  The average glucose 
concentrations were the same for the chronically elevated hyperglycaemia conditions (10.0 mmol·L-1 
and 15.0 mmol·L-1) and oscillation glucose (glucose was kept high every six hours at 15.0 mmol·L-1 
and normalised for the next six hours).  Importantly, the glucose oscillations caused the highest 
increases in oxidative stress and endothelial dysfunction markers in both groups. 
 
Monnier et al. (2006) studied the association between 24-h urinary excretion rates of free 8-iso 
prostaglandin F2⍺ (8-iso-PGF2⍺), a well-recognised marker of oxidative stress, in T2DM patients 
and healthy controls and their two-day CGM-derived mean amplitude of glucose excursions (MAGE) 
(the arithmetic mean of glucose excursions) (Service et al., 1970). MAGE is a measure of intra-day 
glycaemic variability (Monnier et al., 2008).  The T2DM patients exhibited significantly higher 
glucose fluctuations and had a higher production of the oxidative stress marker compared to the 
healthy controls.  MAGE was linearly related to 8-iso-PGF2⍺, with no threshold value.  Furthermore, 
8-iso-PGF2⍺ was not related to measures of long-term glucose control, including HbA1c, fasting 
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Further insight into glycaemic variability is provided by studies from Ceriello et al. (2012) and 
Ceriello et al. (2013).  In both studies, individuals’ recovery from hypoglycaemia was investigated.  
After hypoglycaemia was induced with the use of a clamp, participants (T1DM patients and healthy 
controls) were infused with glucose, either to reach and maintain euglycaemia, or hyperglycaemia for 
two hours, before attaining and maintaining ideal glucose levels for six hours.  Collectively they 
found that the negative effects, namely increased oxidative stress and inflammation, which are 
resultant from hypoglycaemia, are worsened when a period of hyperglycaemia follows a 
hypoglycaemic event.  The effects were seen in both the diabetic, as well as the healthy control 
participants.  
2.6 Measures of glucose control 
Glucose control is traditionally assessed using either one or a combination of the following: fasting 
plasma glucose, HbA1c and the glucose level 2-h after a 75 g oral glucose load (ADA, 2017).  All 
these measures are routinely used to diagnose individuals with either pre-diabetes or overt diabetes 
mellitus, according to certain cut-off criteria for each.  None of these tests can, however, be considered 
the gold standard of glucose control which embodies all facets of glucose homeostasis.  
 
The concept of glycaemic variability as an alternate measure of glucose control, emerged with the 
development and use of CGM in clinical and research settings.  Glycaemic variability is a broad term 
used to describe inter- and intra-day fluctuations in blood glucose levels (Monnier et al., 2008; Suh 
& Kim, 2015).  Glycaemic variability describes more specifically postprandial glucose, as well as the 
differences between peaks and nadirs in glucose levels, compared to the traditional measures of 
glucose control.   
 
It has been suggested that HbA1c is the best indicator of long-term glucose control, whereas the 
measurement of fasting or 2-h OGTT [glucose] is very limited to a specific time-point.  Especially in 
glucose tolerant individuals, fasting or 2-h [glucose] can vary when measurements are repeated and 
thus a single measure may not adequately represent the true, or average values (Kim et al., 2016).   
 
HbA1c is influenced by chronic fasting, as well as postprandial glucose (Roberts et al., 2013), giving 
an indication of the average glucose levels over a period of 2 - 3 months preceding the measurement 
(ADA, 2001).  Concordantly, HbA1c is closely related to mean levels of glucose (r = 0.51; p < 0.001) 
as measured with CGM (Kohnert et al., 2007).  The degree to which postprandial glucose excursions 
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contribute to an individual’s HbA1c, depends on their diabetic status; the relative contribution of 
fasting glucose increases as HbA1c levels rise (Monnier et al., 2003).  For individuals at the upper 
level of healthy HbA1c values, abnormal fasting blood glucose levels are very rare; rather, the increase 
in 2-h OGTT glucose levels seem to be responsible for most of the rise in HbA1c levels, at least 
initially (Woerle et al., 2004).  Individuals who present with similar degrees of glycaemic variability 
may have very different percentages of HbA1c, and vice versa (McDonnell et al., 2005).  Especially 
among individuals without significant decrements in their overall glucose control, HbA1c does not 
adequately account for their glycaemic variability (Suh & Kim, 2015) and is much less indicative of 
short-term glycaemic variability (Kohnert et al., 2007; Roberts et al., 2013; Wang et al., 2012).  Shah 
et al. (2019) also showed that HbA1c cannot predict the variability in glucose levels in a sample of 
healthy persons.  Hanefeld et al., (2014) also proposed that glucose control abnormalities may present 
before a significant rise in HbA1c.   
 
Thus, the greatest limitation in HbA1c measures is its inability to provide information on short-term 
fluctuations, i.e. its magnitude and frequency (ADA, 2001).  Nevertheless, HbA1c is the most useful 
measure to assess overall, long-term glycaemia in T2DM patients as it correlates well with long-term 
complications.  It has, however, little meaning for T1DM patients (ADA, 2001) or apparently healthy 
individuals that may be at risk for future T2DM due to large daily glucose fluctuations, but in the 
absence of high mean levels of blood glucose. 
 
The OGTT is the only diagnostic test that specifically identifies the presence of impaired glucose 
tolerance (Iskandar et al., 2019).  The glucose values at 2-h correlates positively (r = 0.55; p < 0.001) 
with HbA1c levels (Woerle et al., 2004), but there is not perfect concordance between the two 
measures (Iskandar et al., 2019).  Postprandial glucose also does not necessarily correlate with fasting 
glucose levels, especially in non-diabetic individuals.  Only fasting glucose values above a certain 
threshold (5.5 mmol·L-1 to 6.0 mmol·L-1 (Schrot, 2004; Turner, 1998)) are associated with risk, while 
there is no such threshold for postprandial glucose (Blaak et al., 2012; Levitan et al., 2004).  This 
may suggest that postprandial glucose is an earlier indicator of disease risk than fasting glucose.  
Besides, it is well-documented that people with healthy fasting glucose concentrations may have 
impaired glucose tolerance (Bartoli et al., 2011; Woerle et al., 2004).  
 
A high fasting blood glucose level is recognised as a risk factor for CVD (Colagiuri et al., 2002), is 
used as a criterion for the diagnosis of diabetes and pre-diabetes (ADA, 2017) and is useful to identify 
individuals who are at increased risk for T2DM (Tirosh et al., 2005).  Nevertheless, assessing 
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impaired glucose control with an isolated measure of fasting blood glucose will not identify 
individuals who currently present as healthy, but could be at risk due to long-term elevated 
postprandial blood glucose levels.  Fasting blood glucose does not provide adequate information 
about metabolic glucose homeostasis and persistently high fasting glucose also occurs too late in the 
development of T2DM to be utilised as an early risk detector (Bartoli et al., 2011).  
 
Furthermore, the OGTT glucose value at 2-h is probably most relevant to T2DM patients, as this is 
typically when their glucose levels peak after a meal (ADA, 2001).  Healthy individuals, however, 
reach peak glucose levels earlier, i.e. on average after 60-minutes (ADA, 2001).  Measuring 2-h 
[glucose] in healthy individuals may therefore not provide meaningful information when considering 
the clinical importance (as has been discussed) of the actual peak of the postprandial glucose 
response.  
 
Overall, it seems that the measurement of fasting blood glucose alone may be the least specific 
indicator of overall glucose control and it could be deduced that fasting blood glucose is the least 
sensitive in the detection of a deterioration in overall glucose control, at least in the initial phase.  
Concordantly, studies related to glucose control and/or diabetic status, mostly utilises either the 
standard 75 g OGTT (Acciaroli et al.,2018; Hanefeld et al., 2014; Wang et al., 2012), or HbA1c (Shah 
et al., 2019; Zeevi et al., 2015) to classify participants as healthy, pre-diabetic or diabetic.  
 
2.6.1 Continuous glucose monitoring and glycaemic variability 
In diabetic patients, glycaemic variability, in addition to HbA1c, is a known risk factor for 
microvascular complications (Hirsch, 2005) and should be considered a future routine parameter 
when aiming to optimise glucose control (Suh & Kim, 2015). An exercise intervention study on 
T2DM patients by Karstoft et al. (2013) serves as an example of how glycaemic variability measures 
are more sensitive to changes in glucose control than HbA1c and parameters derived from the OGTT.  
After four months of a continuous- or interval walking exercise intervention in T2DM patients, no 
significant changes in fasting glucose, HbA1c, OGTT 2-h glucose, maximum glucose or AUC were 
found. However, significant changes in the average and maximum glucose (as measured by CGM) 
before and after the interval walking intervention were observed.  The authors noted, though, that the 
dissimilar changes in the CGM and OGTT parameters could be the result of a slight delay in the post-
OGTT testing compared with the CGM following the exercise training period. Therefore, the acute 
effects that exercise may have had on glucose control cannot be ignored. 
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The studies by Borg et al. (2010), Hanefeld et al. (2014), and Rodriquez-Segale et al. (2018) add 
further evidence of the disconnect between CGM measures and HbA1c.  They highlighted that it 
cannot be assumed that a person within the healthy ranges of HbA1c will have a completely ideal 
glucose profile, or that they are necessarily safe from potentially harmful glucose excursions.  
Additionally, Madhu et al. (2013) and Wang et al. (2012) provide reasons why the OGTT may also 
not be adequate to predict the risk for future development of T2DM or CVD.  If ideal glucose 
tolerance was the sole factor that predisposed individuals to the harmful effects of postprandial 
glucose excursions or glycaemic variability, the OGTT should have been fully predictive of an 
individual’s CGM profile.  This is not the case.  Bartoli et al. (2011) commented that the OGTT is 
unable to predict future risk in individuals who currently present with normal glucose tolerance.   
 
The two studies by Ceriello and colleagues (2012; 2013) provide valuable insight why increased 
glycaemic variability, specifically, can be regarded an independent risk factor for diabetic 
complications (Hirsch, 2005).  These researchers demonstrated that the oxidative stress and 
inflammation that are caused by hyperglycaemic excursions are greater when a hyperglycaemic 
excursion is followed by hypoglycaemia, compared to normoglycaemia.  Furthermore, it also explains 
why it is potentially important to assess glycaemic variability in apparently healthy individuals.  A 
person with large glycaemic variability may present with the same daily mean glucose value as 
another individual with a more stable glucose profile.  This is because excessive acute 
hyperglycaemia can be “cancelled out”, in terms of mean values, by equally excessive nadirs; an 
important consideration when measuring average glucose or HbA1c. 
 
With the utilisation of CGM in research settings, it was found that study participants with normal 
glucose tolerance present with episodes of postprandial hyperglycaemia in the pre-diabetic range.  
Thomas et al. (2016) recruited 10 sub-elite athletes to investigate their ability to maintain optimal 
levels of blood glucose concentrations together with their typical heightened energy expenditure and 
dietary intake.  The study is limited in terms of sample size, as well as the lack of tests to assess 
glucose tolerance or insulin sensitivity, however, the individuals were all healthy and had good levels 
of fitness (determined by resting heart rate being below 60 beats per minute and 6 or more hours of 
training per week).  The CGM blood glucose profiles of the athletes over a period of 6 days, however, 
showed large interpersonal variation.  Even when the postprandial period of two hours was removed, 
four of the athletes spent over ~ 70% of the time above glucose levels of 6.0 mmol·L-1, which is in 
the range of fasting pre-diabetes concentrations (ADA, 2017).  In fact, three athletes presented with 
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pre-diabetic fasting glucose concentrations.  Although the participants’ diets were not controlled, the 
authors commented on the large difference in sensitivity to carbohydrate foods that was observed 
between the athletes.  
 
Zeevi et al. (2015) developed an algorithm to predict postprandial glucose responses in non-diabetics.  
They integrated numerous factors, namely the gut microbiome, physical activity, habitual diet, 
anthropometrics (height, body mass, waist, and hip circumferences) and blood parameters (HbA1c, 
total cholesterol and HDL-C).  The individuals’ blood glucose responses to identical meals (all 
containing 50 g carbohydrates) could not be predicted by either HbA1c or the glycaemic load of the 
meals.  All the aforementioned factors played a role in the significant inter-individual differences in 
glucose responses to the identical meals.  They also found that it was not the same meal that caused 
the highest glucose response in different individuals.  The data therefore suggest that people have 
individualised sensitivity to carbohydrates.  The effect of adding protein or fats to a meal also differed 
between individuals.  In addition to the observed variation in postprandial glucose responses, the data 
from individual CGM profiles showed that glucose excursions reached levels well above 7.8 
mmol·L-1 on several occasions, and some excursions reached concentrations up to 10.0 mmol·L-1.  
The latter approaches the top range of pre-diabetic post-challenge values and is similar to the glucose 
concentrations that were used in hyperglycaemia experimental studies, for instance Ceriello and 
colleagues (2008).  A glucose concentration of 10.0 mmol·L-1 has previously been used as the targeted 
upper limit in clinical settings for diabetic patients on intensive therapy (Heine et al., 2004; Monnier 
et al., 2008). 
 
A few researchers aimed to assess whether CGM could be used to differentiate between seemingly 
healthy individuals with adequate glucose control and those who show signs of derangements.  For 
instance, Borg et al. (2010) and Rodriquez-Segale et al. (2018) used CGM to investigate the degree 
of glucose control in persons with ideal HbA1c values. Both studies revealed that, in free-living 
conditions, a high percentage (73% and 93%, respectively) of healthy subjects exceeded the OGTT 
pre-diabetes glucose threshold of 7.8 mmol·L-1.  Neither study performed OGTTs, therefore, although 
the participants were healthy according to HbA1c, glucose tolerance was not measured directly.  Diet 
was recorded in both studies, but not statistically controlled for.  Thus, deductions regarding the role 
of diet and glucose tolerance on the prevalence of free-living hyperglycaemia cannot be made from 
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Madhu et al. (2013) questioned whether CGM is more sensitive than the OGTT for early detection 
of T2DM. Participants included individuals ranging from healthy to those diagnosed with T2DM.  
The CGM profiles of the group with healthy glucose tolerance showed many excursions that exceeded 
the pre-diabetic cut-off value.  The degree of glucose control impairment, as assessed by CGM-
derived mean glucose, standard deviation (SD), inter-quartile range (IQR), coefficient of variation 
(CV%), minimum and maximum values and range of glucose, were in line with the  classification of 
the two groups.  Individuals with healthy glucose tolerance and pre-diabetes could be identified as 
higher-risk, based on derangements of their 24-h CGM glucose profiles.  Although Wang et al. (2012) 
used different CGM-derived glycaemic variability indices, namely MAGE, largest amplitude of 
glycaemic excursions (LAGE), mean of daily differences (MODD) and postprandial glucose 
excursion (PPGE), in addition to mean blood glucose and SD of mean blood glucose, their findings 
were similar to that of  Madhu et al. (2013).  Furthermore, they identified 22% of individuals with 
healthy glucose tolerance (n = 53) who had excursions exceeding concentrations as high as 11.1 
mmol·L-1.  In the latter two studies, the participants’ meals were controlled during the CGM period, 
making the findings even more important.  The findings of both studies are in agreement with the 
suggestion that individuals with similar glucose tolerance may have variable sensitivity to 
carbohydrates and subsequent different glucose responses to mixed meals (Zeevi et al., 2015),      
possibly irrespective of insulin sensitivity.   
 
The relevance of the 7.8 mmol·L-1 cut-off value for peak postprandial glucose, additionally to its use 
as the target for the 2-h OGTT value is motivated by the ADA (2001) as follow: “In nondiabetic 
individuals, plasma glucose concentrations peak ~60 minutes after the start of a meal, rarely exceeds 
7.8 mmol·L-1 and return to pre-prandial levels within 2–3 hours.”  This threshold, however, should 
not be suggested as an absolute value distinguishing between “safe” and “risky” postprandial glucose.  
Rather it can be regarded as a descriptive parameter to quantify relative hyperglycaemia exposure, 
since the risk associated with postprandial glucose excursions do not have a threshold value.  
Researchers agree that risk and deleterious effects increase linearly from healthy blood glucose ranges 
(Brunner et al., 2006; Ceriello & Genovese, 2016; Levitan et al., 2004; Monnier et al., 2006). 
 
CGM and glycaemic variability offers a more comprehensive description of all aspects involved in 
glucose control compared to any of the other measures that are routinely used.  The use of fasting 
glucose measurements, on its own, to screen for impairments in blood glucose levels is not adequate.  
There is strong evidence that points to postprandial hyperglycaemia being an independent risk factor, 
as well as the parameter that associates most strongly with CVD and chronic disease risk (Blaak et 
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al., 2012; Ceriello & Genovese, 2016).  Furthermore, irrespective of diabetic status, it is clear that 
postprandial hyperglycaemia has numerous deleterious health effects.  
 
Considering the evidence in favour of the independent importance of postprandial hyperglycaemia 
and glucose fluctuations over HbA1c and fasting blood glucose levels, CGM-derived measures of 
glucose control could perhaps become the preferred method to detect at-risk individuals.  
Additionally, especially considering the findings of Zeevi et al. (2015), who demonstrated the effects 
of specific dietary constituents on the postprandial glucose response of different individuals, CGM 
could possibly highlight potential risk associated with lifestyle, rather than only assessing general 
glucose tolerance with the standard OGTT.  The isolated assessment of postprandial glucose with an 
OGTT will not necessarily provide any information on whether an individual could be at risk of future 
development of insulin resistance, metabolic syndrome or T2DM, because this test does not 
necessarily give an accurate indication of the free-living postprandial glucose responses of the said 
individual. 
 
It can be argued that CGM profiles are not yet adequately described in healthy populations (Acciaroli 
et al., 2018; Shah et al., 2019).  This is especially regarding risk that may be associated with CGM 
profiles and glycaemic variability among healthy individuals.  To my knowledge, there are also not 
yet any large prospective studies that investigated the long-term effects related to different CGM 
profiles.  Why do once-healthy individuals develop insulin resistance and declining glucose 
tolerance?  Differences in the CGM profiles of healthy individuals would not have been evident if 
glucose tolerance were the only factor influencing free-living glucose control.  Lifestyle factors, such 
as dietary characteristics and physical fitness, in relation to CGM profiles should be investigated 
further.  T2DM is after all described, even by the general public, as a lifestyle disease. 
2.7 Conclusion 
From the literature, it seems that the amount and quality of dietary carbohydrates are the strongest 
predictor of the postprandial glucose response.  Regular exercise and CRF are also important in the 
regulation of postprandial rises in blood glucose and for the maintenance of peripheral insulin 
sensitivity.  The postprandial glucose response has, however, been identified as an independent 
individual characteristic among apparently healthy individuals and studies (Thomas et al., 2016; 
Zeevi et al., 2015) utilising CGM have observed that apparently healthy individuals may present with 
increased free-living glycaemic variability.  High postprandial glucose and subsequent relative 
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hypersecretion of insulin are arguably the primary risk factors for the development and progression 
of obesity, insulin resistance and subsequent related diseases.  The questions that  remain are: i) 
whether certain individuals are more likely to develop insulin resistance-related diseases?; ii) whether 
CGM can be used for earlier detection of those at risk ?; and finally, iii) how important is dietary 
composition and CRF, in relation to each other, and for the maintenance of healthy glucose control 
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Chapter 3 Methodology 
3.1 Study Design 
3.1.1 Participants 
The study was cross-sectional in design and convenience sampling was used to recruit volunteers to 
participate in the study.  The participants included staff of Stellenbosch University; thus, institutional 
permission was sought.  Posters (Appendix C) were posted in buildings on campus.  Invitations to 
participate in the study were spread via word of mouth and adverts posted on the Sport Physiology 
Laboratory website and Twitter account, as well as the Department of Sport Science’s Facebook page. 
 
The required sample size was calculated with G*Power 3 (Faul et al., 2009) and based on the results 
of (Moxley et al., 2018).  It was calculated that 28 participants would be sufficient to detect a 
statistically significant difference in insulin sensitivity (with a power of 0.90 and 5% level of 
significance) in men with low to high levels of fitness.  It was therefore decided to recruit a minimum 
of 30 volunteers to make provision for potential dropouts.  
Participants were included if: 
- they were male; 
- they were 30 to 50 years old; 
- they had a body mass index (BMI) between 20 and 35 kg/m2;  
- they were not on a calorie- or a specific carbohydrate-restrictive diet, or had been in the 3-
month period prior to the study; 
- they did not make any significant changes to their diet or dietary patterns in the 3-months 
prior to their inclusion into the study. 
Participants were excluded if: 
- they reported acute illness, chronic disease or any other medical problems during the health 
screening session (Appendix A) that deemed them not suitable to partake in a maximal 
exercise test; 
- they had any diagnosed metabolic condition or disease (e.g. type 1 or type 2 diabetes mellitus, 
[diabetes is a broad term which covers both ‘mellitus’ and ‘insipidus’ – for the purpose of this 
study, the term ‘diabetes’ will refer only to diabetes mellitus] hypo- or hyperthyroidism), or 
were using any chronic medication for any of these conditions; 
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- they had a musculoskeletal injury which would have constrained their performance during the 
maximal exercise test; 
- they reported any skin conditions or hypersensitivity that would have caused skin irritation 
while wearing the glucose monitoring sensor; 
- they were taking aspirin, as the salicylic acid could cause inaccurate continuous glucose 
monitoring (CGM) readings (https://www.myfreestyle.com/freestyle-libre-pro-cgm-system).  
 
Figure 3.1 shows the inclusion of volunteers into the study, reasons for exclusion, and reasons for 
unsuccessful completion of study participation. 
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3.1.2 Procedures 
On their first visit to the Sport Physiology Laboratory, volunteers who showed interest in the study 
underwent a screening session to determine if they qualified according to the stipulated inclusion and 
exclusion criteria. The screening included the completion of a health screening form (Appendix A).  
After an explanation of the details and practical implications of the study, and the volunteer agreed 
to participate in the study, they were asked to sign the informed consent form (Appendix B).   
 
After being included in the study, the rest of the session comprised of the following: 
1. Body composition and anthropometrical measurements. 
2. The participant was fitted with a Freestyle Libre Pro continuous glucose monitoring sensor 
(Abbott Diabetes Care Inc.) which they were asked to wear for two weeks to assess glycaemic 
variability. They were also given an explanation on how to accurately log all food and drink 
intake while wearing the glucose monitor. 
3. Participants completed a running test on the treadmill to measure their maximal aerobic 
exercise capacity. 
4. An appointment was made for a visit to the nearest pathology laboratory for the collection of 
a fasted blood sample for the measurement of fasting plasma glucose, insulin, and glycated 
haemoglobin (HbA1c), and an oral glucose tolerance test (OGTT) and. 
5. The researcher made appointments with each participant to collect their glucose monitoring 
sensor from a location of their choice when their monitoring period was completed. 
3.2 Tests, Measures and Equipment 
3.2.1 Health Screening Questionnaire (Appendix A) 
A modified version of the American College of Sports Medicine (ACSM) Medical Screening 
Questionnaire (Riebe et al., 2016) was used to identify any medical conditions that may have 
warranted the participant’s exclusion from the study.  The ACSM questionnaire is in the public 
domain and was specifically developed for research laboratories such as the Sport Physiology 
Laboratory in the Department of Sport Science. 
3.2.2 Anthropometric measurements  
While participants were barefoot and wearing minimal clothing, their body mass and stature were 
determined.  Stature is defined as the perpendicular distance between the transverse planes of the 
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vertex and the inferior aspects of the feet.  Stature was measured with a sliding stadiometer (Seca, 
Hamburg, Germany) according to the stretch stature method.  The participants were asked to stand 
barefoot on the scale and with their heels together.  The heels, buttocks and upper part of the back 
touched the scale.  The individual’s head was placed in the Frankfort position (Kent, 2006).  This is 
when the orbital (lower edge of the eye socket) and the tragion (the notch superior to the tragus of the 
ear) are horizontally aligned.  The participant was then asked to take a deep breath and the researcher 
then carefully moved the headboard down the vertex and placed it firmly down on the head of the 
participant, compressing the hair as much as possible.  The measurement was taken to the nearest 0.5 
cm.  
 
Body mass was measured using a calibrated electronic scale (UWE BW-150, 1997 model Brisbane, 
Australia) and recorded to the nearest 0.1 kg.  
 
Waist and hip circumferences were also measured.  Waist circumference was taken as the smallest 
circumference between the last rib and the superior iliac crest while the participant was breathing 
quietly.  While the participant was standing with feet together, hip circumference was measured as 
the largest perimeter around the buttocks.  Both circumferences were measured to the nearest 0.5 cm.  
3.2.3 Body composition 
An ImpediMed® SFB7-08L050042 multi frequency body composition analysis device 
(ImpediMed® Limited, Brisbane, Australia) was used to determine the participants’ body fat 
percentages and fat-free masses. Participants were instructed to avoid all forms of exercise and the 
consumption of alcohol 12 hours prior to the measurement, as well as asked to avoid eating two hours 
before the measurements were recorded. They were also required to empty their bladders prior to 
lying down for their measurements and to remove all jewellery and socks.  Participants lay on a plinth 
in a supine position for 10 minutes before the measurement was taken. At the time when the 
measurement was recorded, they were asked to extend their arms by their sides, while resting their 
hands with their palms down and their legs slightly apart. After the anatomical placement areas were 
cleaned with an alcohol swab and allowed to dry, the electrodes were placed on the right hand and 
right foot, at least 5 cm apart. Hand placements were on the wrist between the radial styloid process 
and ulnar styloid process and on the dorsal surface of the hand, 1 cm proximal to the knuckle of the 
middle finger.  Foot placements were located in the ankle joint region between the two malleoli and 
on the dorsal surface of the foot, 1 cm proximal to the metatarsal phalangeal joint of the second toe. 
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3.2.4 Continuous glucose monitoring (CGM) 
Participants were fitted with a FreeStyle Libre Pro glucose monitoring sensor (Abbott Diabetes Care 
Inc.) in the Sport Physiology Laboratory.  The monitor contains a small sensor that is inserted through 
the skin by a small needle.  This sensor stays in place and automatically measures the of the adipose 
tissue interstitial fluid glucose concentration every minute, for up to two weeks.  According to the 
manufacturer the Freestyle Libre Pro is, on average, within 12.3% of the Yellow Springs Instrument 
analyser reference standard.  This was confirmed by Bailey et al. (2015) in which the FreeStyle Libre 
sensor’s glucose results were highly correlated with capillary blood glucose readings (r = 0.95).  The 
accuracy remained throughout the 14 days of wear and readings were not affected by BMI, age, 
clinical site, or HbA1C.  The manufacturers do, however, warn that caution should be exercised when 
identifying hypoglycaemia or when interpreting sensor glucose readings under 3.3 mmol·L-1, as there 
is a slight possibility of false low values.  Bailey et al. (2015) reported that 40% of the low values (< 
3.3 mmol·L-1) in their study were in actual fact above 4.5 mmol·L-1. 
 
The sensors were applied to the participants’ triceps area, as instructed by the manufacturers, and 
participants were requested to take utmost care that it remained fixed until it was removed 2 weeks 
later.  Non-allergenic waterproof plasters were applied over the sensors to prevent them from 
dislodging.  Participants were also supplied with extra plasters.  They were allowed to apply any tape 
that they were comfortable with in order to protect their sensors.  Participants were blinded to their 
live glucose data as the sensor stored all the readings until it was extracted by the researcher using 
the digital reader, which remained in the laboratory.  Sensors that were dislodged within the first 
week (< 7 days) were replaced with a new sensor, so that a minimum of 7 days were recorded for 
each participant.   
 
The data obtained from the glucose monitors was used to determine the following parameters: 
• Mean: the average of all the glucose values (mmol·L-1) over the total glucose monitoring 
period, calculated as the sum of all the glucose values, divided by the total number of values 
(Hill et al., 2011). 
• Standard deviation (SD) (mmol·L-1) around a mean glucose value.  
• Coefficient of variation (CV%): SD normalised by the mean and expressed as percentage 
(Valletta et al., 2014). 
• MAGE (mean amplitude of glycaemic excursions): the mean value of the average height of 
glucose excursions or deviations greater than 1 SD (Hill et al., 2011). 
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• MODD (mean of daily differences): the average of the differences between glucose values on 
the same time of each monitoring day (Hill et al., 2011). 
• Average time per day (minutes) above 6 mmol·L-1 (Thomas et al. 2016; Ceriello et al. 2008) 
and 7.8 mmol·L-1 (Shah et al., 2019; Rodriguez-Segade et al.; Borg et al., 2010) and below 3 
mmol·L-1 (Danne et al., 2017).  
 
MAGE (mmol·L-1) is typically used to assess intra-day variability, whereas MODD (mmol·L-1) 
depicts the inter-day variability for each individual (Monnier et al., 2008; Rodbard, 2009).  A higher 
MAGE value therefore means larger intra-day variability, while a higher MODD value depicts greater 
day-to-day variation.  Values below a MODD of 1 represent similarity in glucose patterns of each 
day analysed (McDonnell et al., 2005). 
 
CV% was used to assess over-all glycaemic variability.  According to Acciaroli et al. (2018) it is a 
powerful statistical measure for this purpose.  The higher the coefficient of variation, the greater the 
level of dispersion around the mean glucose value.   
 
MAGE, MODD, mean glucose and SD around the mean [glucose] were calculated using the 
EasyGV© software developed by Nathan R. Hill (Oxford Centre for Diabetes, Endocrinology and 
Metabolism, Churchill Hospital and Tse Medical Academy, Harris Manchester College, University 
of Oxford, Oxford, United Kingdom) (https://www.phc.ox.ac.uk/research/technology-
outputs/easygv). 
3.2.5 Blood measurements 
Participants went to the nearest pathology laboratory in the morning and after an overnight fast (> 8 
hours). Blood plasma samples were taken for the following tests: 
Glycated haemoglobin (HbA1c) 
HbA1c is a single measure that reflects the average plasma [glucose] of the prior two- to three 
months (WHO, 2006). 6.5% (48 mmol·mol
-1) is considered the cut-off diagnostic value for 
diabetes mellitus (WHO, 2019; SEMDSA, 2017), while 5.7% is considered the lower 
threshold for pre-diabetes (ADA, 2017). 
Fasting plasma glucose (FPG) 
FPG ≥ 5.6 mmol·L-1 is considered a pre-diabetic value (ADA, 2017; SEMDSA, 2017). 
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Fasting insulin  
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using 
the fasted concentrations of glucose and insulin: HOMA-IR = (fasting insulin [μU·L-1] × 
fasting glucose [mmol·L-1])/22.5.  A HOMA-IR score > 1.7 – 2.0 was considered higher than 
a healthy value (Gayoso-Diz et al., 2013). 
Oral Glucose Tolerance Test (OGTT) 
The standard procedure of the OGTT was followed. The test requires participants to drink a 
syrup solution containing 75 g of glucose.  Blood samples were collected before 
consumption of the glucose solution (0 min), as well as at 30 min, 60 min, 90 min and 120 
min post-consumption. Blood samples were analysed at all time points to obtain the plasma 
glucose and insulin concentrations. 
Healthy glucose tolerance is defined as a glucose concentration < 7.8 mmol·L-1 after two 
hours of consuming the glucose solution (ADA, 2017). 
Whole-body insulin sensitivity index was calculated using the area under the glucose and 
insulin curves, as described by Matsuda & DeFronzo (1999) and using the following 
formula: 
𝑀𝑎𝑡𝑠𝑢𝑑𝑎 𝑖𝑛𝑑𝑒𝑥 = 
 
10000
√𝑔0 × 𝑖0 ×
(𝑔0 ∙ 15 + 𝑔30 ∙ 30 + 𝑔60 ∙ 30 + 𝑔90 ∙ 30 + 𝑔120 ∙ 15)
120
×
𝑖0 ∙ 15 + 𝑖30 ∙ 30 + 𝑖60 ∙ 30 + 𝑖90 ∙ 30 + 𝑖120 ∙ 15
120
 
gxtime – glucose concentration after x minutes (mg·dL-1) 
ixtime – insulin concentration after x minutes (mIU·L-1) 
 
Participants were classified as insulin-resistant if they had values < 4.3 (Gutch et al, 2015). 
3.2.6 Vam-éval (VO2peak running exercise test) 
A modified treadmill Vam-éval (Cazorla & Léger, 1993) ramp test was completed by the participants 
to measure their peak aerobic exercise capacity as an indication of their cardiorespiratory fitness 
(CRF).  A Saturn h/p/cosmos treadmill (Nussdorf-Traunstein, Germany) with specialised computer 
software (Cosmed Quark CPET, Rome, Italy) was used. This software integrates the breath-by-breath 
gas sampling and heart rate recordings (COSMED wireless HR monitor, Italy) to continuously record 
exercise intensity and selected cardiorespiratory parameters throughout the test.  The gas analysers 
were calibrated to 16% O2, 4% CO2 and balance N2 calibration gases, while the turbine flow meter 
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Before initiation of each test, participants were fitted with an adjustable safety harness while standing 
stationary on the treadmill.  They then warmed up for 5 min at a speed of 8 km·h-1 after which they 
were allowed to drink water.  The test began at a speed of either 9 or 11 km·h-1, depending on the 
participant’s subjective assessment of general fitness status.  Three of the participants started the test 
at 11 km·h-1, whereas the remaining 24 participants started at 9 km·h-1.  The speed of the treadmill 
increased by 0.5 km·h-1 after each minute.  The test was terminated once the participant indicated he 
was unable to continue.  
 
According to the 10th edition of ACSM’s Guidelines for Exercise Testing and Prescription (Riebe et 
al., 2016), respiratory exchange rate (RER) is considered the most accurate non-invasive indicator of 
a maximal exercise effort.  However, not all participants were able to reach a RER of ≥ 1.10 indicative 
of a maximal test.  Peak VO2peak was therefore reported instead of VO2max. 
 
Nonetheless, in accordance with the ASCM’s guidelines (Riebe et al., 2018), the following criteria 
were considered indicators of a maximal test: 
(i) a plateau in VO2 (or failure to increase VO2 by 150 mL∙min−1) with increased workload; 
(ii) failure of heart rate to increase with increases in workload; 
(iii) a rating of perceived exertion (RPE) at peak exercise > 17 on the 6–20 scale (Borg, 1982) 
(Appendix D); 
(iv) a peak RER ≥ 1.10. 
Pre-exercise test requirements: 
VO2peak testing was conducted in the Sport Physiology Laboratory in the Department of Sport 
Science, Stellenbosch University. The ambient temperature in the laboratory was kept between 20°C 
and 24°C for all testing. To standardise the participant’s metabolic state during the testing sessions 
they: 
• did not eat for at least two hours prior to testing; 
• avoided alcohol ingestion at least 12 hours before testing;  
• avoided caffeine-containing drinks at least 4 hours before testing; 
• avoided vigorous activities: RPE above 12 on the Borg scale (Borg, 1982) or any 
unaccustomed exercise at least 24 hours before testing. 
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3.2.7 Logging of food and drink 
Participants either used a link to a Google form (Appendix E) to log all their food and drink 
consumption, or they kept a written diary (Appendix F) during the glucose monitoring period.  A 
thorough explanation as to how all dietary intake were to be logged was given individually to each 
participant.  Participants were encouraged to continue with their usual dietary habits and to not make 
any changes to their habitual dietary routine or intake until they completed their participation in the 
study.  An ISSN (International Society of Sports Nutrition) certified sport nutritionist analysed the 
dietary data, using the South African MRC FoodFinder® software, to calculate the macronutrient 
contents.  Glycaemic load (GL) (i.e. glycaemic index multiplied by the amount [g] of carbohydrate) 
of the logged food consumption was calculated using this data. Glycaemic index (GI) values were 
obtained from the South African GI and GL Guide (Steenkamp & Delport, 2016).  Because the 
addition of fat and protein influence the postprandial glucose and insulin responses, participants were 
also grouped according to their macronutrient intakes by means of a K-means cluster analysis. 
3.3 Statistical Analyses 
Data and statistical analysis were conducted using Microsoft® Excel® for Microsoft 365 MSO 
(16.0.12827.20438) 64-bit. 
 
Descriptive statistics for body composition, CRF, blood parameters, insulin sensitivity and glycaemic 
variability are reported as mean ± SD.  The Kolmogorov-Smirnov test confirmed that all the variables 
followed a Gaussian distribution. 
 
Glycaemic variability was calculated from the CGM data using the EasyGV© software (section 3.2.4).  
Missing glucose readings were interpolated with a straight-line estimation using the same EasyGV© 
software.  At least seven full days of glucose monitoring was needed for a participant’s data to be 
included into the analysis.  
 
T-tests for independent groups were performed for all the variables of interest (body composition, 
dietary intake, CRF, glucose control, insulin sensitivity or glycaemic variability) to determine 
whether there were statistically significant differences between participants with a full set of CGM 
data and those whose sensors dislodged or ceased working before 14 days of monitoring were  
recorded.  There were no statistically significant differences in either the CGM data, nor the personal 
characteristics of the 18 men who had 12 or more valid CGM monitoring days and the 9 men who 
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had 7 – 11 days of CGM data (0.16 < p < 0.98) (see Appendix G for complete results).  For this 
reason, the complete CGM data set of each participant was used for analysis, except for the day on 
which the person underwent the OGTT.  The data on this particular day were excluded from the CGM 
analyses for all participants. 
 
K-means cluster analysis (Likas et al., 2003) was used (algorithm run by MATLAB® R2020a 
[9.8.0.1380330]) to identify three groups based on the macronutrient intake of the participants.  
Single-factor analyses of variance (ANOVA) and post hoc T-tests for independent groups (with 
Bonferroni’s correction) were performed to confirm differences in percentage intakes of fat, 
carbohydrates, and protein.  The same statistical analysis was done to test for differences in body 
composition, glucose control, insulin sensitivity, OGTT concentrations of glucose and insulin, and 
glycaemic variability indices between the three groups.  Glucose and insulin AUC’s for the OGTTs 
of each cluster were calculated according to the method of Matthews et al. (1990).  Additionally, 
Cohen’s effect sizes and 90% confidence intervals were calculated to describe the magnitude of the 
differences between the clusters for all these variables.  The smallest worthwhile difference between 
clusters was calculated as 0.2 x the pooled standard deviation of the variable.  Threshold values for 
Cohen’s d were > 0.2 (small), > 0.6 (moderate), > 0.8 (large) and > 1.2 (very large) (Hopkins et al., 
2009).   
 
Pearson’s product-moment correlation coefficient (r) was used to describe the association between 
dietary glycaemic load, and CRF and glucose control, insulin sensitivity, glycaemic variability, and 
body composition measures.  The effect sizes of the correlations were described as small (> 0.1), 
moderate (> 0.3), large (> 0.5), very large (> 0.7) (Hopkins et al., 2009). 
3.4 Ethical considerations 
The study protocol was approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University (S19/10/262; Project ID: 12997).  All testing and laboratory procedures were performed 
in accordance to the Declaration of Helsinki.  
 
The participants were informed that their participation was completely voluntary and that they could 
withdraw at any time.  Each individual signed an informed consent form before partaking in the study.  
There were no serious risks involved as all participants were healthy, nonetheless, dizziness, fainting 
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and discomfort during the maximal exercise test could have been experienced and participants were 
aware thereof.  
 
All tests and procedures were thoroughly explained to the participants and full understanding thereof 
was confirmed before any test or measurement was initiated.  This was to ensure minimal risk and to 
ensure accuracy and consistency of measurements.   
 
Emergency personnel that were qualified in basic life support (BLS), able to perform 
cardiopulmonary resuscitation (CPR) and able to use an Automated External Defibrillator (AED) 
(which was in the Sport Physiology Laboratory) were on the premises during all laboratory testing 
sessions.  No adverse events took place during any of the exercise tests.  
Blood samples were all taken in pathology laboratories by qualified personnel who all followed the 
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Chapter 4 Results 
4.1 Participants 
Twenty-nine healthy men qualified to participate in the study and 27 complete data sets were included 
for analysis.  Table 4.1 describes the physical characteristics of these participants.  Nineteen men 
were aged 30 to 39 years and the remaining eight participants were aged between 40 and 47 years. 
Table 4.1  Age and body composition characteristics of the participants (n = 27). 
 Mean ± SD Minimum - Maximum 
Age (years) 36.85 ± 4.84 30 – 47 
Body mass (kg)   87.87 ± 14.02   70.6 – 120.0 
Body fat % 20.71 ± 6.17   5.9 – 30.5 
Fat free mass (kg) 69.35 ± 9.73   54.0 – 87.57 
Waist:Height   0.50 ± 0.06 0.42 – 0.67 
Waist:Hip   0.86 ± 0.05 0.78 – 1.00 
 
The body fat percentages of five (18.5%) participants were very poor, five (18.5%) were poor, six 
(22%) were fair, seven (26%) were good, two (7%) were very lean and two (7%) were excellent 
(Riebe et al., 2016).   
 
Ten (37%) participants had waist-to-hip circumferences ≥ 0.9 (WHO, 2008). These same participants 
also had unhealthy waist-to-height ratios of ≥ 0.5 (Ashwell & Gibson, 2016).  Except for one of these 
participants, who had a fair body fat percentage, the remaining nine had poor or very poor body fat 
percentages.  An additional three participants who had healthy waist-to-hip and waist-to-height ratios, 
had poor body fat percentages. 
4.2 Cardiorespiratory fitness (CRF) 
Only six (22%) participants were able to reach RER values ≥ 1.10.  All participants indicated that 
they were exhausted and no longer able to continue when their tests were terminated.  Four (15%) of 
the participants indicated that they were too exhausted to continue with the exercise test before any 
of the other three criteria for a maximal exercise test, as per the ACSM (Riebe et al., 2016), were 
reached.  Two of the four criteria for a maximal test were met by five (18.5%) of the participants, 
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three criteria were met by 15 (55.6%) participants and four (15%) of the participants met all four 
criteria. 
 
One participant (4%) had very poor CRF, two (7%) poor, eight participants’ (30%) fitness levels were 
classified as fair, six (22%) had good CRF and 10 participants (37 %) had excellent CRF (Riebe et 
al., 2016:126).   
Table 4.2  Peak cardiorespiratory fitness characteristics of the participants (n = 27). 
 Mean ± SD Minimum - Maximum 
VO2peak (ml·kg-1·min-1)   45.91 ± 7.40 30.4 – 58.7 
VO2peak (ml·kg-1)   3979 ± 585 2619 – 4941 
HRpeak (bpm) 186 ± 9 173 – 205 
RERpeak     1.06 ± 0.04 0.99 – 1.13 
Peak running speed (km·h-1)   13 ± 2    10 – 17.5 
bpm, beats per minute; HR, heart rate; RER, respiratory exchange rate. 
 
Only one participant with poor or fair fitness had a “good” body fat percentage; the rest (n = 10) had 
either fair, poor, or very poor body fat percentage classifications.  Likewise, only one participant with 
a good level of CRF, was in the “poor” category of body fat percentage, while the rest of the 
participants with good or excellent CRF (n = 15), had fair to excellent body fat percentages. 
4.3 Continuous glucose monitoring (CGM) period 
The participants were asked to wear their continuous glucose monitoring (CGM) sensors for a full 
two-week period.  Unfortunately, the sensors in some participants detached from their arms or ceased 
recording data before the two weeks were completed.  In six cases, the sensor came off either within 
two days of the monitoring period, or it failed to record more than a day or two; these were 
subsequently replaced with a new sensor.  The first sensor’s data were discarded.  If the sensor failed 
or detached after seven days, it was not replaced.  Therefore, the minimum number of days that 
constituted a complete data set was seven full days, which included five workdays and one two-day 
weekend for all the participants.  Figure 4.1 illustrates the distribution of CGM monitoring days 
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Figure 4.1  Number of glucose monitoring days for the group of participants. 
 
There were no statistically significant differences in body composition, dietary intake, CRF, glucose 
control, insulin sensitivity or glycaemic variability between the participants with 12 or 13 days’ CGM 
data and those with 7 – 11 days of CGM data. Results for this analysis are shown in Appendix G. 
4.4 Dietary characteristics 
Judging by the range in values, the dietary characteristics and eating patterns among participants 
varied considerably, especially regarding absolute carbohydrate and energy intake (Table 4.3).  The 
average daily contribution of sugar to the energy intake of the participants was 9.8% (± SD 3.9%) 
(range: 2.8 – 17.5%). There was also large interpersonal and intrapersonal daily variation in energy 
intake as evidenced by Figures 4.2 – 4.4 and Table 4.4. 
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Table 4.3  Dietary characteristics of the participants during the continuous glucose monitoring period (n = 27). 
 Mean ± SD Minimum - Maximum 
Average daily GL    149 ± 49   43 – 239 
Average daily CHO intake (g)    267 ± 72 105 – 398 
Average daily dietary fibre intake (g)    20.6 ± 6.3 10 – 33 
Average daily sugar intake (g)      65.7 ± 28.3   22 – 130 
Average daily energy intake (kJ)    11245 ± 1831   7976 – 15125 
% dietary CHO intake    41 ± 7 24 – 54 
% dietary protein intake    19 ± 4 13 – 27 
% dietary fat intake    40 ± 5 32 – 53 
GL, glycaemic load; CHO, carbohydrate.  Sugar refers to all monosaccharides and disaccharides; CHO refers 
to polysaccharides. 
 
For the whole group, the intake of protein as percentage of total energy intake was statistically 
significantly lower than the intake of carbohydrates (p < 0.0001; ES = 3.889; 90% CI: 19 - 26) and 
fat (p < 0.0001; ES = 4.786; 90% CI: 20 - 24).  The relative intake of carbohydrates and fat did not 
differ significantly (p = 0.82; ES = 0.083; 90% CI: -3.4 – 4.4). 
 
There were no significant differences in the average GL intake between monitoring days (p = 0.988; 
ES = 0.060; 90% CI: -270 – 270) (figure A1 in Appendix H).   
 
The participants’ daily average carbohydrate intake did not differ significantly between days (p = 
0.949; ES = 0.057; 90% CI: -85 – 92) (Figure A2 in Appendix H) 
 
There were no statistically significant differences in average fat intake between the CGM days (p = 
0.295; ES = 0.020; 90% CI: -0.22 – 0.95) (Figure A3 in Appendix H).   
 
There were no statistically significant differences in average protein intake across the monitoring 
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Table 4.4 The average group day-to-day variation (mean ± SD) in dietary energy intake, glycaemic load, and 
macronutrient consumption. 
 SD CV% 
Energy intake      3586 ± 1059 kJ 32.6 ± 5.9% 
Glycaemic load 60.5 ± 25.4   41.8 ± 15.7% 
Carbohydrate  121.4 ± 20.0 g 46.1 ± 7.4% 
Fat    55.1 ± 13.3 g 45.4 ± 8.5% 
Protein   42.5 ± 5.9 g 37.6 ± 5.7% 
 
The day-to-day dietary composition of the participants’ food varied more than the energy intake 
(Table 4.4).  The group’s day-to-day variability (CV%) was larger for carbohydrate intake than for 
fat (ES = 0.083; 90% CI: -4.4 – 5.7) and protein intake (ES = 1.290; 90% CI: 4.6 – 12).  There was a 
large difference in fat intake variability compared with protein variability (CV%) between individuals 
(ES = 1.086; 90% CI: 2.8 – 13). 
 
Tables showing the group’s day-to-day macronutrient variability, average day-to-day individual 
(intrapersonal) variation in dietary components, and the differences in the intrapersonal variations of 
the participants’ dietary macronutrient intakes are included in Appendix H. 
4.4.1 Characteristics of the macronutrient clusters 
Based on the proportions of individual dietary macronutrient intake, three clusters were identified 
(Figure 4.2).  Cluster 1 (n = 9, 33.3%), in comparison to the other two clusters, could be described as 
the high carbohydrate-low fat (high CHO) group, whereas cluster 2 (n = 6, 22.2%) can be described 
as the low carbohydrate-high fat (low CHO-high fat) group and cluster 3 (n = 12, 44.4%) the high 
carbohydrate-high fat group (high CHO-high fat). 
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Figure 4.2 The percentage energy contribution from the macronutrients for participants in the three clusters. 
 
The intake of fat and carbohydrates differed significantly between the three groups (p < 0.01).  There 
was a large difference in protein intake between clusters 1 and 2 (16.9% vs 22%, p = 0.019; ES = 
1.41; 90% CI: 1.7 – 8.5), and clusters 2 and 3 (22% vs 18 %, p = 0.013; ES = 1.38; 90% CI: 1.5 – 
6.5), but only a small difference between clusters 1 and 3 (16.9% vs 18%, p = 0.51; ES = 0.30; 90% 
CI: -1.8 – 4.0). 
 
The average glycaemic load was 185.7 (± SD 42.0) for cluster 1, 99.5 (± SD 28.3) for cluster 2 and 
146.1 (± SD 40.3) for cluster 3 (p = 0.001).  The differences in glycaemic load between  clusters 1 
and 2 (p = 0.0007; ES 2.301; 90% CI: 51 - 120), clusters 1 and 3 (p = 0.041; ES = 0.965; 90% CI: 8.3 
– 71) and clusters 2 and 3 (p = 0.023; ES = 1.260; 90% CI: 14 – 79) were all large.  The average daily 
energy intake of cluster 2 was 10 309 (± SD 1593 kJ), which was less than for cluster 1, which was 
11 557 (± SD 1243 kJ) (p = 0.112; ES = 0.898; 90% CI: 13 – 21) and cluster 3, which was 11 478 (± 
SD 2243) (p = 0.27; ES = 0.567; 90% CI: -630 – 3000).  There was no difference in energy intake 
between clusters 1 and 3 (p = 0.925; ES = 0.042; 90% CI: -1400 – 1500).  
4.4.2 Differences between the body composition measures of the clusters 
The average BF%, waist-to-hip and waist-to-height ratios, as measures of obesity, were highest for 
cluster 3, while BF% was lowest for cluster 2.  Moderate differences in BF% were detected between 
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as indicators of central obesity, were both lowest for cluster 1, although the differences between 
cluster 1 and 2 was small to negligible.   
Table 4.5 Body composition of individuals per cluster (means +- SD) and differences between the clusters. 
Difference values are ES (90% CI). 
 Mean ± SD ES (90% CI) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 1 vs 2 Cluster 1 vs 3 Cluster 2 vs 3 
Body mass 
(kg) 
82.1 ± 6.84 88.8 ± 14.56 91.7 ± 17.05 0.645** 
(-16 – 3.1) 
0.698** 
(-20 – 0.9) 
0.178  
(-17 – 11) 
BF% 20.2 ± 3.53 16.6 ± 7.91 23.2 ± 6.03 0.641**  
(-1.6 – 8.9) 
0.576*  
(-6.9 – 1.0) 
0.984***  
(-12 – -0.7) 
FFM (kg) 65.5 ± 5.53 73.5 ± 10.37 70.2 ± 11.42 1.032***  
(-15 – -0.77) 
0.496*  
(-12 – 2.5) 
0.301*  
(-6.4 – 13) 
Waist:Hip 0.84 ± 0.045 0.87 ± 0.046 0.88 ± 0.061 0.071  
(-0.046 – 0.039) 
0.763**  
(-0.83 – 0.0) 
0.680**  
(-0.088 – 0.011) 
Waist:Height 0.47 ± 0.039 0.48 ± 0.040 0.53 ± 0.072 0.332*  
(-0.05 – 0.024) 
1.033#***  
(-0.11 – -0.02) 
0.771**  
(-0.1 – 0.007) 
#p = 0.03; all other p-values are > 0.05; *small difference, **moderate difference, ***large difference. 
 
4.5 Glucose control 
4.5.1 Whole group results 
A summary of the laboratory blood tests for measures of glucose control and insulin resistance are 
presented in Table 4.6.  All participants, except one (participant 01), presented with healthy fasting 
plasma glucose concentrations (< 5.6 mmol·L-1).  One of the participants with a healthy fasting 
glucose (5.1 mmol·L-1) had a 2-hr post OGTT glucose level of 7.8 mmol·L-1, which is the cut-off 
value for the classification of pre-diabetes.  All the other participants had healthy 2-hr glucose 
concentrations.  
 
Four participants had HbA1C levels on or above the cut-off value for healthy individuals (pre-diabetic 
range: 5.7% – 6.1%).  None of them, however, reached an HbA1C level of 6.5% that is typically used 
for the diagnosis of diabetes (WHO, 2019; SEMDSA, 2017).  The remaining 23 participants presented 
with healthy HbA1C values. 
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Table 4.6 Traditional glucose control measures and insulin sensitivity indexes (n = 27). 
 
Mean ± SD 
Minimum - 
Maximum Healthy values 
HbA1C (%) 5.43 ± 0.27 5.1 – 6.1 < 5.7* 
Fasting plasma glucose 
(mmol·L-1) 
5.01 ± 0.32 4.3 – 5.7 < 5.6*$ 
2-h glucose (mmol·L-1) 4.63 ± 1.44 1.7 – 7.8 < 7.8*# 
Maximum glucose (mmol·L-1) 7.48 ± 1.37   5.1 – 10.3 - 
Fasting insulin (mIU·L-1) 5.95 ± 3.66   1.9 – 18.6 < 10.7** 
HOMA-IR 1.31 ± 0.77 0.43 – 3.64    < 1.7-2.0*** 
Matsuda Index 9.36 ± 4.37   2.69 – 21.16     > 4.3**** 
HbA1c, Glycated haemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; *healthy 
values as per the American Diabetes Association (2017); $SEMDSA (2017) #World Health Organization 
(2006); **(Ter Horst et al., 2015); ***Gayoso-Giz et al. (2013); ****Gutch et al. (2015). 
 
According to the Matsuda index, four of the participants were identified as insulin-resistant (Figure 
4.3).  Among these was the participant (03) with the high 2-h glucose value (7.8 mmol·L-1) and one 
of the participants (07) with a HbA1C value in the pre-diabetes range.  These four individuals also had 
HOMA-IR values of 2.04 and higher.  Another individual was identified as insulin-resistant according 
to the HOMA-IR (value of 2.09), but not by the Matsuda index (value of 5.07) (cut-off value of 4.3 
as suggested by Gutch et al.; 2015).  None of the participants had HOMA-IR values within the cut-
off range (1.7 - 2.0). 
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Figure 4.3 Individual insulin sensitivity/-resistance indices. The blue and yellow dashed lines represent the 
cut-off value for the Matsuda index and range for HOMA-IR, respectively.  The overlapping of the bars 
presents as green.  Matsuda index values to the right of the blue dashed line (4.3) represent the healthy values, 
while HOMA-IR values left of the range between the two yellow dashed lines (1.7 and 2.0), represent the 
healthy values.  * Unhealthy HOMA-IR; ** unhealthy Matsuda and HOMA-IR indexes. 
 
The maximum glucose concentration during the OGTT was measured after 30 minutes for 22 (81%) 
of the participants.  Four participants (15%) reached maximum [glucose] after one hour and one 
participant after 90 min.  The latter participant’s maximum [glucose] was, however, a mere 5.1 
mmol·L-1.   
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The participants’ average maximum [glucose] during the OGTT was 7.5 (± SD 1.4) mmol·L-1 (range 
5.1 – 10.3 mmol·L-1).  The maximum [glucose] of ten (37%) of the participants exceeded 7.8 
mmol·L-1.  In 16 (59%) participants the 2-h post OGTT glucose level was lower than their individual 
fasting level.  Eight (30%) participants’ 2-h glucose levels were higher than their fasting levels, while 
three (11%) participants had identical fasting and 2-h glucose concentrations.  The participant with 
the highest 2-h [glucose] also had the highest [insulin] at 90 and 120 min. In fact, his final insulin 
measurement (120 min) was the highest of all his values.  This participant’s Matsuda index was the 
second lowest.  The participant with the lowest Matsuda index had the highest overall [insulin], 
namely 165.2 mIU·L-1 after 60 min.  His insulin levels, however, returned to normal (i.e. below 40 
mIU·L-1) after 120 min, namely 28.9 mIU·L-1.   
 
The average ± SD [glucose] and [insulin] trend of the participants during the OGTT is illustrated in 
Figure 4.4.  The average variability (CV%) in glucose values (21.5 ± 9.9%) was less than for insulin 
values (80.9 ± 27.5%) (p = 0.004). 
 
Figure 4.4 The average (± SD) of the [glucose] and [insulin] of the study sample during the OGTT. 
 
4.5.2 Macronutrient clusters 
4.5.2.1 Glucose control and insulin sensitivity 
Table 4.7 illustrates that the differences between the clusters were more evident and consistent for 
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Table 4.7 Glucose control and insulin sensitivity measures for the respective macronutrient clusters. 
 Clusters (mean ± SD) Cluster differences ES (90% CI) 
 1 2 3 1 vs 2 1 vs 3 2 vs 3 






FPG (mmol·L-1)   4.87 ± 0.30   5.07 ± 0.22 5.08 ±0.36    0.731** 
(-0.46 –0.055) 






  4.49 ± 1.85   4.50 ± 1.21  4.80 ± 1.30 0.007  
(-1.5 –1.5) 
  0.200*  
(-1.5 – 0.88) 
 0.235*  
(-1.4 –0.81) 
HOMA-IR   1.09 ± 0.43   0.87 ± 0.19    1.7 ± 0.97   0.621**  
(-0.11 –0.55) 
   0.779**  
( -1.2 – -0.01) 
   1.028***  
(-1.5 – -0.13) 
Matsuda Index 10.03 ± 3.92 11.23 ± 2.24    7.9 ± 5.21  0.357*  
(-4.3 –1.9) 
 0.446*  
(-1.5 – 5.7) 
 0.734** 
 (-0.62 –7.2) 
All p-values > 0.05; *small difference, **moderate difference, ***large difference. 
 
There were no significant differences in HbA1c between the clusters (p > 0.05; ES < 0.2). The 2-h 
[glucose] between clusters 1 and 2 and FPG between clusters 2 and 3 did not differ either (p > 0.05; 
ES < 0.2).  There was a small increase in 2-h [glucose] from clusters 1 to 3 (p = 0.656; ES = 0.200) 
and from cluster 2 to 3 (p = 0.644; 0.235).  There was a moderate increase in FPG from cluster 1 to 
cluster 2 (p = 0.189; ES = 0.731) and from cluster 1 to cluster 3 (p = 0.165; ES = 0.637). 
 
Insulin sensitivity (as determined by the Matsuda index) was highest in cluster 2 (compared to cluster 
1: p = 0.510; ES = 0.357; compared to cluster 3: p = 0.161; ES = 0.734).  Likewise, insulin resistance 
(HOMA-IR) was the highest in cluster 3 (p = 0.093; ES = 0.779, compared to cluster 1 and p = 0.057; 
ES = 1.028, compared to cluster 2).   
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Figure 4.5 Differences in glucose control and insulin sensitivity between clusters 1 & 2, 1 & 3, and 2 & 3. 
The blue dots represent the mean difference in the respective measures between the clusters with error bars 
representing the 90% confidence intervals.  The yellow bars show the smallest worthwhile difference.  
 
4.5.2.2 Oral Glucose Tolerance test 
There was a small difference in average OGTT [glucose] between cluster 3 and  cluster 1 (p = 0.054; 
ES = 0.293) and cluster 2 (p = 0.082; ES = 0.241), but there was no difference in the average [glucose] 
of cluster 1 and 2 (p = 0.708; ES = 0.049). 
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Figure 4.6 A comparison of the blood glucose responses during the 2-hr OGTT among clusters. Values are 
means ± SD. * Small difference between average [glucose] of cluster 1 and 3, and cluster 2 and 3. 
 
The differences in the average [insulin] during the OGTT between the clusters were larger than the 
differences in the average [glucose].  There were large differences between the average OGTT 
[insulin] of cluster 2 compared to cluster 1 (p = 0.023; ES = 1.262) and cluster 3 (p = 0.013; ES = 
























Cluster 1 Cluster 2 Cluster 3
5.7 ± 1.2 mmol·L-1 * 
5.4 ± 1.0 mmol·L-1  
5.4 ± 1.0 mmol·L-1  
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Figure 4.7 A comparison of serum insulin responses during the 2-hr OGTT among clusters. Values are means 
+ SD. * The difference in average [insulin] between cluster 1 and 3 was small; ** the differences in the average 
[insulin] between cluster 1 and 2, and cluster 2 and 3 were large. 
 
The differences in [insulin] between the clusters at individual time points during the OGTT were 
generally larger than the differences in [glucose] (See Tables A4 and A5 in Appendix H).  This was 
evident in effect sizes, even though post hoc tests revealed no statistically significant differences (p 
> 0.05) between either [insulin] or [glucose] at any time point. 
 
There was no meaningful difference in [glucose] between clusters 1 and 2 at 120 min, clusters 1 and 
3 at 60 min, and clusters 2 and 3 at 0 min and 90 min (p > 0.05; ES < 0.02).  Small differences were 
evident between clusters 1 and 2, at 30 min, 60 min and 90 min, between clusters 1 and 3 at 90 and 
120 min, and between clusters 2 and 3 at 30 min, 60 min, and 90 min.  A moderate difference was 
seen between clusters 1 and 2 for fasting [glucose], as well as between clusters 1 and 3 for fasting 
and 30 min [glucose].   
 
There was a difference in [insulin] between all the clusters at all time points during the OGTT. The 
size of the difference in [insulin] during the OGTT between clusters 1 and 2 was moderate at fasting 
and 120 min, and small at all other time points; the [insulin] of cluster 1 were higher at all time points.  
A moderate difference was seen between clusters 1 and 3 for fasting and 60 min [insulin], with a 
small difference at all other time points; the average [insulin] of cluster 3 were higher. There was a 



















Cluster 1 Cluster 2 Cluster 3
39.0 ± 22.9 mIU·L-1  
29.9 ± 19.3 mIU·L-1  
9.6 ± 8.4 mIU·L-1 ** 
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cluster 2 and 3 were moderate.  The [insulin] at all time points were the highest in cluster 3 and the 
lowest in cluster 2. 
 
There was no meaningful difference in the [glucose] AUCs of clusters 1 and 2 (p = 0.987; ES = 
0.009).  There was a small increase in [insulin] AUC for cluster 1, compared to cluster 2 (p = 0.338; 
ES = 0.481).  The [glucose] and [insulin] AUCs were larger for cluster 3 than cluster 1 (p = 0.492; 
ES = 0.309 and p = 0.417; ES = 0.365, respectively).  The AUCs of both [glucose] and [insulin] of 
cluster 3 were larger than cluster 2 (p = 0.553; ES = 0.303 and p = 0.111; ES = 0.776, respectively).   
4.6 Glycaemic variability 
4.6.1 Whole group results 
The means ± SD for the glycaemic variability parameters and time above and below set 
concentrations of the study sample are depicted in Table 4.8.  None of the individuals presented with 
glucose concentrations at or above 10.0 mmol·L-1 at any time point during the period of CGM.  10.0 
mmol·L-1 is frequently used as the value to describe hyperglycaemia (Danne et al., 2017; Paing et al., 
2020). 
Table 4.8  Glycaemic variability indices from continuous glucose monitoring data (n = 27). 
 
Mean ± SD Minimum – Maximum 
Healthy population 
reference values 
Mean glucose (mmol·L-1)     4.6 ± 0.4 3.9 – 5.4 5.03 – 6.69* 
SD (mmol·L-1)     0.79 ± 0.15 0.57 – 1.19 0.44 – 1.37* 
CV% 17.32 ± 4.1 10.67 – 30.16   7.74 – 22.45* 
MAGE (mmol·L-1) (intra-
day variability) 
    1.00 ± 0.20 0.72 – 1.54   0.8 – 3.02* 
  0.0 – 2.8** 
MODD (mmol·L-1) (inter-
day variability) 
    0.70 ± 0.16 0.46 – 1.08    0.4 – 1.41* 
  0.0 – 3.5** 
SD, Standard deviation from the average glucose concentration over the CGM monitoring period; CV%, 
coefficient of variation; MAGE, mean amplitude of glycaemic excursions; MODD, mean of daily differences. 
*Reference values according to Foreman et al. (2020) (2.5th – 97.5th percentile) and **Hill et al. (2011) (mean 
+ 2 SD). 
 
The average (± SD) time per day that the participants spent above [glucose] of 6 mmol·L-1, was 84 
min (± 57) (range: 10 – 205).  The average (± SD) time per day that the participants spent at and 
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above [glucose] of 7.8 mmol·L-1, and at or below 3 mmol·L-1 was 4 min (± 5) (range: 0 – 15) and 22 
min (± 44) (range: 0 – 188) , respectively. 
 
Figure 4.8 Average time per day spent at, above and below specified [glucose] thresholds. 
 
Seventeen (63%) participants recorded glucose values ≥ 7.8 mmol·L-1 during the CGM period (Figure 
4.9).   
t > 6 mmol·L-1  t ≥ 7.8 mmol·L-1  t ≤ 3 mmol·L-1 
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Figure 4.9  Individuals’ average (+ SD) time per day with high (≥ 7.8 mmol·L-1) glucose values. *Participant 
1: least overall glycaemic variability, ##participant 7: most inter- and intra-day glycaemic variability and 
#participant 11: most overall glycaemic variability. 
 
Glucose values below 3 mmol·L-1 were recorded on one or more occasions by 18 (67%) participants 
(Figure 4.10).  Among these 18 participants, minimum values of 2.2 mmol·L-1 were recorded on at 
least one occasion for some individuals (n = 8), however, only two of these participants spent a 
significant amount of time at this minimum value (on average 58 and 101 min per day, respectively).  
Collectively, participants had more often low (≤ 3 mmol·L-1) [glucose] (22 ± 44 minutes per day), 
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Figure 4.10  Individuals’ average (+ SD) time per day with low (≤ 3 mmol·L-1) glucose values. ##Participant 
7: most inter- and intra-day glycaemic variability, **participant 11: most overall glycaemic variability and *** 
participant 14: least inter-day glycaemic variability. 
 
Representative continuous glucose monitoring profiles 
The highest inter- and intra-day glycaemic variability as per MODD and MAGE, respectively, was 
observed in the same individual (Figure 4.12 and Figure 4.13).  His overall glycaemic variability 
(CV%) was the second highest among the study sample.  This individual also spent most time per 
day above 6 mmol·L-1 and his average daily GL was the highest of all participants.  His HOMA-IR 
and Matsuda indexes were 1.3 and 6.66, respectively, which does not classify him as being insulin-
resistant.  The individual with the highest CV% (Figure 4.11) had the second highest MAGE and 
MODD values.  He was deemed the most insulin sensitive in the study sample, with an HOMA-IR of 
0.43 and a Matsuda index of 21.16.  The participants with the least inter- and intra-day and overall 
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Figure 4.11  Individual CGM profiles of the participant with (A) the least (participant 01) and (B) most (participant 11) overall glycaemic variability (CV%).
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4.6.2 Clusters 
The glycaemic variability indices between the clusters are compared in Table 4.9 The glycaemic 
variability indices of the clusters and differences between the clusters.   The highest average values 
for all the indices were in cluster 1.  The lowest glycaemic variability is not attributed to a single 
cluster but are distributed between clusters 2 and 3.  None of these differences was statistically 
significant. Small differences were evident between clusters 1 and 2 for CGM glucose SD (lower for 
cluster 2), between clusters 1 and 3 for MODD (lower for cluster 3) and time per day spent above 6 
mmol·L-1 (lower for cluster 3). Differences were seen between clusters 2 and 3 in CGM glucose SD 
(lower for cluster 3), CV% (lower for cluster 3), MODD (lower for cluster 3) and time per day spent 
above 6 mmol·L-1 (lower for cluster 2). Moderate differences were evident between clusters 1 and 2 
for MAGE (lower for cluster 2) and time per day spent above 6 mmol·L-1 (lower for cluster 2), and 
between cluster 1 and 3 for CGM glucose SD (lower for cluster 3) and MAGE (lower for cluster 3). 
 
Table 4.9 The glycaemic variability indices of the clusters and differences between the clusters.  
 Clusters (mean ± SD) Cluster differences ES (90% CI) 
 1 2 3 1 vs 2 1 vs 3 2 vs 3 
Mean glucose 
(mmol·L-1) 
 4.6 ± 0.35   4.6 ± 0.34   4.6 ± 0.47 0.150  
(-27 – 37) 
0.017  
(-0.31 – 0.33) 
0.104  
(-0.42 – 0.33) 
SD (mmol·L-1)  0.83 ± 0.14  0.81 ± 0.13  0.74 ± 0.16  0.199*  
(-0.15 – 0.1) 
0.590*  
(-0.03 – 0.21) 
 0.415*  
(-0.07 – 0.2) 
CV% 18.3 ± 3.5 17.8 ± 3.5 16.4 ± 4.8 0.151  
(-2.7 – 3.8) 
0.134  
(-1.4 – 5.2) 
 0.313*  
(-2.5 – 5.3) 
MAGE (intra-
day variability) 
1.10 ± 0.2 0.93 ± 0.2 0.95 ± 0.2 0.784**  
(-0.37 – 0.03) 
 0.749**  
(-0.003 – 0.3) 
0.136  
(-0.16 – 0.12) 
MODD (inter-
day variability) 
0.73 ± 0.2 0.71 ± 0.1 0.66 ± 0.2 0.156  
(-0.17 – 0.12) 
0.414*  
(-0.06 – 0.2) 
 0.296*  
(-0.09 – 0.18) 
t > 6 mmol·L-1 
(min·day-1) 
  95 ± 58   61 ± 39   86 ± 64 0.666**  
(-14 – 82) 
 0.151  
(-38 – 56) 
0.431*  
(-75 – 25) 
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4.7 Associations between cardiorespiratory fitness and glycaemic 
variability, glucose control and insulin sensitivity. 
There was no clear association between CRF and the glycaemic variability indices – either small 
(CV%, t > 6 mmol·L-1, mean glucose, SD) or trivial correlations (MODD and MAGE) were found.  
HbA1c was moderately and negatively correlated with CFR, but fasting plasma glucose and 2-h 
glucose did not correlate with CRF.  HOMA-IR and the Matsuda index were both very strongly 
associated with CRF.  Higher CRF values were associated with lower insulin resistance (lower 
HOMA-IR), better insulin sensitivity (increased Matsuda index), lower OGTT insulin AUC (large 
correlation), and a higher OGTT glucose AUC (small correlation). 
 
 
Figure 4.14 Correlations between CRF and glycaemic variability, glucose control and insulin sensitivity. 
Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed lines represent the r-
values of -0.1 and 0.1, respectively.  Correlation coefficients and confidence intervals that cross both lines are 
deemed unclear. Correlation effect sizes: *small, **moderate, *** large, # very large. 
 
4.8 Associations between average daily glycaemic load and glycaemic 
variability, glucose control, and insulin sensitivity. 
Insulin sensitivity and/or -resistance did not correlate with habitual daily dietary glycaemic load.  2-h 
glucose showed the strongest (moderate negative) correlation with glycaemic load among all the 
glucose control measures.  A high glycaemic load was associated with moderate increases in intra-
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day (MAGE) and inter-day (MODD) glycaemic variability, as well as daily time spent above 6 
mmol·L-1.  Overall, glycaemic variability (CV% and SD) and mean CGM glucose revealed only small 
correlations with dietary glycaemic load. 
 
 
Figure 4.15 Correlations between glycaemic load and glycaemic variability, glucose control and insulin 
sensitivity.  Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed lines 
represent the r-values of -0.1 and 0.1, respectively.  Correlation coefficients and confidence intervals that cross 
both lines are deemed unclear. Correlation effect sizes: *small, **moderate. 
 
4.9 Associations between glycaemic variability and glucose control. 
Higher HbA1c values were related to moderate increases in both mean glucose and average daily time 
above 6 mmol·L-1, as well as a small increase in MAGE.  Increased fasting plasma glucose was 
associated with small increases in time per day spent above 6 mmol·L-1, overall glycaemic variability 
(CV% and SD) and moderate increases in inter- and intra-day glycaemic variability (MODD and 
MAGE, respectively).  2-h OGTT [glucose] was slightly and negatively correlated with time per day 
spent above 6 mmol·L-1 and overall glycaemic variability (CV% and SD).  2-h OGTT [glucose] 
revealed moderate negative correlations with inter-day (MODD), and intra-day glycaemic variability 
(MAGE).  
Glycaemic Load
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Figure 4.16 Correlations between glucose control measures and glycaemic variability indices. 
Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed lines represent the r-
values of -0.1 and 0.1, respectively.  Correlations between these two values and confidence intervals that cross 
both lines are deemed unclear. Correlation effect sizes: *small, **moderate. 
 
4.10 Association between glycaemic variability and insulin sensitivity. 
Small positive correlations were found between insulin resistance and daily time spent above 
[glucose] of 6 mmol·L-1, as well as mean glucose. Insulin resistance were negatively correlated with 
overall glycaemic variability (CV% and SD) and intra-day glycaemic variability (MAGE).   
 
Higher insulin sensitivity was moderately correlated with both CGM glucose CV% and SD, but less 
with MAGE and MODD.  Mean glucose and average time per day spent above 6 mmol·L-1 both were 
negatively correlated with insulin sensitivity.   
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Figure 4.17 Correlations between insulin sensitivity and glycaemic variability (per person over monitoring 
period).  Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed lines 
represent the r-values of -0.1 and 0.1, respectively.  Correlations between these two values and confidence 
intervals that cross both lines are deemed unclear. Correlation effect sizes: *small, ** moderate. 
 
4.11 Association between insulin sensitivity and glucose control. 
The strongest correlation was observed between the Matsuda index and HbA1c.  Insulin resistance 
(HOMA-IR) was positively associated with HbA1c and 2-h glucose.  FPG did not correlate with either 
insulin sensitivity or resistance.   
 
 
Figure 4.18 Correlations between insulin sensitivity indexes and glucose control measures. 
Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed lines represent the r-
values of -0.1 and 0.1, respectively.  Correlation coefficients and confidence intervals that cross both lines are 
deemed unclear. Correlation effect sizes: *small, **moderate. 
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4.11 Association between age and body composition, CRF, glucose control, 
insulin resistance, and glycaemic variability. 
Advancing age was associated with small decreases in body mass and insulin sensitivity and a 
moderate decrease in fat free mass.  Advancing age was also associated with small increases in body 
fat percentage, mean glucose, insulin AUC, MAGE and average time per day spent above 6 mmol·L-1. 
 
 
Figure 4.19 Correlations of body composition, CRF, glucose control, insulin sensitivity and glycaemic 
variability with age. Correlations are represented as r-values ± 90% confidence intervals.  The vertical dashed 
lines represent the r-values of -0.1 and 0.1, respectively.  Correlations between these two values and confidence 
intervals that cross both lines are deemed unclear. Correlation effect sizes: *small, **moderate, ***large. 
 
4.12 Associations between body composition and glycaemic load, glycaemic 
variability, glucose control, and insulin sensitivity. 
Overall CRF levels and insulin sensitivity / -resistance were most strongly associated with measures 
of body composition.  The strongest correlation was observed between CRF and waist-to-height ratio 
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HbA1c was the only traditional glucose control measure that correlated meaningfully with body 
composition; however, all correlations were small.  The association between HbA1c and waist-to-hip 
ratio was the strongest. 
 
The Matsuda index and HOMA-IR correlated the strongest, but only moderately with the waist-to-
hip and waist-to-height ratios, with HOMA-IR having stronger associations with both ratios 
compared with the Matsuda index. 
 
The body composition markers that correlated best with glycaemic variability, varied between all 
indices.  MODD did not have any meaningful associations with the body composition measures.  The 
strongest correlation was between fat free mass and the average time per day spent at [glucose] of 6 
mmol·L-1.  Increases in fat free mass was associated with a small to medium decrease in time spent 
above 6 mmol·L-1 [glucose].  
 
Table 4.10 Associations between body composition measures with age, CRF, GL, glucose control, insulin 
sensitivity and glycaemic variability (Pearson's product-moment correlation coefficients). 
  Body mass (kg) BF % FFM (kg) Waist:Hip Waist:Height 
Age (years)    -0.38**    0.31*      -0.58***   0.13*  -0.03 
VO2peak (ml·kg·min-1)      -0.54***  -0.71#  -0.23*  -0.74#   -0.80# 
Glycaemic load   0.11*  0.07    0.29* -0.07     0.11* 
HbA1c (%)    0.22*      0.42**  0.03       0.47**       0.33** 
FPG (mmol·L-1)  0.03 -0.05  0.06 -0.07 -0.03 
2-h glucose (mmol·L-1) -0.04 -0.07 -0.01     0.13*  0.09 
HOMA-IR    0.27*      0.48**  0.03    0.77#   0.79# 
Matsuda Index   -0.16*       -0.52***    0.10*        -0.68***       -0.67*** 
CGM glucose CV %   -0.15*  -0.19* -0.05   -0.29*   -0.26* 
t > 6 mmol·L-1   -0.24*      0.37**     -0.45**    0.24*  0.09 
Mean glucose (mmol·L-1)   -0.12*      0.37**     -0.32**      0.32**    0.15* 
SD (mmol·L-1)   -0.24* -0.09   -0.20*   -0.22*   -0.25* 
MODD (mmol·L-1) -0.06    0.17* -0.12  0.00 -0.01 
MAGE (mmol·L-1)   -0.21*    0.25*     -0.34** -0.07   -0.14* 
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4.13 Summary of results 
Table 4.11, Table 4.12, and Table 4.13  highlights the specific outcomes for which individual 
participants’ recorded an atypical outcome measure. An outcome measure was regarded atypical if it 
surpassed the cut-off values as depicted in Table 4.8.  The participants are listed according to their 
macronutrient clusters.   
 
In total, 56 (14%) atypical markers were recorded among all the participants.  The average atypical 
markers per participant is 1.0 in cluster 1, 0.83 in cluster 2, and 3.5 in cluster 3.  Thirty-four (42% of 
the total possible body composition markers) of the atypical markers (60%) were related to body 
composition and of these, 24 were present in cluster 3.  Only five of the 34 (15%) markers were 
concomitant with unhealthy glucose control measures, while 11 (32%) were concomitant with either 
elevated fasting insulin, or the presence of insulin resistance.   
 
Only two participants had increased overall glycaemic variability, of which one participant did not 
present with any atypical body composition markers.  Five participants had atypical body composition 
markers, but no other accompanying atypical markers.  In all cases, low CRF was accompanied with 
at least one other atypical marker for glucose control, insulin resistance, or glycaemic variability, in 
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Table 4.11 Summary of atypical measures for the participants in cluster 1. 
 
  
  Participants in cluster 1 (high carbohydrate-low fat) 
 Atypical values 4 7 9 13 16 19 20 22 24 
Age (years)  32 45 43 42 33 30 35 41 39 
BF% Poor & very poor  X        
Waist:Hip ≥ 0.9    X     X 
Waist:Height ≥ 0.5    X     X 
CRF Poor & very poor  X        
HbA1c ≥ 5.7%          
FPG ≥ 5.6 mmol·L-1          
2-h glucose ≥ 7.8 mmol·L-1          
Fasting insulin ≥ 10.7 mlU·L-1          
HOMA-IR ≥ 1.7 – 2.0    X      
Matsuda Index ≥ 4.3    X      
Mean glucose ≥ 6.7 mmol·L-1          
SD ≥ 1.37 mmol·L-1          
CV% ≥ 22.45 mmol·L-1  X        
MAGE ≥ 2.80 mmol·L-1          
MODD ≥ 1.41 mmol·L-1          
Total unhealthy markers 0 3 1 4 0 0 0 0 2 
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Table 4.12 Summary of atypical measures for the participants in cluster 2. 
 
  
  Participants in cluster 2 (low carbohydrate-high fat) 
 Atypical values 5 6 12 15 25 29 
Age (years)  39 32 34 30 38 35 
BF% Poor & very poor     X  
Waist:Hip ≥ 0.9    X X  
Waist:Height ≥ 0.5    X X  
CRF Poor & very poor       
HbA1c ≥ 5.7%       
FPG ≥ 5.6 mmol·L-1       
2-h glucose ≥ 7.8 mmol·L-1       
Fasting insulin ≥ 10.7 mlU·L-1       
HOMA-IR ≥ 1.7 – 2.0       
Matsuda Index ≥ 4.3       
Mean glucose ≥ 6.7 mmol·L-1       
SD ≥ 1.37 mmol·L-1       
CV% ≥ 22.45 mmol·L-1       
MAGE ≥ 2.80 mmol·L-1       
MODD ≥ 1.41 mmol·L-1       
Total 0 0 0 2 3 0 
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Table 4.13 Summary of atypical measures for the participants in cluster 3. 
 
  Participants in cluster 3 (high carbohydrate-high fat) 
 Atypical values 1 3 8 10 11 14 17 18 21 23 26 28 
Age (years)  36 36 34 40 36 32 30 36 47 34 44 42 
BF% Poor & very poor X X X X   X X X   X 
Waist:Hip ≥ 0.9 X X X X   X X X   X 
Waist:Height ≥ 0.5 X X X X   X X X   X 
CRF Poor & very poor   X X    X     
HbA1c ≥ 5.7% X       X X    
FPG ≥ 5.6 mmol·L-1 X            
2-h glucose ≥ 7.8 mmol·L-1  X           
Fasting insulin ≥ 10.7 mlU·L-1    X    X     
HOMA-IR ≥ 1.7 – 2.0  X X X    X     
Matsuda Index ≥ 4.3  X  X    X     
Mean glucose ≥ 6.7 mmol·L-1             
SD ≥ 1.37 mmol·L-1             
CV% ≥ 22.45 mmol·L-1     X        
MAGE ≥ 2.80 mmol·L-1             
MODD ≥ 1.41 mmol·L-1             
Total  5 6 5 7 1 0 3 8 4 0 0 3 
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Chapter 5 Discussion 
5.1 Introduction 
The purpose of this study was to investigate the glucose control and free-living glycaemic variability 
of apparently healthy men in relation to cardiorespiratory fitness (CRF) and dietary intake.   
 
Due to the prevalence and incidence of T2DM that is rising to epidemical numbers, it is crucial to 
establish what predisposes people to develop insulin resistance, as this condition is a key role-player 
in the pathogenesis of pre-diabetes and eventually, overt T2DM and metabolic disease.  Since it is in 
every sense better to prevent than to treat, it is important to know whether the traditional markers of 
glucose control and insulin sensitivity, or alternatively, measures of glycaemic variability, reliably 
detect at risk individuals.   
 
The OGTT is widely used as a diagnostic test to determine whether an individual has impaired glucose 
tolerance.  It has been suggested to be a more sensitive and specific marker of glycaemic control than 
HbA1c, or levels of fasting glucose.  The question remains, though, what causes someone to progress 
from healthy glucose tolerance to impaired glucose tolerance?  Is the information from an OGTT 
sufficient to determine whether an individual’s glucose control is adequate, or are there other factors, 
especially lifestyle factors (specifically, CRF and diet macronutrient composition), that contribute to 
varying degrees of glycaemic variability in individuals, even though they present with normal glucose 
tolerance?  If it is established that intra- and inter-day glycaemic variability, as measured with a CGM, 
show differences between individuals who are otherwise considered having normal glucose control, 
the continuous measurement of blood glucose levels may become a useful diagnostic tool. 
5.2 Overview of findings 
5.2.1 Primary aims 
• To explore the relationships between cardiorespiratory fitness (CRF) and glycaemic 
variability, the traditional markers of glucose control (HbA1c, OGTT, and fasting plasma 
glucose) and insulin sensitivity.  
Hypothesis 1: Cardiorespiratory fitness will be most strongly correlated with insulin 
sensitivity, followed by glycaemic variability and HbA1c. 
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This hypothesis is partly accepted.  CRF was most strongly associated with insulin sensitivity.  
It was negatively correlated to HOMA-IR (proxy indicator of insulin resistance) and positively 
to the Matsuda index (whole body insulin sensitivity).  These associations of insulin sensitivity 
with CRF were stronger compared to the measures of glucose control and glycaemic 
variability.  Among the glucose control and glycaemic variability measures, HbA1c had the 
strongest (positive) correlation with CRF. 
 
• To determine the relationships between dietary glycaemic load and glycaemic variability, 
glycaemic control, and insulin sensitivity.  
Hypothesis 2: Glycaemic load will be most strongly correlated to glycaemic variability, 
followed by insulin sensitivity (negative correlation) and glucose control (negative 
correlation).  
 
This hypothesis is partly accepted.  Dietary glycaemic load was not associated with insulin 
sensitivity or –resistance but was strongly and positively correlated with MAGE (intra-day 
glycaemic variability) and time per day spent above 6.0 mmol·L-1.  Weak correlations were 
found between dietary glycaemic load and glucose control. 
5.2.3 Secondary aims  
• To investigate the effects of dietary intake with different macronutrient ratios on glycaemic 
variability, glucose control and insulin sensitivity. 
Hypothesis 3:  Low carbohydrate-high fat food consumption will be associated with least 
glycaemic variability, healthy glucose control and high insulin sensitivity. 
 
This hypothesis is accepted.  The lowest glycaemic variability and best insulin sensitivity was 
observed for the low CHO-high fat cluster.  Glycaemic variability was the highest in the high 
CHO-low fat cluster, whereas insulin sensitivity was the lowest in the high CHO-high fat 
cluster.  Significant differences between the clusters in glucose control measures were not 
found. 
 
• To investigate the relationship between glycaemic variability and markers of glucose control.  
Hypothesis 4: There will be weak correlations between glycaemic variability and traditional 
glucose control measures. 
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This hypothesis is accepted.  Glycaemic variability did not correlate well with the traditional 
measures of glucose control.   
 
• To determine the relationships between the parameters of glycaemic variability and insulin 
sensitivity. 
Hypothesis 5: There will be an inverse relationship between insulin sensitivity and glycaemic 
variability. 
 
This hypothesis is rejected.  An increase in insulin resistance was associated with small 
decreases in glycaemic variability.  Likewise, an increase in whole-body insulin sensitivity 
was associated with increases in glycaemic variability.   
5.3 Purpose of the study 
The purpose of this study was to explore the potential of CGM as an early detector of 
glycaemic/glucose control (and insulin resistance) and its relation to CRF and dietary intake.   
 
Twenty-seven apparently healthy individuals participated in the study; 22 participants were classified 
as healthy according to their glucose control (as per the traditional measures and glycaemic 
variability).  Four participants could be classified as potentially prediabetic according to the 
traditional measures of glucose control – three according to HbA1c (of which one also had a FPG 
concentration equal to the pre-diabetic cut-off value) and one according to the OGTT 2-h [glucose].   
 
Although the participant with the elevated FPG reported to be fasted when his bloods were drawn, 
one cannot dismiss the possibility that he was not completely fasted for at least 8 hours.  The latter 
participant was also the person with the highest average CGM glucose value, which is in line with 
the high FPG measure.  All the participants’ glucose control measures were well below the diabetic 
values (ADA, 2017). 
 
Only two participants were identified with glycaemic variability above the healthy range of CGM 
CV% values.  One of these participants also had a pre-diabetic HbA1c value, but the other participant 
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From the above, it does not appear that CGM-derived glycaemic variability indices are more useful 
than the traditional glucose control measures in the identification of individuals with diminishing 
glucose control.  Notably, however, the results of this study should be interpreted in light of the 
considerations and limitations regarding CGM and the measurement of glycaemic variability.  These 
will be discussed next, before discussing the findings of the study from section 5.5 onwards. 
5.4 Continuous glucose monitoring 
5.4.1 Accuracy of glucose sensor readings 
As per the manufacturer, the correlation between the readings of the FreeStyle Libre Pro sensor (the 
sensors that were used in this study) and capillary [glucose] is very high (r = 0.954; n = 8739).  The 
mean absolute relative difference (MARD) (the average relative error of all sensor readings) of the 
sensor versus the finger-prick reference [glucose] is 11.1%.   
 
Parkes et al. (2000) developed a consensus error grid with different zones (A to E) to distinguish 
between discordant results that will have clinical implications or not. Two methods or instruments 
that agree completely (e.g. exactly the same concentration), will provide a data point in the centre of 
zone A on a correlation line graph.  Zone A represents the area on the graph where slight errors in 
measurement have no effect on clinical action.  Zone B represents the degree of errors where slightly 
different clinical actions are required.  In the comparison of the FreeStyle Libre Pro sensor with the 
YSI (Yellow Springs Instrument) analyser reference tests, 86.7% of the sensor’s glucose values fell 
within zone A and 99.7% fell in zones A and B (Bailey et al., 2015).  These findings strongly support 
the manufacturer’s claims regarding the sensor’s accuracy.   
 
Bailey et al. (2015) also showed that the sensors remain stable throughout the 14-day wear period 
after they were calibrated in the factory.  Tsoukas et al. (2020) reported a MARD of 11.2% (compared 
to plasma [glucose]) for sensors that were 1 – 2 days old and 13 – 14 days old, and a MARD of 6.6% 
when the sensors were 5 – 7 days old.  Dye et al. (2010) reported a concordance correlation of 0.8764 
(Kendall’s W, n = 15, p < 0.001) between glucose sensor values and capillary whole blood 
concentrations.  Although the latter researchers used Glucoday® continuous ambulatory glucose 
monitoring devices, these sensors also measure interstitial [glucose]. 
 
It should also be considered that the CGM sensors measures interstitial glucose and not blood glucose.  
It has been reported that interstitial glucose yields up to 10% lower OGTT AUCs, compared to blood 
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glucose values (Hasson et al., 2010).  On the other hand, interstitial glucose assessment is considered 
a suitable replacement for the measurement of blood glucose (Rebrin & Steil, 2000).  The main 
consideration when using a sensor to record OGTT responses, is the time lag in interstitial [glucose] 
that could range between 5 to 12 minutes (Rebrin & Steil, 2000) or even 15 minutes (Dye et al., 
2010).  Considering the aims of the current study, the lag-time of the sensors was not a confounding 
factor.   
 
Several authors reported the occurrence of low [glucose] (< 3.9 mmol·L-1) in their data (Mazze et al., 
2008; Shah et al., 2019; Thomas et al., 2016).  For instance, Mazze et al. (2008) found that 
participants with normal glucose tolerance spent an average of 3 ± 3% of the day (equating to ± 45 
min per day) below 3.9 mmol·L-1 and an average of 1 ± 1% of the day (equating to ± 15 min per day) 
below 3.3 mmol·L-1.  These findings are comparable to those of the current study where the average 
time per day spent below 3.0 mmol·L-1 was 22 min).  However, none of the participants in our study 
reported symptoms of hypoglycaemia.  The manufacturer of the Freestyle Libre Pro glucose sensors 
reported that 40% of the values that they recorded below 3.3 mmol·L-1 were actually > 4.4 mmol·L-1 
according to standard laboratory analysis of blood glucose.  Therefore, these hypoglycaemic glucose 
concentrations should be interpreted with caution. 
5.4.2 Glucose profiles of the participants 
It is a common finding that healthy individuals can present with glucose excursions of up to and 
above 10.0 mmol·L-1 (Borg et al., 2010; Madhu et al., 2013; Thomas et al., 2016; Zeevi et al., 2015).  
In a more recent study, Hall et al. (2018) investigated the CGM profiles of individuals with healthy 
glucose control according to the traditional measures.  In agreement with previous studies, they 
identified normal glucose tolerant individuals with postprandial glucose excursions, as measured by 
CGM, in the pre-diabetic and diabetic ranges.  They also confirmed the finding of Zeevi et al. (2015) 
that showed individuals react differently to the same meals when looking at the extent of the 
postprandial glucose excursions.   
 
None of the participants in the current study reached the degree of glucose excursions that have been 
reported in the previous studies, although 17 (63%) participants did exceed 7.8 mmol·L-1 at least once 
during their monitoring period.  No participant reached a 10.0 mmol·L-1 [glucose], which, according 
to experimental studies, is the extent of hyperglycaemia that causes inflammation (Esposito et al., 
2002), oxidative stress (Ceriello, et al., 2008; Monnier et al., 2006), and endothelial damage (Ceriello 
et al., 2013).  The clinical significance and possible long-term effects of the glycaemic variability and 
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glucose excursions in the profiles of the participants in the current study is therefore difficult to 
interpret.  Possible reasons for the lower observed peak [glucose] in this study might be related to the 
small number of participants and the strict inclusion criteria, as well as the fact that the glucose 
monitors only record 15-min average [glucose].  Furthermore, the athletes in the study by Thomas et 
al. (2016) were consuming very large amounts of carbohydrates and sugar, while standard meals were 
given to the participants in the studies of Hall et al. (2018) and Zeevi et al. (2015).  These standard 
meals were specifically planned to elicit high postprandial glucose responses.  Also, as described in 
section 5.6, South Africans typically do not follow diets that are low in fat (Vorster et al., 2013) and 
this was consistent with the current study sample.  The addition of fat to a meal typically lowers the 
postprandial glucose response (Collier & O’Dea, 1983). 
5.4.3 The glycaemic variability profiles of the participants  
Foreman et al. (2020) considered 48 hours as the minimum time needed to reliably measure 
glycaemic variability.  With the exception of two previous studies (Borg et al., 2010; Riddlesworth 
et al., 2018) where CGM was used for more than a week, most other studies are limited to 2 – 3 days 
of CGM data (Gude et al., 2017; Hanefeld et al 2014; Hill et al., 2011; Paing et al., 2020; Shah et al., 
2019).  In this study, glycaemic variability was calculated from at least 7 full days’ CGM recordings, 
thus exceeding most other studies.  Hence, the findings of this study can be considered with 
confidence. 
 
The participants in this study presented with varying degrees of glycaemic variability, however, none 
of the indices were higher (indicating large variability) than the normative values for healthy 
populations, as defined by Hill et al. (2011).  The latter study included 70 non-diabetic individuals, 
however, some had fasting plasma [glucose] of < 6.7 mmol·L-1, which is 1.1 mmol·L-1 above the 5.7 
mmol·L-1 cut-off value for pre-diabetes (American Diabetes Association, 2017; SEMDSA, 2017).  
Tabák et al. (2012) noted that overt T2DM is only diagnosed after the disease state has already 
progressed to the point of beta-cell dysfunction.  Thus, even though the study participants of Hill et 
al. (2011) excluded individuals with overt T2DM, they undoubtedly included individuals who were 
pre-diabetic, and thus not healthy.  Therefore, the reported normative glycaemic variability values of 
Hill et al. (2011) cannot be considered true and valid normal ranges for healthy individuals.   
 
Foreman et al. (2020) also aimed to determine reference values for CGM-derived glycaemic 
variability indices (mean glucose, SD, CV, MAGE, MODD) of healthy (n = 470), pre-diabetes (n = 
184) and T2DM participants (n = 197).  However, their reference values largely overlapped between 
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the different categories.  In other words, the range of values (2.5th – 97.5th percentiles) that was 
suggested for heathy participants, overlapped between 86% to 99% with the prediabetic range and 
between 63.8% – 81.1% with the diabetic range.  In the case of the 10th – 90th percentiles for healthy 
persons, 76.4% – 84.3% of the values overlapped with the pre-diabetic range, while 27.7% – 54.7% 
overlapped with the diabetic range.   
 
In the absence of clear reference values, the interpretation of glycaemic variability indices is 
problematic and thus the biggest obstacle in its utilisation in clinical practice.  Hence, despite the 
convenience of CGM sensors and the valuable data it records, it is currently not possible to 
definitively categorise individuals as healthy, or in varying degrees of disease states; at least not based 
on glycaemic variability indices alone.  The findings of the current study are confirmation of this 
inference.   
 
Some individuals presented with insulin resistance and postprandial hyperinsulinaemia, however, 
their CGM-derived indices of glycaemic variability were not atypical.  Thus, it is plausible that the 
postprandial glycaemic excursions that is currently deemed healthy or without risk, is actually lower 
than the level of 7.8 mmol·L-1 that is presently accepted (American Diabetes Association, 2017; 
González-Rodríguez et al., 2019).  Neither Foreman et al. (2020) and Hill et al. (2011), who provided 
reference values for CGM-derived indices, nor studies that aimed to characterise typical ambulatory 
glucose profiles (Borg et al., 2010; Nomura et al., 2011; Mazze et al., 2008) provide suitable 
information to assess potential future risk for the development of insulin resistance-related chronic 
disease states.  In order to derive reliable reference values that can be used in clinical settings, the 
long-term monitoring of exclusively healthy individuals is needed.   
5.4.5 Limitations and considerations of glycaemic variability measures 
The current study was unable to conclude that glycaemic variability may be a better and earlier 
method than traditional measures of glucose control for the detection of individuals possibly at risk 
of deteriorating metabolic health.  Nonetheless, the current limitations of the measures of glycaemic 
variability should be considered before summarily dismissing the potential importance of CGM in 
healthy individuals.  
 
CV% has been suggested by multiple authors as the best measure of overall glycaemic variability 
(Acciaroli et al., 2018; Danne et al., 2017; Foreman et al., 2020).  Conversely, it is also frequently 
said that no single measure has yet been identified to optimally represent glycaemic variability and 
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no single measure is able to characterize  all aspects of glucose control and metabolism (Monnier et 
al., 2008; Peyser et al., 2018; Rodbard, 2009; Suh & Kim, 2015).  Multiple measures and in 
combination are therefore used when assessing glycaemic variability.  For instance, MODD is a 
measure of inter-day glycaemic variability, describing the average difference in daily glycaemic 
patterns (Hill et al., 2011).  Overall stability of day-to-day glucose is thus assessed by this measure. 
A limitation, though, is that individuals without fixed daily mealtimes will have a larger MODD value 
compared to another individual with fixed eating patterns, even though their glucose control, average 
glucose, times-in-zone and glucose tolerance may be the same.  Furthermore, there is no evidence in 
the literature that these two hypothetical individuals will be at different degrees of risk should MODD 
be the only difference between them.   
 
MAGE is the most-used parameter to quantify average intra-day glycaemic variability (Hill et al., 
2011) since it is related to the extent of postprandial glucose excursions (Suh & Kim, 2015).  
Unfortunately, none of the glycaemic variability measures give information regarding the frequency 
of glucose excursions.  Equal MAGE values for two individuals can, for example, be originating from 
two different glucose profiles.  For example, a single glycaemic excursion of 1.0 mmol·L-1 above SD 
will equate to an individual having a MAGE value of 1, while a second individual may experience 
four glucose excursions, e.g. one of 2.0 mmol·L-1 above his SD, another 1.2 mmol·L-1 above SD and 
two of 0.7 mmol·L-1 SD which will also result in a  MAGE value of 1.  The latter individual, however, 
clearly experience more severe glycaemic variability.   
 
Time spent in the range of 3.9 mmol·L-1 to 7.8 mmol·L-1 (Shah et al., 2019), or 10.0 mmol·L-1 is 
widely used (Paing et al., 2020; Rodbard, 2009; Vigersky & McMahon, 2019) and recommended 
when investigating glucose control (Danne et al., 2017).  These limits may, however, create an 
inaccurate picture of the degree of glucose control, or glycaemic variability, in a healthy individual, 
especially with regards to the lower limit.  As was reported by Rodbard (2020), time spent within a 
zone decreases when an individual’s mean glucose is below 6.6 mmol·L-1, increasing the time spent 
in hypoglycaemia([glucose] < 3.9 mmol·L-1).  Furthermore, [glucose] below 3.0 mmol·L-1 is widely 
considered a clinical hypoglycaemic concentration, especially in healthy persons  (Danne et al., 2017; 
Shah et al., 2019; ) and without any signs or symptoms that accompany hypoglycaemia (mainly 
involving the nervous system and brain dysfunction).  Venous [glucose] as low as 2.75 mmol·L-1 may 
be deemed normal (Guerci et al., 2013).  This leaves the question how applicable the lower limit of 
3.9 mmol·L-1 is to describe glucose control in non-diabetic populations.  Perhaps this is the exact 
reason why numerous studies involving non-diabetic populations only consider hyperglycaemic 
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excursions, or time spent above 7.8 mmol·L-1 (Borg et al., 2010; Gonzalez-Rodriguez et al., 2019; 
Márquez-Pardo et al, 2020).   
 
It is uncertain whether it is the relative or the absolute height of a glucose excursion that holds most 
associated risk.  If two hypothetical individuals namely, person X with a baseline [glucose] of 3.3 
mmol·L-1 and person Y with a baseline [glucose] of 5.4 mmol·L-1 both present with excursions up to 
7.7 mmol·L-1, will the excursions be associated with the same risk?  Uncertainty regarding this 
scenario questions the true risk associated with large glycaemic variability in healthy, non-diabetic 
populations.  Considering that the normal postprandial increase in [glucose] is 3.0 mmol·L-1 (Tabák 
et al., 2012), one wonders whether higher glycaemic variability, but lower average [glucose] (person 
X) , means higher risk for future development of insulin resistance or CVD.  Alternatively, is person 
Y with lower overall glycaemic variability, but higher average [glucose] and similar average 
glycaemic excursions than person X at higher risk for future disease? 
 
The design of the current study was not suitable to address these uncertainties and larger, longitudinal 
studies are needed for definitive answers.  It has not yet been investigated what the potential long-
term implications of varying degrees of glycaemic variability have in the development of insulin 
resistance.  Nonetheless, an important finding of the current study was that hyperinsulinaemia can be 
present without any abnormalities in glucose control or glycaemic variability parameters.   
5.5 Associations between cardiorespiratory fitness and measures of glucose 
control 
The findings of this study suggest that CRF is most strongly related to insulin sensitivity in 
comparison to glucose control and glycaemic variability.  This finding adds to the existing evidence 
that insulin sensitivity improves with high levels of CRF (Carcino-Ramirez et al., 2018; Grace et al., 
2017; Solomon et al., 2015).  Although maximal aerobic capacity (up to ~ 40% of VO2max) (Bouchard 
et al., 1998; Bouchard et al., 1986) and the potential to improve maximal aerobic capacity with 
exercise training is. to a certain degree, genetically determined (Keller et al., 2011; Timmons et al., 
2010), different types of training is well known to improve maximal aerobic capacity (Lundby et al., 
2017; Roca et al., 1992; Vollaard et al., 2009).  Thus, it remains a possibility that the correlation 
between insulin sensitivity and CRF is not due to CRF level per se.  Rather, it could be due to the 
effects of the regular and increasing levels of physical exercise training that are needed to elicit 
notable changes in CRF.  In other words, improved insulin sensitivity that is associated with high 
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CRF could, in fact, be due to the cumulative effects of acute exercise that have been shown previously 
to improve insulin sensitivity, even in young and healthy individuals (Blaak et al., 2012; Duvivier et 
al., 2017; Short et al., 2013).   
 
Following insulin sensitivity and -resistance, HbA1c was the next strongest (negative) associated with 
CRF.  Neither FPG, 2-h [glucose], nor glycaemic variability indices revealed meaningful associations 
with CRF.  Insulin sensitivity had, in turn, the strongest association with HbA1c among all the glucose 
control and glycaemic variability measures.  A small association was found between insulin 
sensitivity and overall glycaemic variability.  From this study it thus seems that overall glucose levels 
may decrease with increased CRF, but it does not seem that glycaemic variability or fluctuations and 
overall postprandial glucose excursions are related to CRF.  
 
It must be mentioned that there is no consensus as to what constitutes a true maximal aerobic capacity 
test (Riebe et al., 2016).  Researchers apply any single, or any combination of five criteria to declare 
a test maximal, however, the implementation of these criteria to assess whether a test was maximal 
has been found not viable (Poole et al., 2008).  All participants in the current study reached at least 
one criterion indicating a maximal test, but not all attained definitive plateaus in VO2.  For these 
reasons, VO2peak was reported instead of VO2max and it is thus possible that the participants’ true 
cardiorespiratory fitness was underestimated.  It is also possible that another parameter of physical 
exercise, such as frequency, duration or intensity may in fact correlate better with glucose control, 
rather than aerobic fitness (CRF) level.   
5.6 Dietary characteristics of the participants 
All the participants were encouraged to follow their habitual diets and eating patterns.  None of the 
participants followed any restrictive diets and a wide range of foods were consumed.  If any, one 
would classify their diets as high carbohydrate-high fat, with the percentage of energy intake from 
carbohydrates and fats being 41 ± 7% and 40 ± 5%, respectively.  The current dietary guidelines for 
South Africans stipulate that the intake of carbohydrates should constitute 50% of total energy intake, 
with less than 10% of total energy intake from added sugars (Vorster et al., 2013).  South Africans, 
however, typically eat foods with less than 50% of energy from carbohydrates and they also tend to 
consume more sugars than 10% of daily energy.  Their intake of dietary fibre is also low (< 20 g per 
day) (Vorster et al., 2013).  The tendency for lower carbohydrate intake was consistent with the 
average dietary intake of the participants.  The average intake of sugars of the participants met the 
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recommended amount, while their fibre intake bordered on low (average of 20.6 ± 6.3 g per day). The 
participants’ total intake of fats was, on average, 10% higher than is recommended by current national 
and international dietary guidelines (WHO, 2018; Vorster et al., 2013), however, no individual 
participant’s diet could be outrightly called a low-carbohydrate, high-fat diet.  The latter is defined as 
15 – 20% of energy from carbohydrates and 60 – 65% energy from fat (Burke et al., 2018). 
 
Daily caloric intake varied considerably among participants, as well as between days for the same 
individual.  Nevertheless, the average daily energy intake for each participant remained fairly 
consistent.  Unusually high or low energy intake on a particular day was typically followed by a 
reverse pattern on the next day.  
 
The average day-to-day variations in daily macronutrient and glycaemic load consumption for each 
individual, as well as for the group were calculated.  The average individual day-to-day 
(intrapersonal) variation in glycaemic load was larger than the group’s average day-to-day variation.  
The large intrapersonal day-to-day variability in glycaemic load would have negatively influenced 
the strength of the correlations between glycaemic load and glycaemic variability, glucose control 
and insulin sensitivity measures.  Thus, with less variance and a larger sample size, the relationships 
between the outcome variables might be stronger.   
 
The group’s average day-to-day variation in dietary macronutrient intake revealed that there was also 
considerable variation in protein consumption and even more for fat intake.  This finding warranted 
further investigation into the dietary composition of the participants, other than the glycaemic load 
alone.  These results are discussed in section 5.8.1. 
5.7 Associations between glycaemic load and measures relating to glucose 
control 
To my knowledge, this is the first study to specifically investigate the associations of glycaemic 
variability indices with dietary glycaemic load.  The rationale for this analysis was based on the 
known relation between carbohydrate ingestion and postprandial glucose excursions.  
 
It was found that a higher daily dietary glycaemic load was associated with increases in time per day 
spent above 6.0 mmol·L-1, MAGE and MODD.  Of all the variables, MAGE was the variable most 
strongly associated with dietary glycaemic load.  This was an expected finding.  The observation that 
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the height of postprandial glucose excursions is determined by the type of carbohydrates consumed, 
led to the development of GI values for carbohydrates (Jenkins et al., 1981).  However, it is also 
known that postprandial glucose is independently affected by the amount of CHO ingested.  Thus, 
the concept of glycaemic load was introduced which takes both the type and amount of carbohydrate 
consumed into consideration (Foster-Powell et al., 2002).  It is thus intuitive that the glycaemic load 
of an individual’s diet should, at least in part, affect the magnitude of the spikes in postprandial 
glucose values.   
 
Dietary glycaemic load was minimally correlated to HbA1c, suggesting that this measure of glucose 
control is unable to predict the effect of a healthy individual’s diet on glucose control.  This finding 
is partly supported by the results on the differences between the macronutrient clusters of participants, 
as discussed in section 5.8.1.  Briefly, it was discovered that there were large differences in OGTT 
insulin levels and glycaemic variability indices between the clusters, whereas there were almost no 
differences in traditional glucose control measures. 
5.8 The characteristics of the participant clusters according to dietary 
macronutrient intake  
To gain further insight into the role of diet on glycaemic variability, glucose control and insulin 
sensitivity, the participants in the current study were grouped into three clusters according to their 
reported macronutrient intake.  The cluster analysis was performed to include the collective inputs of 
all the macronutrients, as the postprandial insulin response is not solely dependent on carbohydrates.  
Protein, for example, can cause postprandial insulin secretion that is disproportionate to the 
incremental glucose AUC (Wolever et al., 2016).  Fats do not independently stimulate secretion of 
insulin, but the co-ingestion of fats with other foods has an influence on the postprandial glucose and 
insulin levels (Nuttall & Gannon, 1991).  For instance, Collier & O’Dea, (1983) observed that the 
consumption fat together with carbohydrates lowers the postprandial glucose response, although it 
does not necessarily influence insulin secretion.  This finding is confirmed by the MAGE results of 
the current study, namely that the high CHO-low fat cluster had a higher average MAGE than the 
high CHO-high fat cluster which had higher insulin values.  When considering the role of the incretin 
hormones on insulin secretion, together with the role of the gut microbiome on the postprandial 
glucose and insulin responses, the combined effects of all the macronutrients cannot be ignored by 
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The macronutrient percentages of participants in the high CHO was the closest to current dietary 
recommendations.  Current recommendations stipulate that energy intake should be 50% from 
carbohydrates and less than 30% from fats.  In the case of the high CHO, their energy from 
carbohydrates was 48.2% (± 4.4%) and the energy from fats was 34.9% (± 2.6%).  The low CHO-
high fat was the closest to a low carbohydrate-high fat diet, although their intake of carbohydrates 
(31.3 ± 4.0% of energy intake) was too high and their fat intake (46.5 ± 3.8%) was too low (Burke et 
al., 2018).  The high CHO-high fat cluster’s diet was characterised by almost equal contributions to 
the daily energy intake by carbohydrates and fats (40.3 ± 2.6% and 41.6 ± 2.4% from carbohydrates 
and fats, respectively).  Interestingly, the latter macronutrient breakdown was recently described as a 
moderate-carbohydrate diet (Ebbeling et al., 2020). 
5.8.1 Differences between the dietary macronutrient clusters 
The first secondary aim of this study was to investigate the differences between habitual dietary 
macronutrient compositions on glycaemic variability, glucose control, and insulin sensitivity.  This 
analysis clearly showed that hyperinsulinaemia is prevalent before any meaningful changes in 
[glucose] during the OGTT, average CGM [glucose], or other traditional glucose control measures 
become evident. 
 
The differences between clusters were most pronounced for insulin sensitivity and the [insulin] of the 
OGTTs.  The high CHO-high fat cluster had the highest insulin response during the OGTT, the low 
CHO-high fat cluster had the lowest insulin response during the OGTT, and the intermediate insulin 
response came from the high-CHO cluster.  Similar distinctions were not reflected in the OGTT 
[glucose], fasting plasma glucose, 2-h glucose, HbA1c levels, or average CGM [glucose]. 
 
Regarding glycaemic variability, the most pronounced differences were observed in MAGE (intra-
day variability).  MAGE was highest for the high CHO-high fat cluster, with no significant difference 
between the low CHO-high fat and high CHO-high fat clusters.  Furthermore, the time per day spent 
above [glucose] of 6.0 mmol·L-1 increased between clusters as the percentage of dietary 
carbohydrates increased.  This finding thus supports the correlations between glycaemic load, MAGE 
and time per day spent above 6.0 mmol·L-1 (section 5.7).  Carbohydrates are the principle dietary 
component that causes a rise in blood glucose levels (Ludwig, 2002).  Hence the more carbohydrates 
consumed throughout the day, the higher the expected postprandial glucose excursions, as well as 
time spent above fasting [glucose] levels.  This deduction explains why dietary glycaemic load is 
considered the best predictor of postprandial glucose (Ludwig & Ebbeling, 2018).   
Stellenbosch University https://scholar.sun.ac.za
 
Page | 93  
 
 
Although the glucose variability measures cannot be directly related to insulin levels, as insulin 
cannot be measured continuously with glucose, an interesting observation was nonetheless made.  
The five-point OGTTs revealed higher average insulin levels and insulin AUC for the high CHO-
high fat cluster (moderate intake of carbohydrates), than the high CHO cluster (highest intake of 
carbohydrates), which had the highest MAGE values and daily time spent above 6.0 mmol·L-1.  These 
results suggest that a diet consisting of equally high amounts of carbohydrates and fat might be the 
strongest elicitor of hyperinsulinaemia; but that the presence of hyperinsulinaemia does not 
necessarily coincide with the degree of free-living glycaemic variability or any other measures of 
blood glucose levels.   
 
The role of a high carbohydrate-high fat diet in the development of hyperinsulinaemia and/or insulin 
resistance, as suggested by the findings of the current study, can be considered by looking at the 
metabolic effects of these macronutrients.  The foods that we consume have specific hormonal 
responses that determine the way in the body uses the ingested calories.  The most important hormone 
is insulin, which is secreted directly in response to a rise in blood glucose and subsequently puts the 
body in a state of anabolism during which circulatory metabolic fuels are decreased.  The latter is 
achieved because insulin facilitates glucose uptake into the systemic cells, while also suppressing 
adipose tissue to release fatty acids.  Combined, these actions promote the production and storage of 
glycogen and fat (Ludwig & Ebbeling, 2018).  The addition of fats to a carbohydrate meal might 
lower the postprandial glucose to a degree, but not necessarily the insulin response (Collier & O’Dea, 
1983).  This is explained by the fact that the postprandial insulin response is not only dependent on 
the stimulus from elevated blood glucose levels, but also by incretin hormones that are secreted into 
the circulation by the enteroendocrine cells of the stomach and intestines in response to the ingestion 
of food, especially carbohydrates (Greiner & Bӓckhed, 2011 & Drucker, 2007).   
 
The CIMO (Ludwig & Ebbeling, 2018) proposes that consistently high intakes of carbohydrates cause 
obesity due to the high postprandial levels of insulin and its subsequent effects.  High circulating 
concentrations of insulin promote the storage of carbohydrates and fats and these are consequently 
not readily available for energy production.  It also stimulates feelings of hunger and hence, more 
energy intake.  Hyperinsulinaemia, in response to high carbohydrate intake (as in the high CHO and 
high CHO-high fat clusters), raises one’s appetite due to the suppression of the breakdown and 
utilisation of stored glycogen and fats for energy production.  Hence, hyperinsulinaemia is the 
underlying cause of overnutrition and obesity and not the consequence of overnutrition and obesity.  
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It can also be argued that high intakes of fat, together with high intakes of carbohydrates, can be 
expected to have more detrimental effects than a high carbohydrate-low fat diet.  Even though post 
prandial glucose may not be higher in response to a high carbohydrate-high fat diet, the amount of 
carbohydrates in the latter diet is still enough to keep the body from utilising fats (stored and 
consumed).  The high intake of fats, together with a high intake of carbohydrates, potentially place 
the body in prolonged periods of energy storage, due to high insulin secretion, similar to a high 
carbohydrate-low fat diet.  Ingesting equally high amounts of carbohydrates and fats probably 
exceeds the body’s need for energy, which inevitably are then stored, or utilised for immediate energy 
purposes and the remainder is then stored.  It is possible that overnutrition manifests earlier when 
excessive amounts of fat are consumed with equally high amounts of carbohydrates.  In line with the 
CIMO, Caputo et al. (2017) and Peterson & Shulman (2018) also concluded that chronic overnutrition 
leads to the development of insulin resistance.  
 
The high CHO-high fat cluster’s diet is comparable to the Western diet, which is typically a high-
sugar (or high simple carbohydrates), high-fat diet (Gentile & Weir, 2018; Mente et al., 2009).  
Chronic consumption of this type of diet is highly associated with disease states, such as coronary 
heart disease (Mente et al., 2009), CVD (Ramji & Davies, 2015), obesity and T2DM (Mbanya et al., 
2010; Verma & Hussain, 2017).  The findings of the current study revealed that the highest levels of 
insulin were present among participants whose diets were high in fat, as well as carbohydrates, and 
thus support the association between a typical “Western diet” and chronic disease.  
5.10 Cardiorespiratory fitness, diet, and the maintenance of health  
The findings of the study suggest that CRF is more related to better insulin sensitivity, than it is to 
lower average glucose levels (mean CGM glucose and HbA1c) or postprandial glucose excursions 
(MAGE, 2-h [glucose] and OGTT glucose AUC).  Therefore, even though there is value in studies 
that investigate the effects of exercise on various aspects of glucose control, the findings of studies 
that focus solely on glucose control may possibly underestimate the beneficial health effects of 
exercise regarding the promotion of metabolic health.   
 
The current study revealed very strong associations between CRF and insulin sensitivity, whereas 
average dietary glycaemic load did not correlate with insulin sensitivity.  Based on the strong positive 
correlation between CRF and insulin sensitivity, the importance of CRF as a possible and important 
protective factor against the diminishing of insulin sensitivity cannot be disregarded.  Furthermore, it 
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must be considered that CRF was directly and objectively measured, while glycaemic load is an 
average value that was dependent on the collection of many estimated values.  The strength of the 
association between glycaemic load and insulin sensitivity in the results of this study may be lower 
than the true association.   
 
Considering the studies that have found a positive effect of acute exercise on the insulin sensitivity 
of healthy individuals as discussed in section 2.4.3, it is also plausible that increases in CRF may be 
linked to a larger effect on insulin sensitivity over a shorter period of time, compared to that of dietary 
glycaemic load.  This does, however, not disregard the importance of dietary intake for the prevention 
of insulin resistance. 
 
Glycaemic load was more strongly associated to MAGE than CRF. Neither CRF, nor daily glycaemic 
load revealed any noteworthy associations with overall glycaemic variability.   
 
The findings highlighted above reiterate the view of Malhotra et al. (2015) that “you cannot outrun a 
bad diet”.  On the other hand, insulin responses to the OGTT and insulin sensitivity might be more 
important for health preservation, as both showed stronger associations with CRF than with dietary 
glycaemic load.  This by no means suggests that exercise (as a mediator of CRF) will fully protect 
individuals from becoming hyperinsulinaemic, or insulin-resistant while they are eating a diet of 
ultra-processed and/or junk foods and diets which are high in sugar.  No author argues against these 
types of diets being a sure promoter of health decline (Fernström et al., 2019; Herforth et al., 2019; 
World Health Organization, 2018).  If anything, these findings demonstrate why a ‘good/healthy’ diet 
(which restricts carbohydrates, thus preventing high secretion of insulin), combined with physical 
exercise promotes long-term health better than either diet or exercise alone.  This assertion is 
supported by Hopper et al. (2013) who suggested that the postprandial glucose response to a meal is 
dependent on an individual’s insulin sensitivity, together with the glycaemic load of the meal.   
 
The question regarding the importance of diet versus exercise for the maintenance of health touches 
on the topic of “the fat-but-fit paradox”, as discussed by Ortega et al. (2018).  Findings from many 
observational studies led to the formulation of the phrase “fat-but-fit” which suggests that CRF may 
be more important for the maintenance of health compared with an ideal body weight (Ortega et al, 
2018).  Although the relation between body composition and diet, CRF and glucose control in the 
current study was not a key consideration, it did provide evidence that hyperinsulinaemia can be 
present in healthy weight individuals; reiterating that one is not necessarily healthy when at “healthy” 
Stellenbosch University https://scholar.sun.ac.za
 
Page | 96  
 
weight.  Furthermore, together with insulin sensitivity that was best correlated with CRF, these 
findings add to the proposition of the fit but fat paradox.  This does not, however, contradict the 
evidence on the importance of diet, irrespective of CRF.  The current study’s finding that different 
dietary macronutrient compositions is associated with significant differences in OGTT insulin levels, 
support the importance of dietary intake.  Interestingly, evidence also exists that weight loss is not 
necessarily needed to reap the benefits of either a low-carbohydrate diet (Francois et al., 2017), or 
exercise interventions (Hamer & O’Donovan, 2010). 
 
Central to the notion that both diet and exercise are important for the maintenance of health, is the 
review by Francois et al. (2017).  In their review the authors discuss the benefits of combining dietary 
carbohydrate restriction with HIIT in the treatment of T2DM patients.  It is very reasonable to expect 
added benefits when HIIT is added to a carbohydrate-restricted diet or vice versa.  A combination of 
exercise with a diet that does not stimulate hypersecretion of insulin would promote metabolic health 
to a larger extent, than either intervention independently. 
 
Metabolic health is defined in terms of the presence of the metabolic syndrome criteria (Ortega et al., 
2016).  The manifestation of the metabolic syndrome marks the presence of insulin resistance (Kelly 
et al., 2014; Nolan & Prentki, 2019; Reaven, 1988).  The observation that some overweight 
individuals may be metabolically healthy (related to the fat-but-fit paradox) (Ortega et al., 2016), 
while “healthy” weight individuals present with hyperinsulinaemia or insulin resistance, adds to the 
existing evidence in favour of the measurement of insulin levels for the early detection of individuals 
at risk for future metabolic disease.  Identifying the cause allows for earlier intervention and 
prevention, rather than waiting for symptoms (the metabolic syndrome) to arise before attempting to 
intervene.  Thus, being overweight is not necessarily synonymous to being metabolically unhealthy. 
5.11 Effects of hyperinsulinaemia 
As was apparent from the differences between the dietary clusters, changes in insulin levels occur 
before any changes in glucose control.  This is not a surprising finding, as the literature widely 
supports the notion that hyperinsulinaemia is at the root of the development of non-communicable, 
lifestyle diseases (Crofts et al., 2015).  
 
The sooner any disease risk is identified, the sooner lifestyle changes can be made in order to slow 
down, stop, and reverse developing conditions.  Earlier lifestyle interventions in at-risk individuals 
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will buy more time, leaving more room for the preferred medicine, namely, preventative lifestyle 
changes, to become effective.  The identification of hyperinsulinaemia should thus be the goal for 
early identification of disease risk. 
 
As was already indicated by Rizza et al. (1985), insulin resistance is caused by hyperinsulinaemia in 
a feed-forward control process.  Thus, it can be argued that once insulin resistance develops, the 
postprandial glucose response, that is low enough to prevent harmful metabolic effects downstream, 
is significantly less than what is required in a healthy insulin sensitive individual.  Thus, as insulin 
resistance progresses, the postprandial glucose response that could be deemed healthy, is theoretically 
reduced, which explains why the development of insulin resistance and T2DM is typically described 
to be progressive (Taylor, 2013).  In other words, the same specific postprandial glucose response in 
a glucose tolerant, insulin sensitive individual will not be as damaging as it is in an individual who is 
already insulin-resistant.  This is, however, speculative, and possibly an oversimplified line of 
reasoning.  Either way, future well-designed longitudinal studies will have to be conducted to test this 
theory.  A similar speculation was made by Francois et al. (2018).  They mentioned the degree of 
insulin resistance of an individual may be the determining factor as to how drastically dietary 
carbohydrates should be restricted to elicit health improvements.  
 
One can further argue that measuring glucose control as the primary marker in the screening of an 
individual’s risk for T2DM and subsequent risk for CVD (Ceriello, 2005; Tabák et al., 2012) is not 
optimal, as deteriorations in glucose control indicate that an individual has already progressed to a 
disease state (Tabák et al., 2012; Wilcox, 2005).  It is well-described in the literature that 
hyperinsulinaemia and/or insulin resistance is present before glucose tolerance declines and pre-
diabetes starts to develop (DeFronzo & Ferrannini, 1991).  Impaired glucose tolerance develops due 
to beta-cell dysfunction, secondary to hyperinsulinaemia and subsequent insulin resistance 
(DeFronzo, 2009; Tabák et al., 2012; Wilcox, 2005).  Elevated glucose levels, or abnormal measures 
of glucose control, are thus symptoms that develop due to a longer-standing root cause, i.e., 
hyperinsulinaemia (Crofts et al., 2015).  Addressing metabolic health only once glucose levels are 
atypical is an unnecessarily late reaction.  Instead, measuring insulin levels presents health care 
workers with the opportunity to identify individuals at risk much earlier (Crofts et al., 2015).  The 
definition and manifestation of the metabolic syndrome supports this notion.  Elevated fasting glucose 
is merely one of the symptoms of the metabolic syndrome (Huang, 2009), whereas hyperinsulinaemia 
has been identified as the unifying cause of all the major symptoms (Kelly et al., 2014; Nolan & 
Prentki, 2019; Reaven, 1988), i.e., hypertriglyceridaemia (Raygor et al., 2019), hypertension (Wang 
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et al., 2017), and central obesity (Shimobayashi et al., 2018; Templeman et al., 2017) that collectively 
define a state of being at an increased risk for the development of T2DM and CVD (Huang, 2009; 
McCracken et al., 2018). 
 
Considering that hyperinsulinaemia is directly implicated in the mechanisms of certain cancers, 
atherosclerosis, endothelial dysfunction, gestational- and T2DM, hypertriglyceridaemia, non-
alcoholic fatty liver disease, obesity, dementia and neuropathies (Crofts et al., 2015), it makes sense 
that early detection and subsequent lifestyle interventions (i.e., alterations in diet and the addition of 
physical exercise) will go a long way in the  prevention of the metabolic syndrome and other eventual 
chronic disease states.  Prevention is always preferred above treatment.  If waiting for the 
manifestation of diminished glucose control or other symptoms of the metabolic syndrome before 
intervening, it would mean treatment, not prevention.   
 
There was no clear relation between free-living glycaemic variability and hyperinsulinaemia in the 
current study. Glycaemic variability also did not correlate strongly with glucose tolerance or insulin 
sensitivity.  Whether amplified glycaemic variability within the typical ranges of healthy individuals, 
in the absence of hyperinsulinaemia or insulin resistance, is a possible risk factor for deteriorating 
metabolic health in the future, cannot be deduced from the findings of this cross-sectional study.  
Future longitudinal studies would be needed to investigate this possibility.   
5.12 Associations between glycaemic variability and traditional measures of 
glucose control 
A secondary aim of this study was to investigate the associations between the traditional measures of 
glucose control and glycaemic variability.  These associations are important when considering 
whether CGM would suffice as an early detection method of declining glucose control.   The findings 
of this study, are however, inconclusive, as no meaningful associations were found between 
traditional glucose control measures and glycaemic variability.   
 
Foreman and colleagues (2020) investigated similar relationships in 851 individuals (men and 
women). of which 470 had healthy glucose metabolism, 184 were pre-diabetic and 197 participants 
were T2DM patients.  They reported the strongest correlation between mean glucose and fasting 
plasma glucose, and secondly between mean glucose and HbA1c in glucose tolerant individuals, 
whereas the current study found fasting plasma glucose to be better correlated to MAGE and MODD, 
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rather than mean glucose.  Similar to the current study, Foreman et al. (2020) found a strong 
correlation between mean CGM [glucose] and HbA1c in participants with pre-diabetes or diabetes, 
with no notable association with overall glycaemic variability.  This confirms the views about HbA1c, 
namely that it is unable to reflect individual differences in glycaemic variability (MacLeod et al., 
2013; Roberts et al., 2013).   
 
Foreman et al. (2020) reported larger positive correlations between glycaemic variability and 
traditional glucose control measures for their T2DM group, compared to the group of healthy 
participants.  This finding, together with the generally weak associations found in the current study, 
suggest that the sensitivity of the traditional measures of glucose control may be diminished in healthy 
individuals, compared to individuals with T2DM. 
 
The large difference in the sample size of the current study and that of Foreman et al. (2020) means 
that comparisons should be made with caution.  The small numbers of the current study, as well as 
the narrow age range of the participants, affects the strength of the correlations negatively.  
Nonetheless, the findings should stimulate interest in further and larger-scaled investigations.  Thus 
far, however, it is questionable whether the traditional measures of glucose control adequately 
quantify the degree of glycaemic variability as measured by CGM in healthy individuals.   
5.12.1 Glucose tolerance and its association with free-living glycaemic variability 
Interesting findings regarding the associations between 2-h [glucose], the glycaemic variability 
indices, and glycaemic load, deserve specific attention.  As the name implies, the OGTT is designed 
to quantify individuals’ glucose tolerance.  The 2-h OGTT [glucose], specifically, is used to 
differentiate between individuals with normal or impaired glucose tolerance.  Glucose tolerance is 
dependent on the complex interplay of insulin secretion and clearance and the actions of insulin, 
namely, promoting glucose disposal from the bloodstream and the inhibition of glucose production 
endogenously (Bergman, 1989).  It also predicts the degree of postprandial glucose excursions that 
can be expected during free-living conditions.  However, it is not glucose tolerance per se that is 
important, but the severity and frequency of glucose excursions during free-living conditions 
(Kohnert et al., 2012; Monnier et al., 2008).  It is expected that an individual with impaired glucose 
tolerance will experience higher postprandial glucose excursions, compared to an individual with 
normal glucose tolerance.  Better glucose tolerance should theoretically “protect” an individual 
against excessive postprandial glucose spikes (Hanefeld et al. 2014).  Thus, it was expected that 
individuals with better glucose tolerance will present with lower glycaemic variability.  The relevance 
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of the 2-h [glucose] to quantify glucose tolerance in healthy, non-diabetic individuals, is, however, 
questionable. 
 
Hanefeld et al. (2014) investigated the CGM profiles of individuals with normal and impaired glucose 
tolerance according to their OGTT results.  They found that both overall and intraday glycaemic 
variation (SD of CGM glucose and MAGE, respectively), were significantly higher in the glucose 
intolerant participants, compared with the glucose tolerant individuals.  They also found that the 2-h 
[glucose] of the OGTT is closer related to MAGE in glucose intolerant individuals than healthy, 
glucose tolerant individuals.  Therefore, they proposed that the 2-h [glucose] is more representative 
of the expected postprandial glucose responses during free-living conditions in those who are already 
glucose intolerant in comparison with healthy individuals with healthy glucose tolerance.  Madhu et 
al. (2013) investigated the 24-h CGM glycaemic profiles of normal glucose tolerant individuals and 
T2DM patients, who were categorised based on their OGTT results.  They concluded that the OGTT 
results overestimated the control of glucose in comparison with the 24-h glucose profiles.  In other 
words, the glucose excursions that typically occur during free-living conditions were higher than the 
participants’ 2-h [glucose].  The findings of Madhu et al. (2013) help to explain the findings of the 
current study regarding the associations that were found with 2-h [glucose].  
 
The 2-h [glucose] of the participants in the current study was not related to their free-living glucose 
excursions, i.e. higher 2-h [glucose] did not coincide with higher MAGE.  In fact, the contrary was 
closer to the truth.  Lower 2-h [glucose] was moderately associated with higher MAGE values, as 
well as other glycaemic variability indices.  This finding is somewhat in agreement with Brand-Miller 
et al. (2009) who demonstrated peaks in postprandial [glucose] after as little as 30 min.  Furthermore, 
the ADA (2001) suggested that the 1-h OGTT glucose value may be a better measure of glucose 
tolerance in non-diabetic individuals, than the 2-h value.  This is exactly what Foreman et al. (2020) 
reported, namely, overall glycaemic variability correlated best with the 1-h OGTT glucose value, as 
opposed to the [glucose] at other time points during the OGTT.  The 1-h [glucose] was the peak 
[glucose] during the OGTT.  Foreman et al. (2020) subsequently suggested that more attention be 
given to the peak [glucose] during a 2-h OGTT, instead of only considering whether the 2-h value is 
above or below a threshold value.   
 
It would make sense that the 2-h [glucose] will only be representative of peak postprandial [glucose] 
once considerable insulin resistance or impaired glucose tolerance has developed, as explained by 
Matsuda & DeFronzo (1999).  Furthermore, since hyperinsulinaemia is present before insulin 
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resistance, which again is present before impaired glucose tolerance develops (Crofts et al., 2015; 
Tabák et al., 2012), the OGTT and especially the 2-h [glucose] is probably largely incapable of early 
risk detection, or of providing any information, really, for normal glucose tolerant, but possibly 
insulin-resistant, individuals.  It can thus be deduced that the 2-h [glucose] from the OGTT cannot be 
used as an interchangeable term for postprandial glucose in normal glucose tolerant individuals and 
is in line with the negative correlation that was observed between 2-h [glucose] and MAGE in the 
current study.  
 
Although from a different perspective, the current study’s results support the suggestion that the 2-h 
[glucose] value cannot be used to quantify a healthy individual’s glucose tolerance.  It was observed 
that an individual can present with significant insulin resistance and postprandial hyperglycaemia 
without an atypical 2-h [glucose] (i.e. exceeding 7.8 mmol·L-1).  The latter is used as the cut-off to 
differentiate between healthy, glucose tolerant individuals and impaired glucose tolerance or 
prediabetic individuals (ADA, 2017; SEMDSA, 2017).  There were four individuals in the current 
study that were insulin-resistant and ten individuals (37% of the participants) whose maximum 
[glucose] during the OGTT (after 30 – 60 min) exceeded 7.8 mmol·L-1, even though their 2-h value 
was well below this cut-off value.   
 
The mismatch between 2-h [glucose] and MAGE is also a possible corroboration of the mechanism 
behind the proposed carbohydrate-insulin model of obesity (CIMO) of Ludwig & Ebbeling (2018).  
The negative correlation between 2-h [glucose] and MAGE in the current study could be understood 
in light of the reactive response to high postprandial glucose excursions.  Ludwig and Ebbeling (2018) 
explained that higher peak [glucose] in response to carbohydrate intake causes greater insulin 
secretion, which is followed by a rapid drop in blood [glucose] and potentially to levels lower than 
fasting [glucose]. The 2-h [glucose] in healthy individuals may thus be more characteristic, or 
descriptive, of the recovery from hyperglycaemia, rather than it being reflective of the postprandial 
glucose excursion.  At the very least, it seems that the 2-h [glucose] does not reliably quantify or 
describe glucose tolerance in non-diabetic individuals.   
 
Further evidence of the above argument is that there were no meaningful associations between the 
2-h [glucose] and insulin sensitivity, body composition or age in the current study.  Decreases in 
glucose tolerance occur secondary to the development of insulin resistance (Crofts et al., 2015; Tabák 
et al., 2012).  Decreased glucose tolerance and increased insulin resistance is subsequently well-
known to be associated with advancing age, as well as obesity (Brunner et al., 2006; Ko et al., 2006; 
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Shimokata et al., 1991; Walker et al., 2005).  There is thus no evidence in this study that the 2-h 
[glucose] is indicative of the presence or absence of health risk related to glucose metabolism in 
apparently healthy individuals.   
5.13 Association between glycaemic variability and insulin sensitivity 
With insulin being largely responsible for the drop in postprandial [glucose] (Gerich, 2000) and 
worsening glucose control being a symptom of insulin resistance (Hall et al., 2018), it was expected 
that glycaemic variability would be correlated with insulin resistance.  In contrast, higher glycaemic 
variability was associated with better insulin sensitivity, as measured by both the Matsuda index and 
the HOMA-IR.  This finding could first and foremost corroborate the model developed by Zeevi et 
al. (2015) which they used to predict the postprandial glucose responses of healthy individuals based 
on specific diets.  An important finding by this study group, which was confirmed by Hall et al. 
(2018), was that healthy individuals do not experience the same postprandial glucose responses to the 
same foods.  A possible explanation for this observation relates to the gut microbiome, which is likely 
an important role player in the absorption and metabolism of ingested foods (Suez et al., 2014; Zeevi 
et al., 2015).   
 
Insulin sensitivity of the glucose-accepting tissues may thus not be the determining factor in the 
magnitude of the postprandial glucose excursions that can be expected.  In fact, better insulin 
sensitivity, theoretically, only enhances the efficiency of glucose disposal.  The incretin hormones 
that elicit the first-phase secretion of insulin may have an influence on the degree that glucose spikes 
directly after the ingestion of carbohydrates (Drucker, 2007). Alternatively, the height of the 
immediate postprandial [glucose] is dependent on how much glucose enters the blood stream and at 
what rate.  Only after blood glucose levels have started to rise, is the pancreas stimulated to secrete 
insulin.   
 
According to the CMIO (Ludwig & Ebbeling, 2018), higher postprandial glucose stimulates higher 
levels of insulin to be secreted.  The more insulin enters the blood stream, and the more insulin 
sensitive the peripheral tissues are, the faster blood glucose levels will drop.  If the rate of glucose 
disposal is high, the mechanisms responsible for homeostasis of blood glucose are challenged and 
cannot transition from the postprandial state to the postabsorptive state fast enough (Ludwig, 2002).  
The resultant high postprandial glucose spike (stimulating high levels of insulin to be secreted which 
leads to fast glucose disposal in an insulin sensitive individual) is thus an over compensatory drop in 
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blood [glucose] to hypoglycaemic concentrations.  A nadir in the blood glucose profile has thus arisen 
following the excessive peak.  Hence, it can theoretically be understood why, in healthy glucose 
tolerance individuals, greater insulin sensitivity was associated with higher degrees of glycaemic 
variability (within the healthy ranges). 
 
Of note, the description of the physiological process above will not be applicable to individuals with 
overt insulin resistance, or after glucose tolerance has developed.  In this case, insulin resistance will 
cause glucose disposal to occur at slower rates, which will subsequently cause higher elevations in 
postprandial [glucose].   
 
Regardless of the explanation behind the association between glycaemic variability and insulin 
sensitivity in healthy, normal glucose tolerant participants, the so-to-speak “inability” of insulin 
sensitivity to protect healthy individuals against postprandial [glucose] spikes, emphasizes  the 
importance of diet composition in  the protection against less than optimal high levels of postprandial 
glucose and insulin. 
5.14 Summary of main findings 
The main finding of this study is that CGM and glycaemic variability indices were not able to detect 
health risk in individuals earlier than traditional glucose control, but that changes in insulin secretion 
(development of hyperinsulinaemia) occur before any abnormalities in glucose metabolism can be 
identified.  The variability in OGTT insulin concentrations was more than the variability in the 
glucose concentrations of the OGTT, suggesting postprandial insulin levels are a better predictor of 
glucose control than postprandial glucose.   
 
CRF was very strongly correlated with insulin sensitivity, more so than dietary glycaemic load.  This 
advocates for the importance of exercise and high levels of aerobic fitness for the maintenance of 
healthy insulin sensitivity and the prevention of deterioration in metabolic health.  
 
Notable differences in insulin resistance and insulin profiles after an OGTT were found between 
groups of participants who habitually consumed diets of varying macronutrient compositions.  These 
differences in insulin resistance and insulin profiles were larger than differences in the OGTT glucose 
levels, HbA1c (no difference between macronutrient clusters) and glycaemic variability indices. The 
largest difference between the three dietary groups, in terms of glycaemic variability indices, was the 
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difference in MAGE.  Interestingly, the highest insulin levels and highest insulin resistance was found 
in the group of participants who habitually consumed foods with equally high percentages of 
carbohydrates and fats, while MAGE was more dependent on the percentage carbohydrates consumed 
per day.  In other words, the results suggest that a diet which is high in carbohydrates and fats is more 
likely to be detrimental by eliciting hyperinsulinaemia, than a diet that is high in carbohydrates, but 
moderately low in total fat intake.  It can thus not be concluded that postprandial glucose excursions 
are the largest determining factor in the development of hyperinsulinaemia and insulin resistance.  It 
seems, from the results of this study, that a diet high in fats and carbohydrates will most likely lead 
to the development of hyperinsulinaemia and insulin resistance.  The participants whose diets were 
high in fat and moderately low in carbohydrates had the lowest insulin levels, insulin resistance, and 
MAGE. 
 
Insulin sensitivity was not a strong predictor of glycaemic variability and average postprandial 
glucose excursions within healthy ranges in non-diabetic men and during free-living conditions.  This 
finding emphasizes the importance of diet to minimize high postprandial levels of glucose and insulin, 
even in healthy, insulin sensitive individuals. 
 
This study was the first, to my knowledge, that investigated glucose control and free-living glycaemic 
variability of apparently healthy men in relation to cardiorespiratory fitness and dietary intake.  To 
my knowledge it is also the first study that compared glycaemic variability, glucose tolerance and 
insulin sensitivity of healthy individuals with habitual diets of different macronutrient compositions.  
The findings of this study provide specific evidence of the presence of hyperinsulinaemia among 
individuals with healthy glucose control and glycaemic variability indices. 
5.15 Study limitations 
The sample size of the study was small, which minimizes the external validity of the study. 
Furthermore, a non-probability sampling method was used to recruit participants.  However, the risk 
for selection bias was mitigated in that volunteers were enrolled consecutively into the study, in other 
words as they announced their interest to participate, provided they met the stipulated inclusion and 
exclusion criteria.  
 
It is possible that the CGM devices that were used might have underestimated the degree of glycaemic 
variability by being unable to record absolute maximum glucose values.  This is due to the sensors 
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measuring glucose concentrations every minute, but only recording the average concentration of 
every 15-minute period.  As briefly discussed under section 5.4.1, interstitial glucose measurements 
are accurate in comparison to blood or plasma glucose concentrations, but it is possible that the degree 
of postprandial glucose may be under-reported by glucose sensors.  The latter consideration is likely 
to have a small but added effect on the measurement of postprandial glucose excursions, compared 
with the possible smoothing effect of the 15-minute average values. 
 
No standardised meals were provided at any time during the study; participants continued with their 
habitual diets.  This could be seen as both a limitation and a strength.  The free-living CGM made it 
impossible to compare the glycaemic variability of the individuals independent of diet.  At the same 
time, however, the findings are arguably more applicable to everyday life, as the results of the study 
are able to address the applicability of the traditional glucose control tests to free-living conditions of 
healthy men.   
 
The dietary analysis, specifically the calculation of glycaemic load, must be interpreted with caution.  
The average glycaemic load for each participant was calculated by only considering the carbohydrate 
constituents of each meal that was consumed.  It is known that other individual meal components 
(such as the addition of fat, protein or vinegar, cooking methods,) have a marked effect on the overall 
GI of a meal (Russell et al., 2016) and the subsequent glycaemic load.  It is unfortunately not possible 
to account for all the possible factors to accurately calculate the glycaemic load of each meal.  Other 
meal components or ingredients, cooking methods, food temperature, etc., were thus ignored.   
 
Accurate cut-off values for a healthy HOMA-IR is difficult to determine as the variability in the 
threshold value that determines insulin resistance is large and is dependent on individual 
characteristics, such as ethnicity (Gayoso-Diz et al., 2013; Wallace, Levy & Matthews, 2004).  
Individuals in the current study were from different ethnic backgrounds and may thus have been 
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Chapter 6 Conclusions 
6.1 Overview of findings  
The findings of this study permit the flowing conclusions: 
 
Hypothesis 1 is partly accepted. 
Cardiorespiratory fitness had the strongest associations with the markers of insulin sensitivity, 
followed by HbA1c, mean glucose and overall glycaemic variability. 
 
Hypothesis 2 is partly accepted.   
Dietary glycaemic load was most strongly associated with intraday glycaemic variability (MAGE), 
followed by time per day spent above 6 mmol·L-1, and inter-day glycaemic variability (MODD).  No 
meaningful associations were found between dietary glycaemic load and insulin sensitivity, or 
glucose control. 
 
Hypothesis 3 is accepted. 
The low carbohydrate-high fat dietary group presented with the lowest indices of glycaemic 
variability and best insulin sensitivity.  MAGE was highest for the high carbohydrate-low fat group, 
while insulin levels during the OGTT were the highest for the high CHO-high fat cluster.  Differences 
in glucose control between the clusters were negligible or small.  
 
Hypothesis 4 is accepted. 
The strongest correlations among the glycaemic variability indices and traditional glucose control 
measures were between 2-h [glucose], MAGE and MODD.  Both correlations were moderately 
negative.  Moderate positive correlations were found between FPG, and MAGE and MODD.  HbA1c 
was not predictive of glycaemic variability. 
 
Hypothesis 5 is rejected. 
Better insulin sensitivity was associated with higher overall glycaemic variability, but lower mean 
[glucose].  Insulin sensitivity does not seem to protect against free-living postprandial 
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6.2 Practical implications 
Instead of looking into the utilisation of CGM and measurement of glycaemic variability for health 
risk detection, the measurement of insulin levels should enjoy more attention.  Collectively, the results 
suggest that insulin, instead of glucose, should be measured to screen and determine risk in 
individuals.  Insulin levels are a better and earlier predictor of future metabolic abnormalities and the 
development of glucose intolerance or diminished glucose control than any measures of blood 
glucose, whether it is the traditional measures of glucose control or CGM-derived indices.   
 
The findings of the current study support the need for both exercise (and increases in cardiovascular 
fitness) and diet for the long-term maintenance of metabolic health.  More specifically, a diet that 
prevents hyperinsulinaemia (i.e. low in carbohydrates and high in healthy fats) and exercise to 
promote insulin sensitivity are very important factors to prevent the development of insulin resistance 
and subsequent cardiometabolic disease. 
6.3 Recommendations for future research 
It would be valuable to repeat the study on a larger group of individuals and over a broader age range 
in order to test the findings of the current study.  This would help to gain further insight into the 
relationships of cardiorespiratory fitness and diet with glycaemic variability, glucose control, and 
insulin resistance.  A larger study sample could also provide more insight into the prevalence of 
increased free-living glycaemic variability in individuals with healthy HbA1c and fasting glucose 
levels and healthy glucose tolerance.   
 
Conducting a similar study, but with the inclusion of some standard meals will allow the 
determination of individuals’ responses to carbohydrate foods.  This may help to make more sense of 
the glycaemic variability data and the relations thereof to glucose control and insulin sensitivity.   
 
Due to the cross-sectional design of the current study, it could not be elucidated whether increased 
glycaemic variability (within the normal ranges of healthy individuals), in the absence of 
hyperinsulinaemia or insulin resistance, is a possible risk factor for future manifestation of 
deteriorating metabolic health.  This study will have to be repeated on a larger sample and including 
individuals with higher glycaemic excursions and with the addition of a longitudinal component, to 
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Available glycaemic variability reference values have, been derived from large cohorts that were 
grouped according to the traditional measures of glucose control.  Reference values are needed that 
are based on the risk associated with various degrees of glycaemic variability.   
6.4 Conclusion 
This is the first study, to my knowledge, to specifically investigate the associations of glycaemic 
variability indices with dietary glycaemic load.  Glycaemic variability better reflects the impact of 
dietary intake on glucose levels, compared to the traditional measures of glucose control. 
 
Glycaemic variability indices were not able to identify atypical glucose metabolism independently 
from the traditional measures of glucose control.  The variability in insulin levels during the OGTT 
was higher than the variability in the glucose levels during the OGTT and is additive support that 
changes in insulin secretion are evident before glucose levels become abnormal.   
 
Furthermore, this study provides evidence to support the importance for both exercise and a healthy 
diet for the maintenance of metabolic health.  More specifically, the current study found that 
cardiorespiratory was strongly associated to insulin sensitivity, while dietary glycaemic load and 
macronutrient composition as important considerations in the prevention of hypersecretion of insulin 
and subsequent development of insulin resistance.  The results of this study suggest a diet that is 
equally high in carbohydrates and fat, is most likely to illicit hyperinsulinaemia and thus, over time, 
insulin resistance. 
 
The results of this study, combined with the extensive literature on the detrimental effects of 
hyperinsulinaemia and insulin resistance, provide motivation to highly recommend shifting the focus 
from various means of measuring glucose control to the measurement of fasting and postprandial 
insulin levels.  More attention should also be given to the definition of “healthy” insulin levels that 
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Modified ACSM Medical Screening Questionnaire taken from ACSM’s guidelines for exercise testing 
and prescription 9th ed. (Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, pp.25.) 
Health Status Questionnaire 
On this questionnaire, a number of questions regarding your physical health are to be answered.    
Please answer every question as accurately as possible so that a correct assessment can be made. 
Please mark the space to the left of the question to answer “yes”. Leave blank if your answer is “no”. 
Please ask if you have any questions. Your response will be treated in a confidential manner. 
Name:____________________________________________ Date:_______________________ 
Medical Screening – ACSM Medical Screening Questionnaire 
- Do you have any personal history of heart disease?
- Do you suffer from chronic migraines?
- Do you suffer from any anxiety disorders?
- Do you have any personal history of metabolic disease (thyroid, renal, liver)?
- Do you know of any traumatic brain injury you have obtained? Are you using medication to treat
a previous incident?
- Have you suffered from a severe head injury/concussion within 6 months of this study?
- Have you had diabetes for less than 15 years?
- Have you had diabetes for 15 years or more?
- Have you experienced pain or discomfort in your chest apparently due to blood flow deficiency?
- Any unaccustomed shortness of breath (perhaps during light exercise)?
- Have you had any problems with dizziness or fainting?
- Do you have difficulty breathing while standing or sudden breathing problems at night?
- Do you suffer from ankle oedema (swelling of the ankles)?
- Have you experienced a rapid throbbing or fluttering of the heart?
- Have you experienced severe pain in leg muscles during walking?
- Do you have a known heart murmur?
- Do you have any family history of cardiac or pulmonary disease prior to age 55?
- Have you been assessed as hypertensive on at least 2 occasions?
- Has your serum cholesterol been measured at greater than 5.4mmol/l?
- Are you a cigarette smoker?
- Would you characterize your lifestyle as "sedentary"?
Medical History 
__  Are you currently being treated for high blood pressure? 
If you know your average blood pressure, please enter: ________/________ 
Please Check All That Apply. 
o Has    _  has doctor ever found an
sjdjdjd        abnormal ECG?    
_  Limited Range of Motion? _  Stroke?  
_  Abnormal Chest X-Ray? _  Arthritis? o Do Y  _ Epilepsy or Seizures?
_  Rheumatic Fever? _  Bursitis? o _ chronic Headaches or Migraines?
_  Low Blood Pressure? _  Swollen or Painful Joints? _  Persistent Fatigue?
_  Asthma? _  Foot Problems? _  Stomach Problems? 
_  Bronchitis? _  Knee Problems? _  Hernia? 
_  Emphysema? _  Back Problems? _  Anemia?
_  Other Lung Problems? _  Shoulder Problems? 
_  Recently Broken Bones?
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_ Has a doctor imposed any activity restrictions? If so, please describe:
Family History 
Have your mother, father, or siblings suffered from (please select all that apply): 
__ Heart attack or surgery prior to age 55 
__ Stroke prior to age 50 
__ Congenital heart disease or left ventricular hypertrophy 






__ Leukemia or cancer prior to age 60 
Medications 
Please Select Any Medications You Are Currently Using 
_ Diuretics _ Other Cardiovascular
_ Beta Blockers _ NSAIDS/Anti-inflammatories (Motrin, Advil)
_ Vasodilators _ Cholesterol
_ Alpha Blockers _ Diabetes/Insulin
_ Calcium Channel Blockers _ Other Drugs (record below).
Please list the specific medications that you currently take: 
Emergency Contacts 
Please list your general practitioner and person to be contacted in case of emergency 
Doctor:  Phone: 
Contact: Phone: 
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Activities and Goals 
On average, how many times do you exercise per week? ______ 
On average, how long do you exercise? ______  minutes 
On a scale from 1 to 10, how intense is your typical workout (circle one): 
Very Easy    1      2      3      4      5      6      7      8      9  10    Very Intense 
For each activity that you participate in, indicate your typical exercise time in minutes per session: 
Running/Joggin
g: 
______ Weight Training: ______ Skiing/Boarding: ______ 





Stair Climbing: ______ Swimming: ______ Other: ______ 
Bicycle/Spinning ______ Racquet Sports: ______ 
Lifestyle 
Are you a cigarette smoker? _____ If so, how many per day? ________ 
Previously a cigarette smoker? _____ If so, when did you quit? ________ 
How many years have you smoked or did you smoke before quitting? ________ 
Do you/did you smoke:  cigarettes? cigars?  pipe? 
Please rate your daily stress levels (select one): 
Low Moderate High: I enjoy High: sometimes High: often difficult 
the challenge difficult to handle to handle 
Do you drink alcoholic beverages? _______ 
How many units of alcohol do you consume per week: ______  (see Alcohol Units Calculator below) 
Alcohol Units Calculator 
Type of Drink Units 
1 glass of wine 1 
1 pub measure of spirits (Gin, Vodka etc.) 1 
1 can of beer 1.5 
1 bottle of strong lager 2.5 
1 can of strong lager 4 
1 bottle of wine 7
1 litre bottle of wine 10 
1 bottle of fortified wine (port, sherry etc.) 14 
1 bottle of spirits 30 
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Dietary Habits: Please select all that apply 
__ I seldom consume red or high fat meats 
__ I pursue a low-fat diet 
__ I eat at least 5 servings of fruits/vegetables per day 
__ I almost always eat a full, healthy breakfast 
__ My diet includes many high-fiber foods 
__ I rarely eat sugar of high-fat dessert 
Other 
Please indicate any other medical conditions or activity restrictions that you may have. It is important 
that this information be as accurate and complete as possible. 
Is any of this information critical to understanding your readiness for exercise?  Are there any other 
restrictions on activity that we should know about? 
Thank you for taking the time to complete this questionnaire! 
Stellenbosch University https://scholar.sun.ac.za
HREC General ICF Version 4.1, April 2016 Page 1 of 4 
Appendix B 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF RESEARCH PROJECT: 
The role of cardiorespiratory fitness on measures of glucose control and glycaemic variability in healthy 
men aged 30 - 50 years. 
DETAILS OF PRINCIPAL INVESTIGATOR (PI): 
Title, first name, surname: Ms Jonine Möller Ethics reference number: 
 S19/10/262 
Full postal address: Department Sport Science, Stellenbosch 
University, Private Bag X1, Matieland, Stellenbosch, 7601 
PI Contact number: 
0727833633 
We would like to invite you to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff any questions about 
any part of this project that you do not fully understand. It is very important that you are completely satisfied 
that you clearly understand what this research entails and how you could be involved. Also, your 
participation is entirely voluntary, and you are free to decline to participate. In other words, you may 
choose to take part, or you may choose not to take part. Nothing bad will come of it if you say no: it will not 
affect you negatively in any way whatsoever. Refusal to participate will involve no penalty or loss of benefits 
or reduction in the level of care to which you are otherwise entitled to. You are also free to withdraw from 
the study at any point, even if you do agree to take part initially. 
This study has been approved by the Health Research Ethics Committee at Stellenbosch University. 
The study will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, the South African Guidelines for Good Clinical Practice (2006), the Medical 
Research Council (MRC) Ethical Guidelines for Research (2002), and the Department of Health Ethics in 
Health Research: Principles, Processes and Studies (2015). 
What is this research study all about? 
The study will be conducted in the Sport Physiology Laboratory in the Department of Sport Science. We 
will invite 30 men to participate in the study and recruitment will continue until we achieve this number.  
The aim of the study is to assess fluctuations in glucose during your everyday life in comparison to the 
usual diagnostic tests which are used to determine glucose control. We also want to determine to what 
degree fitness and dietary influence these measures. 
If you agree to take part in the study and the screening procedure (which will involve the filling in of a 
questionnaire about your health status) indicate that you are eligible (if medical clearance needs to be 
obtained before you may partake in the study; the doctor’s consultation will be paid for by the study’s 
insurance), you will continue with the rest of the session in the laboratory, which could last an hour. Your 
height, weight, waist and hip circumferences and % body fat will be measured, after which you will be fitted 
with a continuous glucose monitor which you will wear continuously for two weeks.  The application and 
wearing of the monitor are completely painless.  It will be applied to the back of your upper arm.  The 
glucose monitor will measure your glucose levels every minute for as long as it stays on your arm until the 
two weeks are over.  You won’t be aware of the measurements.  You may sleep, shower, swim and exercise 
with the sensor on. You will not be able to see your live glucose readings, but you will receive a full report 
after you have completed the study.  While wearing the glucose monitor, you will be asked to log all food 
and drink and keep a diary of the exercise and physical activity that you do.  It will be thoroughly explained 
to you how to go about doing this.  Google forms will be used for the purpose of loggings, but you may keep 
a paper-based diary if you prefer.  You will then perform a maximal exercise test on the treadmill, to end off 
Stellenbosch University https://scholar.sun.ac.za
HREC General ICF Version 4.1, April 2016 Page 2 of 4 
the session with. We will fit you with a heart rate monitor around your chest and a face mask to measure 
your respiratory gas exchange. You will be required to run on the treadmill while the speed is increased by 
0.5 km/h after every minute. You will be asked to run until you are exhausted. The data that we gather from 
this test will allow us to determine your maximal aerobic capacity.  
We will also make an appointment for a morning on which you will be accompanied to the nearest pathology 
laboratory.  You will need to fast overnight.  A fasting blood sample will be drawn to measure glycated 
haemoglobin (HbA1c), glucose and insulin.  You will then drink a solution of 75 g of glucose after which 
blood samples will be taken every 30 min, again for glucose and insulin, until 120 min have passed.  You 
will be allowed to take your laptop to work or a book to read while you sit and wait. 
Why do we invite you to participate? 
You are invited to take part in this study because you have indicated your interest in the research project 
by responding voluntarily to the invitation asking for participants and you meet the inclusion criteria for the 
study. The inclusion criteria stipulate that you are a healthy male, not restricting dietary carbohydrates, 
didn’t change your dietary habits in the last 6 months and are between 30 and 50 years of age. 
What will your responsibilities be? 
We ask that you complete all questionnaires as honestly as possible and that you follow the instructions 
of the researchers before, during and after the testing sessions as best you can. You will also be asked to 
give your best efforts during the exercise test. In case of any deviations from the instructions (see below), 
we ask that you inform the researchers. 
Prior to the testing session, we ask that you do the following: 
1. do not eat for the 2 hours prior to testing;
2. avoid caffeine-containing drinks and alcohol ingestion at least 12 hours before testing;
3. avoid vigorous activities or any unaccustomed exercise at least 24 hours before testing.
You are also required to report your daily food intake honestly and as accurately as possible.  It is also very 
important for you to make sure the glucose sensor does not come off your arm. It cannot be reapplied once 
it has been put on your arm. You will be given plasters to help to keep it in place. 
Will you benefit from taking part in this research? 
The continuous glucose monitoring data together with your meal-loggings could provide very important and 
useful insight into your glucose responses to certain foods and meals. You will receive a personal report 
on all your test results and these findings will be discussed with you in person. 
Are there any risks involved in your taking part in this research? 
There will be no serious risks involved in the study; nonetheless, you may experience dizziness, physical 
discomfort, muscle fatigue and in rare instances, fainting, during the maximal aerobic capacity exercise 
test. In the case that you experience any of these symptoms the exercise test will be stopped immediately, 
and the researchers will take the necessary steps to make you comfortable. Biokineticists are on standby 
in the Department of Sport Science who are trained in first aid and willing to assist. Should any serious 
emergency arise, you will be stabilized and transported to the emergency room of Stellenbosch Medi-Clinic. 
Although scarce, some people may experience a hyposensitive skin reaction (such as an allergic reaction, 
itching, pain, redness and burning) to the adhesive of the glucose monitoring sensors.  Other side effects 
may also develop, such as sleep disturbances, muscle soreness or subcutaneous haemorrhage. You may 
choose to withdraw from the study should any side effect be experienced.  You will also be referred to a 
doctor, if necessary.  All medical costs will be covered by the study insurance.  
Even though it is unlikely, what will happen if you get injured somehow because you took part in 
this research study? 
Stellenbosch University will provide comprehensive no-fault insurance and will pay for any medical costs 
that came about because participants took part in the research. The participant will not need to prove that 
the researchers were at fault. 
Will you be paid to take part in this study and are there any costs involved? 
For your time invested in the laboratory tests, you will receive R21.00/hour commensurate with unskilled 
labour rates in accordance with NHREC (2012) guidelines for “Payment of trial participants in South 
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Africa”. In addition, you will receive R100 for each visit to the laboratory to cover travel expenses if you do 
not reside in Stellenbosch. 
Protection of participant information, confidentiality and identity 
Upon induction into the study you will receive a coded identification which will be used on all your 
documents and computer files related to the project. All the hard copies of your documents will be locked 
in the office of the supervisor, Prof Terblanche. Only the student investigator (Ms Möller), the laboratory 
manager (Ms Engelbrecht) and the supervisor (Prof Terblanche) will have access to the original records, 
the data and the locked cabinet where hard copies of documents will be stored. A sign in and out method 
will be implemented to ensure the safety of the documents. 
All computer files (i.e. Excel spreadsheets) and data which are collected via instruments in the Sport 
Physiology Laboratory (i.e. the data during the exercise tests) will be saved in a dedicated password 
protected folder on the laboratory computer and the password will only be available to the student 
investigator. This computer is also password protected and only the laboratory manager, Ms Engelbrecht, 
has access to the computer. Data files that are saved on computers for access by the research team will 
be de-identified. In other words, your data will be stored using your project identification number and not 
your name or other identifiable information. 
It is likely that the results from this study will be presented at national and international conferences and 
published in international peer-reviewed academic journals. Only group data and related statistics will be 
reported. You will therefore not be personally identifiable in these presentations and publications. 
Is there anything else that you should know or do? 
If you have any questions or concerns about this study, please feel free to contact Jonine Möller [072783 
3633; 18266231@sun.ac.za] and/or the supervisor Prof Elmarie Terblanche [082 707 6501; 
et2@sun.ac.za]. 
You may phone the Health Research Ethics Committee at 021 938 9677/9819 if there still is something that 
the researchers have not explained to you, or if you have a complaint.   
You will receive a copy of this information and consent form for you to keep safe. 
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Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a research study 
entitled “The role of cardiorespiratory fitness on measures of glucose control and glycaemic variability in 
healthy men aged 30 - 50 years.” 
I declare that: 
• I have read this information and consent form, or it was read to me, and it is written in a
language in which I am fluent and with which I am comfortable.
• I have had a chance to ask questions and I am satisfied that all my questions have been
answered.
• I understand that taking part in this study is voluntary, and I have not been pressurised to
take part.
• I may choose to leave the study at any time and nothing bad will come of it – I will not be
penalised or prejudiced in any way.
• I may be asked to leave the study before it has finished, if the study doctor or researcher feels
it is in my best interests, or if I do not follow the study plan that we have agreed on.
Signed at (place) ......................…........…………….. on (date) …………....……….. 20…. 
 ............................................................................  .......................................................................... 
Signature of participant Signature of witness 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
• I explained the information in this document in a simple and clear manner to
………………………………….. 
• I encouraged him/her to ask questions and took enough time to answer them.
• I am satisfied that he/she completely understands all aspects of the research, as discussed
above.
• I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the
declaration below.)
Signed at (place) ......................…........…………….. on (date) …………....……….. 20….. 
 ............................................................................  .......................................................................... 
Signature of investigator Signature of witness 
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Are you:
30 - 50 years old;
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Food & Drink intake
- Please log EVERYTHING that you eat or drink (water and non-caloric drinks excluded).
- Provide a description of the quantity, for example, 1 apple, 100 g chicken, 1 tsp honey. If you
don't have a kitchen scale please provide any description that will help us determine the
quantity, for example, a palmful, heaped tablespoon, the size of a deck of cards, etc.
- Please be as precise as possible - too much information is better than too little.
- Remember to include sauces/dressings and the oil or butter used for frying or milk in coffee
and tea, for example.
- If making a dish, list the total ingredients of the recipe the first time you eat of the dish;
thereafter you can just log portion size with a shorter description of the meal.
- Please try to avoid eating foods that you do not know the ingredients of for as long as you
are wearing your glucose monitor.
- Food labels may by photographed and uploaded if/when applicable.
- If logging several meals at once, please clearly mark the time of intake of each item in the
description.
* Required
Name & Surname: *
Date? *
Time?
What did you eat / drink and how much of it? *
Appendix E 
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If making a dish, list the total ingredients of the recipe the first time you eat of the dish; thereafter you can just 
log portion size with a shorter description of the meal.
Please try to avoid eating foods that you do not know the ingredients of for as long as you are wearing your 
glucose monitor.
Food & Drink Intake
Meal description (with ingredients & quantity)
Food labels may by photographed and attached if/when applicable.
Please log EVERYTHING that you eat or drink (water and non-caloric drinks excluded).
Provide a description of the quantity, for example, 1 apple, 100 g chicken, 1 tsp honey. If you don't have a 
kitchen scale please provide any description that will help us determine the quantity, for example, a palmful, 
heaped tablespoon, a the size of a deck of cards, etc.
Please be as precise as possible - too much information is better than too little.







7 – 11 days CGM 12 & 13 days CGM 
Mean ± SD Mean ± SD p; ES 
n 9 18 
Age (years) 36 ± 5  37 ± 5 0.64; 0.20 
Body mass (kg)   88.3 ± 15.9    87.7 ± 13.5 0.91; 0.04 
Body fat % 22.9 ± 5.4   19.6 ± 6.4 0.19; 0.54 
Fat free mass (kg)   67.7 ± 10.7   70.2 ± 9.4 0.55; 0.25 
Waist:Height   0.49 ± 0.04    0.50 ± 0.07 0.73; 0.16 
Waist:Hip   0.85 ± 0.04    0.86 ± 0.06 0.73; 0.18 
VO2peak (ml·kg-1·min-1) 45.3 ± 6.9 46.23 ± 7.8 0.75; 0.21 
Average daily GL 158.8 ± 55.8   144.0 ± 46.5 0.47; 0.30 
Average daily CHO intake (g) 276.8 ± 71.6 262.33 ± 74.4 0.63; 0.20 
Average daily energy intake (kJ) 11641 ± 1822   11046 ± 1855 0.44; 0.32 
% dietary CHO intake 42.1 ± 8.3     40.4 ± 6.74 0.57; 0.23 
% dietary protein intake 16.7 ± 3.2   19.4 ± 3.9 0.08; 0.73 
% dietary fat intake 41.2 ± 5.9   40.1 ± 5.0 0.59; 0.21 
HbA1C (%) 5.47 ± 0.5   5.41 ± 0.2 0.62; 0.18 
Fasting plasma glucose (mmol·L-1) 5.04 ± 0.5   4.99 ± 0.2 0.68; 0.15 
2-hour glucose (mmol·L-1) 4.08 ± 1.2   4.91 ± 1.5 0.16; 0.59 
HOMA-IR 1.11 ± 0.3   1.42 ± 0.9 0.35; 0.41 
Matsuda Index 9.52 ± 3.0   9.29 ± 5.0 0.90; 0.05 
Mean glucose (mmol·L-1)   4.7 ± 0.4     4.6 ± 0.4 0.37; 0.25 
SD (mmol·L-1)   0.79 ± 0.16     0.79 ± 0.15 0.98; 0.00 
CV% 17.06 ± 3.96   17.46 ± 4.28 0.82; 0.10 
MAGE (intraday variability) 1.05 ± 0.23 0.97 ± 0.18 0.32; 0.41 





Figure A1. The daily dietary GL of the participants during the CGM period.  The horizontal line in the 
box represents the median value, while the X marks the mean GL value. 
 
The outlying GL values (defined as 1.5 times the interquartile range larger than the third 
quartile) were from different individuals each day.   




Figure A2. Daily dietary carbohydrate intake of the participants during the CGM period. The horizontal 
line in the box represents the median value, while the X marks the mean carbohydrate intake value. 
 




Figure A3. Daily dietary fat intake of the participants during the CGM period. The horizontal line in 




Figure A4. Daily dietary protein intake of the participants during the CGM period.  The horizontal line 
in the box represents the median value, while the X marks the mean protein intake value. 
 
Table A1. Summary of the magnitude of differences (ES + CI 90%) in the group’s day-to-day 
macronutrient variability. 
 SD (ES; 90% CI) CV% (ES; 90% CI) 
Carbohydrate vs. fat 3.901; 50 – 83* 0.083; -4.4 – 5.7 
Carbohydrate vs. protein 5.342; 63 – 94* 1.290; 4.6 – 12* 
Fat vs. protein  1.227; 5.1 – 20* 1.086; 2.8 – 13* 
*p < 0.05. 
 
The average day-to-day individual (intrapersonal) variation in dietary glycaemic load was more 
than the average day-to-day individual (intrapersonal) variation of the macronutrient intakes 
(Table ).  The average day-to-day individual (intrapersonal) variation in glycaemic load was 
also more than the group’s average day-to-day variation in glycaemic load.  
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Table A2. The average day-to-day individual (intrapersonal) variation (mean ± SD) in dietary energy, 
glycaemic load, and macronutrient intakes. 
 SD CV% 
Energy intake  4020 ± 501 kJ 36.1 ± 5.2% 
Glycaemic load 78.5 ±13.9 g 53.6 ± 8.8% 
Carbohydrates  95.5 ± 38.6 g   36.6 ± 14.7% 
Fat  52.3 ± 17.4 g   43.5 ± 12.2% 
Protein   38.8 ± 10.2 g 35.0 ± 9.8% 
 
The average day-to-day individual (intrapersonal) variability (CV%) in carbohydrate intake 
was smaller than for fat intake (ES = 0.510; 90% CI: -11 – -2.4), but not for protein intake (ES 
= 0.130; 90% CI: -2.3 – 5.6).  The day-to-day individual (intrapersonal) variability (CV%) in 
fat consumption was larger than the variability of protein consumption (ES = 0.769; 90% CI: 
5.3 – 12). 
 
Table A3. The differences in the intrapersonal variations of the participants’ dietary macronutrient 
intakes. 
 SD (ES; 90% CI) CV% (ES; 90% CI) 
Carbohydrate vs. fat 1.443; 1.443* -0.510; -11 – -2.4* 
Carbohydrate vs. protein    2.009; 45 – 68* 0.130; -2.3 – 5.6 
Fats vs. proteins     0.947; 7.4 – 20* 0.769; 5.3 – 12* 
*p < 0.05. 
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Table A4. [Glucose] and comparisons between the clusters of the individual time points. 
  Clusters (mean ± SD)  Cluster differences (ES (90% CI)) 
 1 2 3 1 - 2 1 - 3 2 - 3 
    0 min 4.9 ± 0.3 5.1 ± 0.2 5.1 ± 0.4  0.731**  
(-0.06 –0.46) 




  30 min 7.0 ± 1.5 7.2 ± 1.6 7.8 ± 1.1 0.153  
(-1.2 –1.7) 
 0.637**  
(-4.0 –5.6) 
0.444*  
(-0.55 – - 1.7) 






  90 min 4.9 ± 1.2 5.1 ± 1.0 5.1 ± 1.4  0.186 
 (-0.85 –1.3) 








 0.235*  
(-0.81 –1.4) 
All p > 0.05; *small difference, **moderate difference. 
 
Table A5. [Insulin] means ± SD and comparisons between the clusters of the individual time points. 
  Clusters (Mean ± SD) Cluster differences (ES; 90% CI) 
 1 2 3 1 vs 2 1 vs 3 2 vs 3 




 0.978***  
(0.37 – 7.2) 
  30 min 56.9 ± 45.0 41.3 ± 19.3 67.6 ± 41.0 0.420*  
(-50 – 19) 
 0.251*  
(-22 – 43) 
 0.740**  
(-4.8 – 57) 
  60 min 37.0 ± 20.8 29.4 ± 18.0 52.9 ± 37.5  0.382*  
(-26 –11)  
 0.505*  
(-8.1 –40) 
 0.719**  
(-5 – 52) 
  90 min 30.5 ± 24.8 22.3 ± 4.0 38.0 ± 33.6  0.417*  
(-26 –10)  
 0.248*  
(-16 – 31) 
 0.561*  
(-8.7 – 40) 
120 min 20.0 ± 20.0 10.5 ± 6.1 29.0 ± 38.7  0.592*  
(-25 – 5.5) 
0.278*  
(-16 – 33) 
 0.573*  
(-9.7 – 47) 
All p > 0.05; *small difference, **moderate difference, ***large difference 
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